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General Introduction
1.1 STRUCTURE AND FUNCTION OF THE EPIDERMIS
1.1.1. Anatomy and organisation of human epidermis 1
The normal epidermis is a non-vascularized, terminally differentiating, 
stratified squamous epithelium, which is supplied of nutrients by diffusion through 
the underlying dermis and through the basement membrane. The major cell, making 
up 95% of the total, is the keratinocyte and its differentiation product, the corneocyte. 
Originating from a pool of cells with a limited proliferative potential, called transient 
amplifying cells, the newly formed keratinocytes move from the epidermal basement 
membrane towards the skin surface in two weeks. Microscopically we can distinguish 
the epidermis in four layers: stratum basale or stratum germinativum, stratum 
spinosum, stratum granulosum, and stratum corneum (SC). The stratum basale 
consists of a continuous one cell thick layer, attached to the basement membrane 
by hemidesmosomes and integrin receptors. The basal cells are small and cuboidal 
and have large, dark-staining nuclei. Immediately above the basal cell layer, the 
differentiating keratinocytes enlarge and form a layer, which is called the stratum 
spinosum because of the many desmosomes. In this layer the protein involucrin is 
expressed. The stratum granulosum consists of cells with microscopically visible 
intracellular structures called keratohyalin granules, which contain many proteins 
needed for terminal differentiation. This is the last living layer which is very active. 
The cytoplasm of these cells also contains lamellar granules or bodies. The outermost 
layer of the epidermis is the stratum corneum where cells (corneocytes) have lost 
nuclei and cytoplasmic organelles. The cells become flattened and have a highly 
insoluble cornified envelope within the plasma membrane, formed by cross-linking of 
the soluble precursor, protein. In many areas of the skin, especially of the palms and 
soles a fifth layer can be observed called the stratum lucidum. It is the lower part of 
the stratum corneum, which stains as a homogeneous eosinophilic zone.
During the migration from the inner layer to the outer layers of the epidermis, the 
keratinocytes undergo the following processes of proliferation and differentiation.
Epidermal proliferation
Corneocytes are continuously shed from the skin surface and replaced by 
cells from deeper layers. The increase of keratinocytes by proliferation in the basal 
and first suprabasal layer is under normal circumstances perfectly in balance with 
the loss from the outermost layer. This process is not observed by the naked eye 
and therefore it is called ‘desquamatio invisibilis’. In normal skin only 5-10 % 
of the basal cells is actively cycling.2 Several skin condition including psoriasis3 
and wound healing are characterized by a strong increase of cycling cells. This 
phenomenon, called hyperproliferation, may serve the aim to repair, structurally and 
functionally, a damaged stratum corneum as quickly as possible. It may, however, 
also be a consequence of pathological processes, harmful to the subject. In irritant 
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contact dermatitis (ICD), environmental influences are responsible for damage to 
either the cellular or the intracellular compartment. It may result in an increase in 
cellular proliferation. This adaptive response may be caused by a direct interaction 
of irritants with the keratinocytes or by effects on the intercellular lipid domain and 
subsequent functional disturbances. Increased permeability for water may be a trigger 
for increased proliferation.4
Because corneocytes lack a nucleus, adaptive phenomena are the result of 
cellular responses in deeper layers. The stratum corneum is called a dead layer, 
but it should be realized that the stratum corneum contain many active enzymes in 
order to desquamate in the extremely orchestrated way as it does. In this thesis skin 
irritation by sodium lauryl sulfate (SDS) and dithranol is studied. SDS brings about 
strong effects on the skin barrier in contrast with dithranol. Both are, however, strong 
irritants inducing hyperproliferation.5;6
Epidermal differentiation
As the epidermal keratinocytes move through the epidermis after losing 
their attachment to the basal lamina, they undergo the complex process of terminal 
differentiation, also known as keratinization, to produce SC. During this process 
plasma membrane is replaced by a tough, insoluble proteinaceous envelope. This 
layer, which is called the cornified envelope, consists of cross-linked proteins. First 
the proteins involucrin, envoplakin, and periplakin are sequentially cross-linked by 
epidermal transglutaminases (TGases), that promote the formation of disulphide 
and (-glutamyl)lysine isopeptide bonds. Proteins such as loricrin, elafin, S100, and 
small proline-rich region proteins (SPRRs) are incorporated later to form a mature 
envelope.7-9 This leads to a highly rigid insoluble structure, which is embedded in 
lipids from the plasma membrane and lipids secreted by the granular cells. 
During epidermal differentiation, epidermal lipids undergo a dramatic change 
both in composition and localisation resulting from activities of multiple enzymes.10 
Basal and spinous cells show a complex lipid composition with phospholipids as 
the major constituents. The phospholipids contain a high proportion of linoleic 
acid. With progressive differentiation of the epidermis into the stratum, a marked 
decrease in phospholipids is observed while the amount of sphingolipids (ceramides 
and glucosylceramides) and cholesterol proved to be increased.11;12 At the end of the 
differentiation, the content of ceramides and neutral lipids is increased from the inner 
to the outermost layer. Free sterol and free fatty acid contents are also significantly 
increased. A mixture of polar and neutral lipids is replaced by a more nonpolar mixture, 
including ceramides, free sterols and free fatty acids. Epidermal differentiation is of 
great importance for the integrity of the permeability barrier.13
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1.1.2 Epidermal functions
For terrestrial animals, the skin’s most important role is to act as a barrier. 
Cornified layers protect the skin from transepidermal water loss (TEWL) and loss 
of nutrients from inside. The stratum corneum also protects against penetration of 
potentially harmful substances, against the invasion of micro-organisms from the 
outside, and against UV light. In addition, the skin is involved in regulation of body 
temperature and in vitamin D production. In this thesis we focus on water-holding 
properties of epidermis and on the skin as a barrier to microorganisms.
1.1.2.1 Water barrier function
In 1944 it was established that water barrier function of skin can be attributed 
to the most outer skin layer, the stratum corneum (SC)14 and later this was shown to be 
associated with multilayered lipid lamellae localized in the extracellular spaces.15;16 A 
unique, two-compartment model of the SC as a barrier is accepted, in which protein-
rich enucleate cells, the corneocytes, are embedded within a continuous lipid-rich 
matrix.17 (Figure 1)
Figure 1: The stratum corneum can be represented as a two-compartment system, called by Elias as 
the ‘brick and mortar’ model.17 The bricks are the cornified cells with thickened membranes and the 
mortar is the intercellular lipid domein.
The lipids only account for about 10 % of the SC dry weight, but they are 
crucial in providing the barrier to water loss.18;19 They have unique chemical properties, 
high melting point and polarity, which result in the formation of water resistant lipid 
bilayers. This means that they form a hydrophobic compartment which encloses the 
carbon chains that separates them from the water. The hydrophilic head groups face 
the water and form a border between a hydrophobic phase and the water.19;20 SC lipids 
are primarily generated from exocytosis of lipid-containing granules called lamellar 
bodies (LB) or Odland bodies. The lipids of lamellar bodies are phospholipids, 
sphingomyeline, cholesterol sulfate, glucosylceramide and acylglucosylceramides. 
During epidermal differentiation, these lipids are processed to three types of lipids in 
the SC.18;21 At the final stage of keratinocyte differentiation, the lamellar body lipids 
are secreted into the stratum granulosum and form the bilayer structure. 
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An important role in the structure of the barrier plays the hydrophobic envelope 
mainly composed of involucrine, loricrin and filaggrin, formed on the surface of the 
corneocytes.22 The lamellar sheets are covalently bound to the cornified envelope 
by ω-hydroxyceramide and ω-hydroxy fatty acids, forming a lipid envelope, which 
stabilised the intercellular domain.23;24
The unique organisation of the hydrophilic cells within the lipid, hydrophobic 
environment, makes this 10-20 µm layer extremely efficient as a barrier. Its water 
permeability is comparable with a plastic membrane and 1000 times more efficient 
than other membranes of living organisms.25 The lamellar structure of the intercellular 
domain shows a well-balanced range of lipids. If the lipid composition is disturbed 
qualitatively and/or quantitatively by environmental influences or by disease, barrier 
function will be hampered. In particular, the long chained ceramides are essential 
for the barrier function. It should, however, be emphasized that barrier function is 
both the result of the structured lipid domain and the ordering and function of the 
corneocytes.18 The intercellular domain is most important for the water barrier. The 
role of sebum in barrier function is probably very limited.26
We want to emphasize that SC barrier formation is a dynamic process. The 
skin is continuously exposed to environmental influences, which may influence 
barrier integrity. Initially, harm to the skin may lead to decrease of barrier function, 
but subsequently, to either recovery and hardening, or to disease, dependent on the 
size and nature of the assault and relevant constitutional factors of the exposed 
individual.27 Increased lipid synthesis, lamellar body secretion and lipid processing are 
aimed at barrier repair. If these adaptive phenomena fail, chronic barrier dysfunction 
may be the result. Moreover, the SC is the end product of epidermal differentiation. 
This means that, e.g. nutritional deficiencies, neuroendocrine responses or skin 
diseases, influencing epidemal growth and differentiation, may change the structure 
and function of the SC and may, therefore, induce barrier abnormalities.
Epidermal lipids
The skin is a very active lipid-synthesising tissue, with a production rate of 
100 mg per day. The lipid composition of the SC differs from the other layers of 
the epidermis and other tissues.21 As mentioned above, the SC is composed of three 
classes of lipids: free sterols, ceramides and free fatty acids. A small amount of 
cholesterol sulfate has also been reported as an intercellular lipid.28 
Ceramides are the major constituents of the SC - more than 40% of total lipid 
mass29 - and represent a unique, heterogenous group of at least eight subclasses that 
differ from each other by the head group architecture and by the mean fatty acid 
chain lenght. They are composed of sphingosine base and fatty acid. The fatty acid 
chain lenght varies between 16 C atoms in ceramide 5 to C30-C34 atoms in ceramide 
1.30 Ceramides play an important role in the barrier function. There are a number 
of experimental observation that indicate the role of ceramides in preventing water 
loss throught the SC.(Table 1) The profile of the various ceramides is probably an 
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important determinant.31 Especially, ceramide 1 is assumed to be of importance 
barrier function due to its exceptional molecular structure contains linoleic acid 
linked to the long chain (C>30) ω-hydroxy fatty acid.32 Ceramides, next to their 
structural role in the SC can also have a bioactive, signaling function. They play a key 
role as lipid second messenger and have effects in multiple cell signaling pathways. 
They have been described as intracellular lipid messengers of the sphingomyelin 
cycle. Increased levels of intracellular ceramides induced cell differentiation and/or 
apoptosis and reduce cell proliferation. There is evidence that not only intracellular 
ceramides but also extracellular barrier-forming ceramides may affect epidermal 
proliferation and differentiation.33 The different biological effects of the ceramides 
are shown in Table 1. 
Table 1 Activity of Ceramides (modified from 34)
Modulation of lamellar gel crystal of the horny layer lipids
Opponent of cholesterol concerning interlayer distance
Solution aid for cholesterol
Augmentation of crystalline parts
Influence on the SC properties 35-38
Decrease of TEWL
Increase of water content
Decrease of skin scalines
Cellular response 33
Downregulation of cell proliferation
Induction of cell differentiation
Initiation of apoptosis
Second messenger function
Fatty acids (FA) are important substrates for energy production, synthesis 
of phospholipids and participation in signal transduction pathways in mammalian 
cells.39 Fatty acids are a major component of the SC lipids, in which linoleic acid is 
the most abundant unsaturated fatty acid.40 It is generally accepted their important 
role in the maintenance of water barrier function of epidermis. Previous studies have 
demonstrated that both acute and chronic disruptions of the barrier stimulate epidermal 
fatty acid synthesis by approximately twofold.41;42 This increase of the synthesis of 
fatty acids can be accounted for by increases in the enzymatic activities of fatty acid 
synthase (FAS) and acetyl CoA carboxylase (ACC).43 Moreover, it has been shown 
16
Chapter 1
17
General Introduction
that FA synthesis leads to the recovery of the barrier and the inhibition of enzymes 
of fatty acid synthesis delays barrier recovery.42;44 Barrier disruption also stimulates 
epidermal DNA synthesis leading to epidermal hyperplasia which requires fatty acids 
as components of various membrane structures in the epidermal cells themselves.45
 
E-FABP as fatty acid carrier 
Since FA are poorly soluble in water, special binding and transport proteins 
are required to increase FA solubility. In the circulation, FA are bound to albumin.46 
Within the cells, FA are bound to cytosolic, nonenzymatic fatty-acid-binding-proteins 
(FABP’s), which belong to a family of low molecular mass (14-15 kDa) proteins 
displaying tissue-specific expression.47 In 1993, epidermal type FABP (E-FABP) with 
a high affinity for C-18 FA has been characterized in human epidermis.48 Later it was 
shown that E-FABP is also expressed in the mammary gland, lens, brain, liver, kidney, 
adipose tissue and some endothelial cells. 
The function of E-FABP in skin has not been elucidated. Since there is a 
close relationship between FA metabolism and keratinocyte differentiation, E-FABP 
expression may be related to the commitment of keratinocyte differentiation. There is 
some evidence indicating the role of E-FABP in water barrier function, however, its 
function only with respect to water barrier has been questioned. Normal human skin 
contains small amounts of E-FABP (<0.5 pmol/mg protein) localized to the stratum 
granulosum. In this layer the activity of rate limiting enzymes required for barrier lipid 
synthesis is highest.49 Upregulation of E-FABP has been observed in sodium dodecyl 
sulphate induced skin barrier dysfunction.50 Further, delayed recovery of TEWL after 
acetone application to the normal skin of E-FABP-deficient mice has been reported.51 
These studies demonstrate that the role of E-FABP is associated with maintaining 
of the skin barrier function although the exact mechanism remains to be elucidated. 
In lesional psoriatic epidermis, the strong overexpression of E-FABP correlates with 
only a slight increase of transepidermal water loss. Since the levels of linoleic acid 
are strongly increased in psoriatic scale52;53 and linoleic acid has a high affinity for 
E-FABP, it is possible that expression of E-FABP in psoriasis is a ligand-depended 
process54 and is linked specifically to epidermal hyperproliferation and abnormal 
differentiation of this disease. The presence of E-FABP in the non-keratinized oral 
mucosa epithelium and its expression in tissues other than skin suggests that the role 
of E-FABP is not restricted to the skin barrier alone. 
In this thesis we studied the expression of E-FABP in specific skin conditions: 
(1) dithranol irritation human model in which the skin barrier for transepidermal water 
loss is not compromised and (2) lesional skin of atopic dermatitis and psoriasis to 
contribute to the elucidation of its epidermal function. 
1.1.2.2 Antimicrobial properties of the epidermis
An intact SC prevents invasion of the skin by normal skin flora or pathogenic 
microorganisms. However, both minor injury to the skin as well as skin diseases 
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can provide portals of entry to microorganisms, particularly to streptococci and 
staphylococci.55 The innate immune system can immediately respond to this intrusion 
by helping to prevent further invasion. The innate immune system provides broad-
spectrum recognition and rapid elimination of invading microorganism. This is 
distinct from the adaptive immune system (acquired immunity) where a host response 
is initiated only after antigen stimulation of specific lymphocyte subpopulations. 
Innate immunity encompasses a variety of host defense modalities ranging in 
complexity from simple inorganic molecules to cellular elements.56 (Table 2) 
Table 2 Elements of innate immunity. Adapted from 56.
Type Examples
Inorganic molecules HCl, nitric oxide, hydrogen peroxide
Simple organic molecules Fatty acids
Antimicrobial peptides (<100 a.a) Cecropins, magainins, defensins, 
cathelicidins, SLPI, SKALP, dermcidin, 
cystatin A, calprotectin
Antimicrobial proteins BPI, PLA2, lysozyme, complement
Binding proteins Mannose binding protein, collectins
Cytokines IL-10, IL-12, TNF-α
Carbohydrates PGC-Glucan
Cells Macrophages, neutrophils, natural killer cells, 
epithelia
Toll-like receptors TLR1-TLR10
As a component of this system, an essential role of Toll-like receptors (TLRs) 
in microbial recognition has been established a few years ago. So far, ten mammalian 
TLRs have been identified which recognize distinct structural components of pathogens 
and evoke inflammatory responses. The TLRs function through signaling molecules, 
including MyD88, IL-1 receptor-associated kinase, TNF receptor associated factor 
6, mitogen-activated protein (MAP) kinases and nuclear factor (NF)-κB.57 Some of 
TLRs were recently demonstrated in human epidermis.58
Further, antimicrobial peptides and proteins are an integral component of the 
innate immune system.59 They have been proposed to provide a first line of defense 
against infection by acting as ‘natural antibiotics’.60;61 A variety of tissues synthesize 
antimicrobial peptides including bone marrow cells, specialized epithelial cells, and 
ciliated epithelium.62;63 In the 1990s there has been a rapid expansion in the field of 
antimicrobial peptides. Over 300 peptides are reported.56 More recently, mammalian 
skin has emerged as a source for these molecules and is now a major point of 
interest.64
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Keratinocytes express constitutively or inducibly a number of antimicrobial 
peptides with bactericidal or bacteriostatic properties.65 Studies have revealed unique 
mechanisms of action for this class of host defense agents. Firstly, these molecules 
are able to kill a variety of microbial organisms. In response to injury, keratinocytes 
rapidly increase synthesis of these peptides that participate with circulating cells 
in killing potential pathogens. Secondly, antimicrobial peptides signal specific 
responses in the dermis and can modulate the activity of circulating neutrophils. 
Initially two classes of antimicrobial peptides have been discovered in mammalian 
skin: cathelicidins (PR-39 and LL-37)66 and β-defensins (hBD1,2 and 3).64;67 LL-37, 
hBD-2 are not normally present in human epidermis but are highly induced upon 
barrier disruption or chronic inflammation such as in psoriasis. In this thesis we have 
studied three host-defense proteins not restricted to these two classes; skin-derivated 
antileukoproteinase (SKALP), secretory leucocytose proteinase inhibitor (SLPI) and 
MRP-8 have been described and are associated with a broad spectrum of biological 
activity.68;69 We briefly describe the properties of these molecules.
Skin-derivated antileukoproteinase (SKALP)/elafin
SKALP also known as elafin70, is a very cationic molecule, which is present 
in an intact form with a calculated molecular weight of approximately 9.9 kDa. 
Immunohistochemical studies have demonstrated the localisation of SKALP in 
different normal human tissues. SKALP appeared, in general, to be present in 
stratified squamous epithelia like tongue, gingiva, epiglottis, pharynx, oesophagus, 
cervix, vagina and hair follicles.71 Normal epidermis and skin adnexae are negative, 
except for the keratinocytes lining the epidermal part of the sweat gland ducts and 
the infundibular part of the hair follicle. SKALP expression in pathological skin 
conditions has been extensively studied. SKALP is known to be expressed in vivo 
when keratinocytes are exposed to inflammatory cytokines (psoriasis, wound healing) 
and after skin barrier disruption by tape stripping or detergents.72-74 In psoriasis, a 
strong cytoplasmic staining in the upper layers of the suprabasal compartment of 
epidermis was found, whereas the basal cell layer was negative.75 The expression of 
SKALP in atopic dermatitis is unknown. SKALP inhibits human leukocyte elastase 
with high affinity, but also porcine pancreatic elastase and proteinase 3, an elastin-
degrading protein also derived from neutrophils. TNF-α was shown to be the most 
potent inducer of SKALP gene expression, whereas interferon-γ and transforming 
growth factor α showed a milder induction of SKALP gene expression.76 Recently, 
antimicrobial activities of SKALP have been demonstrated.68
Secretory Leucocyte Protease Inhibitor (SLPI) 
SLPI, originally described as Human Seminal Inhibitor I (HUSI-I) or 
Antileucoprotease (ALP)77;78 is a small, cationic protein that is known to be 
constitutively expressed by several glandular epithelia. SLPI inhibits leukocyte-
derived proteinases, has anti-HIV-179, antibacterial80 and antifungal properties81 and 
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interferes with the induction of synthesis of proinflammatory mediators in monocytes 
and macrophages.82 In human epidermis, SLPI is an inducible antimicrobial protein, 
which effectively inhibits growth of P.aeruginosa and S.aureus. SLPI expression in 
skin is stimulated by inflammation (psoriasis, wound healing) and tape stripping. 
It is suggested that SLPI plays a role in the innate immune skin system providing 
antimicrobial activity and an antiproteinase shield against proteolysis of dermal 
elastic fibres and structural epidermal proteins.69 SLPI expression in atopic epidermis 
has not been studied so far.
Migration Inhibitory Factor Related Protein (MRP8)
MRP8 also known as calgranulin A, is a S100 Ca++-binding protein that forms 
the heterodimeric calprotectin complex together with MRP14.83 Calprotectin is active 
against intracellular bacteria and C.albicans.84;85 Both proteins are highly abudant 
in human neutrophils and monocytes and they are also found in elevated levels in 
plasma of patients with various inflammatory disorders such as chronic bronchitis, 
cystic fibrosis and rheumatoid arthritis.86 MRP 8 is found in keratinocytes in a variety 
of inflammatory conditions.87;88 Normal epidermis and skin adnexae are negative.89
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1.2 SELECTED INFLAMMATORY SKIN DISORDERS 
ASSOCIATED WITH AN ALTERED EPIDERMAL BARRIER
Abnormalities in epidermal function are present in many inflammatory skin 
disorders. Irritant contact dermatitis (ICD), atopic dermatitis (AD) and psoriasis 
vulgaris (PV) share common characteristics of impaired cutaneous permeability 
barrier function which could eitheir initiate or sustain these cutaneous disorders.90-92 
In this thesis we have performed studies with respect to epidermal barrier in these 
inflammatory skin disorders. We focused on ICD as a clinical condition where 
disturbance of the skin barrier is in most forms a prominent feature and is very 
important in the pathogenesis of ICD. 
1.2.1 Irritant contact dermatitis (ICD) 
Irritant contact reaction is inflammatory reaction of the skin to an external 
agent or agents where, although inflammatory and immunological mediators may 
be activated, no memory T-cel function or antigen-specific immunoglobulins are 
involved. Irritant contact reactions include several inflammatory responses that follow 
damage to the skin. This damage may result from acute toxic insults to the skin, as 
with accidental exposures to acids, alkalis, etc., or they may arise from repeated and 
cumulative damage from marginal irritants, both physically and chemically.93
1.2.1.1 Clinical aspects of ICD
ICD has a spectrum of clinical features. Recently, ten different forms of irritant 
contact dermatitis have been described.94
Acute ICD
Acute irritation results from skin exposure to a strong irritant or caustic 
chemical, such as acids or alkaline solutions. Signs of acute ICD include erythema, 
edema and necrosis in the skin area of the irritant exposure. Irritation is often 
morphologically similar to allergic contact dermatitis and is thus difficult to diagnose. 
One distinction exists in the course of the reaction after the exposure to the causative 
agent. The healing of acute ICD is described as a decrescendo phenomenon, which is 
opposed to the crescendo phenomenon described in acute allergic contact dermatitis.
Delayed acute ICD
The irritation is acute, but the inflammatory response is delayed approximately 
8-48 h following the initial exposure. Dithranol may induce a delayed acute ICD. In 
chapter 5 of this thesis we focus on dithranol induced irritation. Hence, we would like 
to highlight this unique form of ICD.
Dithranol irritation is the most important limiting factor of dithranol treatment, 
which has been a main therapeutic agent for the topical treatment of psoriasis since 
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1916. It is generally assumed that dithranol irritation is caused by the formation of 
super-oxide radicals due to the loss of a hydrogen atom from the methylene group at 
position C-10.95
Dithranol irritation presents as a unique form of ICD. The prominent 
differences between dithranol and a detergent induced irritation are summarized in 
Table 3. Moreover, in the course of treatment with dithranol, the skin adapts and 
becomes less susceptible to the irritant effects of dithranol. This adaptative effect is 
also responsible for the decrease of the antipsoriatic effect after repeated exposures. 
Therefore increasing the concentration of exposure times is nessesary.96 Such an 
adaptation is in contrast with the effect of detergents, where repeated challenges cause 
summation of the irritant response.97;98 The adaptation during repeated applications 
of dithranol discloses an entirely different mechanism, which is suggested to be 
specific for dithranol irritation.99 However, the underlying mechanism of this adaptive 
response of the skin is not elucidated. We will discuss the clinical aspects of this 
adaptive effect of dithranol in chapter 5. 
The sensitivity of the skin to dithranol shows large variations from time to 
time, but also between individuals. The question arises whether it is possible to 
predict susceptibility to dithranol. In analogy to the minimal erythema dose (MED) 
for ultraviolet light, the determination of the minimal irritation dose (MID) may 
optimize finding of the starting dose.100;101 A polymorphism of the TNF-α gene is the 
first demonstrated genetic marker for irritant susceptibility in normal individuals.102 
Whether this marker may contribute to screening of individuals deemed at risk of 
increased susceptibility to dithranol is unknown. Nevertheless, there are other known 
factors relevant to dithranol irritation like the vehicle103;104 application frequency105, 
and skin type.100 Sensitivity to dithranol varies with location, the face, body flexures, 
axilla, scrotum, breasts and inner sides of the thighs being the most vulnerable 
parts of the body. The psoriasis lesions are less sensitive to the oxidative dithranol 
irritation than the surrounding skin probably due to an increased extracellular free 
radical scavenging system (thioredoxin reductase).106 Whether the frequency of 
irritation depends upon the severity of disease before treatment is unknown and will 
be focus of interest in chapter 5. Inflammatory conditions as well as damage to the 
horny layer make the skin more vulnerable. Pretreatment with corticosteroids, which 
make the horny layer thinner, may make the skin more vulnerable and phototherapy 
(UVB radiation or PUVA), which makes the horny layer thicker, renders the skin less 
vulnerable.41 Because of the redness and pain of uninvolved skin strong responses to 
dithranol force to stop the treatment for one or more days.  An interesting question 
is whether skin irritation results in a more-or less favourable clinical response to 
dithranol. In chapter 5 this question is adressed.
Dithranol irritation can be treated by topical corticosteroids, although some 
authors state that it would be ineffective.41;107 Corticosteroids suppress inflammation 
and symptoms like redness and pain. However, steroids may also make the epidermis 
thinner and may make the skin more vulnerable for subsequent dithranol irritation. 
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Consequently the use of corticosteroids may increase dithranol irritation in the long 
run and may influence the effectiveness of dithranol therapy. Emollients are useful to 
cool and soften the skin in case of irritation. Anti-inflammatory effects with emollients 
and other modalities like tar and non-steroidal anti-inflammatory drugs (indometacin, 
scopolamin) in dithranol irritation are not to be expected.107-109 Effect of BN 52021 a 
platelet activating factor antagonist has been described.110 Chapter 5 will focus on 
the modulation of dithranol irritation in a human experimental model with topical 
corticosteroids, a coal tar solution and emollients.
Table 3 Prominent differences between dithranol irritation and SDS induced 
irritation
Dithranol irritation SDS induced irritation
Individual susceptibility
Atopy unknown yes 111
Skin colour unknown yes112;113
Skin phototype type 1 more sensitive 
100;107
unknown
Age no 105 yes 114
Gender no 105 no 98
Ethnic unknown no 115
Application site yes 41 yes 114
Season no yes 116
Horny layer thickness yes 105 no 117
TEWL normal 118 increased 119
Dose response 
relationship
no 96 yes 120;121
Tolerance after repeated 
application
yes122 no 98
Irritant reaction
The irritant reaction is characterised by a monomorphic presentation that 
includes either scaling, redness, vesicles or erosions, often localised to the dorsum of 
the hands and fingers. Upon healing, hardening of the skin occurs. Hairdressers, metal 
workers, and others exposed to wet work are the most affected groups.
Subjective/sensory irritation 93
Sensory irritation refers to a chemical-induced burning, stinging or itch 
sensation without accompanying erythema or edema. Histologically is usually 
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unchanged. These sensations most commonly affect the head and neck and may 
present as one form of cosmetic intolerance. Some chemicals will cause sensations 
within seconds after contact. Such immediate-type stinging follows after exposure 
to chloroform and methanol. The sensation abates quickly following removal of 
the irritant substance. A number of chemicals will cause discomfort within 1-2 
min, reaching a maximum in 5-10 min., and disappears slowly over the next half 
hour. Among the substances able to induce such a reaction known as delayed-type 
stinging are the sunscreen agent amyldimethyl-p-aminobenzoate, the insect repellant 
diethyltoluamide and several other agents and vehicles used in both cosmetics and 
medicaments.
Suberythematous irritation
Suberythematous irritation indicates a state in which the irritation is not 
visually apparent, but is histologically visible upon microscopic examination. 
Common symptoms of this irritation include burning, itching or stinging.
Cumulative ICD
Cumulative ICD is thought to be caused by repeated exposures to various weak 
irritant factors. These minor stimuli in itself may impair the skin, but this impairment 
is not strong enought to cause a visible skin disorders. If the skin is exposed to irritants 
before it completely repairs from the previous challenge, ICD may develop. After a 
series of cumulative insults, which may be of varying nature, the threshold may be 
surpassed. Beyond this level irritant dermatitis will supervene and even a low level of 
exposure will cause dermatitis. 
Traumiterative ICD
This form is similar to cumulative ICD with one exception. Repetitive exposure 
from only one type of irritant is involved in this irritant response.
Traumatic ICD
Traumatic ICD is caused by acute skin trauma. Common symptoms include 
burns or lacerations. These are most commonly localised on the hands.
Pustular and acneiform dermatitis
Tars, mineral oils, croton oils and naphtalene exposure may result in pustular 
and acneiform dermatitis, especially in atopic and seborrhoic patients.
Exsiccation eczematid
Patients, especially elderly persons, who frequently shower tend to get this 
form of dermatitis. Common symptoms are intense itching, dry skin and ichthyosiform 
scaling.
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1.2.1.2 Pathogenesis of ICD
ICD is a heterogenous disorder with many different mechanisms contributing 
to its pathogenesis. 
Impairment of the skin barrier is thought to play a dominant role in the 
pathogenesis of ICD. The integrity of the epidermal barrier is important in protecting 
the skin against irritants. Without penetration no damage to the skin can be done. A 
well-functioning epidermal barrier is of utmost importance. Therefore, to protect the 
skin against environmental influences, we must aim at optimal barrier integrity. The 
skin, although under most environmental conditions capable of protecting us, is not 
always a perfect barrier. Firstly, in some genetic123 or acquired skin disorders the barrier 
may indirectly have a deficient barrier capacity, resulting in increased penetration of 
chemicals and increased risks of contact reactions. In atopic individuals, a greater 
vulnerability to irritants is associated with endogenous SC lipid abnormalities.124-126 
Also in non-atopic individuals with a higher tendency for skin irritation, baseline 
abnormalities in SC lipid composition has been observed.127 Secondly, environmental 
factors may also have a direct effect on the barrier. For example detergents may 
wash-out SC lipids, giving rise to damage to cellular components, but especially 
to the intercellular space of the SC. Abnormalities in the lipid profile of the SC 
has been observed after application of organic solvents or detergents.119;128;129 Also 
strong hydration may cause histological and electronmicroscopical changes.130 These 
abnormalities are consistent with impairment of the skin barrier. Direct and indirect 
effects of physical, chemical and biological factors on the integrity of the SC, may 
result in chronic insufficiency of the epidermal barrier and may lead to chronic 
diseases like irritant contact dermatitis.27 Some chemicals like dithranol have strong 
inflammatory effects on the skin, without direct effects on the SC131, exposure to 
other chemicals like the detergent sodium dodecyl sufate (SDS) give rise to strong 
erythematous reactions, correlating with skin barrier impairment.117;132
Cytokines carry the focus of interest within contact dermatitis over the last 10 
years. Cytokines form a heterogeneous group of short-range, cell-derived peptides 
which can be released by a variety of nucleated cells. Cytokines may act directly, as 
inducers and regulators of cell growth, division and differentiation, as stimulators of 
cell movement and migration and as controllers of cellular function and indirectly 
interaction via induced changes in the expression of adhesion molecules and receptor 
for cytokines.133 Resting keratinocytes produce some cytokines constitutively. A 
variety of environmental stimuli, such as tumor promoters, ultraviolet light and 
chemical irritants, can induce epidermal keratinocytes to release inflammatory 
cytokines (IL-1, TNF-α), chemotactic cytokines (IL-8, IP-10) growth promoting 
cytokines (IL-6, IL-7, IL-15, GM-CSF, TGF-alpha) and cytokines regulating humoral 
versus cellular immunity (IL-10, IL-12, IL-18).97 Of all the cytokines, TNF-α and 
IL-1 are the only cytokines capable of activating sufficient effector mechanisms 
to independently trigger cutaneous inflammation.134 The main pool of TNF-α lies 
within dermal mast cells, although keratinocytes produce TNF-α constitutively and 
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could be stimulated to increase expression.135 Also Langerhans cells and melanocytes 
are capable of constitutive or inducible expression.136 TNF-α have important pro-
inflammatory properties, such as the induction of adhesion molecules, production of 
other cytokines and up-regulation of MHC class I and II expression.137 In a variety 
of experimental models of ICD, the release of TNF-α has been demonstrated by a 
number of investigators.6;138;139 Piquet at al described TNF-α as a critical mediator in 
ICD.101;140 An important aspect of TNF-α production is an interindividual variability 
probably due to TNF-α gene-308 polymorphism which is recently associated with 
susceptibility to ICD.102 Remarkably, not all irritants are able to induce TNF-α, 
indicating that exposure to irritants can lead to specific cutaneous reactions depending 
on the nature of irritants.141 Data on expression of TNF-α in dithranol induced irritation 
are not available, but it is known that dithranol in vitro inhibits human monocytes to 
secrete TNF-α.142
Oxidative stress is a situation in which an inbalance in pro-oxidant/anti-
oxidant equilibrium occurs within cells and tissues, resulting in damage to lipids, 
proteins, carbohydrates and DNA. Such inbalance may result from excessive 
endogenous generation of free radicals during physiologic processes, but may also 
occur through exposure to exogenous sources of free radicals such as tobacco smoke 
and ultraviolet radiation.143 Irritants may also generate reactive oxygen species, both 
directly and indirectly. Dithranol-induced skin irritation is a well known example of 
ICD to be caused by the direct generation of free radicals and oxygen radicals.144 
Dithranol slightly elevates lipid peroxidation in mouse skin after topical application, 
demonstrated by the exhalation of ethane, which is produced from gamma-3 
polyunsaturated fatty acids and by malondialdehyde production.145 In addition, 
singlet oxygen can accelerate lipid peroxidation by directly reacting with unsaturated 
fatty acyl moieties to give hydroperoxides, which was also already demonstrated 
for dithranol.146 Thus the peroxidative damage to membrane lipids after dithranol 
application is generally believed to be related to its antipsoriatic action as wel as 
induction of skin irritation.147 Furthermore, changes in the levels of the antioxidant 
enzymes, glutathione S-transferase (GST) and superoxide dismutase (SOD) provide 
evidence that oxidative stress is also a component of irritation induced by some 
detergents and that oxidative stress plays a more important role in the pathogenesis 
of ICD than previously thought.148;149 For most irritants, except dithranol, the major 
source of free radicals is of an endogenous origin. A possible source is formed by 
infiltrating neutrophils and macrophages which generate and release of reactive 
oxygen species.118;143 Interesting is an association between cytokines and oxidative 
stress. Oxidative stress is known to induce the upregulation of TNF-α, IL-1 and IL-8, 
but paradoxically, increased TNF-α induced oxidative stress.150
Other mediators such as prostaglandins, leukotriens, neuropeptides etc. seem 
of less importance for the development of ICD.
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Althought the nature, concentration and duration of contact with the irritant 
chemical are of primary importance, there are many other factors which are important 
in modification and/or enhancing the irritant respons. Table 4 summarizes these 
factors.93
Table 4 Factors which influence susceptibility to irritation
Exogenous Endogenous Cofactors
Chemical characteristics Individual susceptibilty Mechanical
Molecular structure Atopy Thermal
pH Race/skin colour Climatic
Hydrophobicity Skin phototype Hormonal
Inherent toxicity Age
Concentration/dose Barrier function
Penetration 
characteristics
Repair capacity
Vehicle Eczema elsewhere
Solubility Other skin diseases
Duration of contact Application site
Type of contact
1.2.1.3 Treatment of ICD
To date, there is no general agreement about how to treat ICD. The aim of this 
section is to provide a review on topical treatment of ICD, focusing on non-steroidal 
agents, corticosteroids and topical lipids.
New non-steroidal, anti-inflammatory modulators
Cytokines are important in the development of ICD and inhibition of their 
function can inhibit the site of the inflammatory response. In this thesis the question is 
addressed whether topical cytokine inhibitors can influence skin irritation and repair 
of barrier damage. As mentioned before, of all cytokines, TNF-α is a critical mediator 
in ICD.101 Modulating TNF-α activity in the skin may provide therapeutic benefits for 
a variety of skin conditions. Recently anti-TNF-α and TNF-α receptor constructs have 
been shown to have clinical efficacy in the treatment of psoriasis.151 Pretreatment with 
anti-TNF-α antibodies or with topical N-acetylcysteine, which is an selective inhibitor 
of gene expression for TNF-α 152, is able to inhibit ICD in mice.140;153 This effect was 
not observed in human studies where N-acetylcysteine failed to inhibit ICD induced 
by SDS or dimethylsulfoxide.154 
Xantine derivates could be new promising therapeutical agents targeting 
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TNF-α and other cytokines. They function as phosphodiesterase inhibitors and are 
able to suppress the production of TNF-α and other cytokines in murine and human 
leukocytes and keratinocytes.155;156 A great advantage of the xantine derivates is 
their well-known pharmacokinetics and safety. They have been used therapeutically 
in humans with vascular disorders for more than two decades without major side 
effects.157 Chapter 4 will discuss the effect of cipamfylline, a new phosphodiesterase-
4 inhibitor, on human models of ICD.
Macrolide antibiotics may improve dermatitis by suppressing the immune 
response. Tacrolimus inhibits activation of calcineurin in T-cells. Several studies have 
documented a benefit of topical tacrolimus in inflammatory dermatoses, e.g. atopic 
dermatits, psoriasis, allergic contact dermatitis, lichen planus etc.158 However in SDS 
induced ICD, the widely reported anti-inflammatory effect of tacrolimus could not be 
confirmed. In one experimental human study on ICD, tacrolimus did not accelerate 
healing, even enhanced skin irritation.159 Pimecrolimus, as the other member of 
macrolide antibiotics seems to be effective in chronic irritant hand dermatitis.160
Other new nonsteroidal anti-inflammatory modulators as antiflammin 1 
peptide161, phenoxyacetic acid methyl ester162, azaspiranes163, activators of liver X 
receptor164, strontium165;166 have been shown to be effective in a variety of animal and 
human experimental models of ICD. A curious rapport about anti-inflammatory effect 
of acetone has been published.167
Since there is strong evidence that free radicals and reactive oxygen species are 
important in ICD, potent antioxidants has been examined to influence ICD. Quercin, 
as a bioflavinoid with antioxidant and anti-inflammatory activity, does not appear to 
increase barrier recovery in SDS induced ICD.168
Topical lipids
The benefits of lipids in treatment of the skin were already known by Cleopatra 
who took her bath in donkey’s milk. From this ancient on time on, waxes, oils, 
amphiphilic lipidic material have been used in various dermatological and cosmetic 
formulations. Galen’s formula for cold cream is thought to be the first example of 
an emulsion written down in the London Pharmacopoeia from 1618. The original 
formula did not contain borax, which was introduced in 1890 for the manufacture 
of cold cream. Borax was discovered in California in 1859.169 Despite the extensive 
clinical experience with lipids in dermatological formulations and more than 40 years 
of skin lipid research, understanding of the interaction of topically applied lipids with 
skin barrier lipids is lacking.
As mentioned before, lipids of the stratum corneum (SC) play a significant 
role in maintaining the permeability barrier of the skin. Changes in lipid composition 
in the SC are associated with different skin conditions and disorders. There is 
evidence that topical application of skin related lipids (ceramides, cholesterol, fatty 
acids) may improve the skin barrier function. Effects of topical application of SC 
lipids on ICD were evaluated by the group of Elias. Firstly, they demonstrated that 
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the application of a single SC lipid and mixture with two SC lipids delayed barrier 
repair in mice. Secondly, the topical application of an equimolar three-component 
system of ceramides, cholesterol and fatty acid allows normal barrier repair.170 Finally 
they found the optimal molar ratio of the SC lipids that accelerated barrier recovery 
in acetone induced barrier impairment in mice.171 Out of a number of preparations, 
those with a lipid ratio most comparable to that present in the human skin barrier, is 
considered to be effective.172 They also compared the mixture of skin related lipids 
with petrolatum on the barrier repair process. Petrolatum repaired the barrier more 
quickly than the related lipids, but 2 or 4 h later, the application of a skin related 
lipid resulted in a better recovery than petrolatum.173 Using fluorescence and electron 
microscopy has also been demonstrated by that the mixture of cholesterol, fatty acid 
and ceramides rapidly traversed the SC with subsequent uptake into the epidermal 
nucleated layers170;171;173, whereas the applied petrolatum stayed in the SC. 
A new generation of emollients with specific lipid profiles and lipid contents 
adjusted to specific skin condition is under development, but the evidence for 
superiority to the traditional products in human is still lacking. In this thesis (chapter 
4) the question is addressed whether certain mixture of skin related lipids is effective 
in human models of experimentally induced ICD and in some clinical conditions 
associated with barrier damage. 
Corticosteroids
Dermatologists use topical corticosteroids to treat numerous disorders, 
however their use in ICD remains controversial. The anti-inflammtory properties of 
corticosteroids could improve the dermatitis, however, their antiproliferative effects 
might slow recovery of the skin barrier and may enhance penetration of irritants. 
Several authors reported a lack of efficacy of topical corticosteroids in skin irritation, 
whereas others clearly showed such an effect.174-179 However, there are considerable 
differences between the designs of these studies with regard to corticosteroid potency, 
the duration and site of the irritation, open or closed application, and the concentration 
of the irritant, which apparently may influence the outcome of the study. Acute and 
repetitive open application testing on the hands of volunteers with several irritants are 
recommended in order to establish the efficacy of corticosteriods in ICD.180
In case of radiation dermatitis, barrier enhancing properties of topical 
corticosteroids have been observed. It is suggested that the positive effect of topical 
corticosteroids on barrier damage in this skin condition is caused by a primary 
reduction in the inflammatory response.181 In nonanonic acid - induced irritation which 
associated with minimaly skin barrier dysfunction corticosteroids has been shown to 
be effective.182 In SDS induced ICD, barrier dysfunction precedes inflammation and 
therefore damage to the skin barrier may only partly be a reflection of an inflammatory 
response. This may explain the modest or absent efficacy of a topical corticosteroid 
in models of ICD, since barrier dysfunction is considered to play a prominent role in 
its pathogenesis. 
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1.2.2 Atopic dermatitis (AD)
AD is a chronic, itching skin disease with a relapsing course. It forms part of 
the atopic syndrome, also known as atopy. Clinical and laboratory criteria have been 
developed for the definition of AD. The most widely used are those of Hanifin and 
Rajka (1980). AD is one of the most common skin diseases with a life-time prevalence 
of up to 30 %. Its incidence is increasing in Western countries. The highest incidence 
is among children.183
AD starts usually in early chilhood. The infant phase starts during the third 
month and is characterised by dry red scaling areas on the cheeks and chin, sparing the 
perioral and paranasal region. More severe cases show generalised papulation, redness, 
scaling, vesicles and crustae. The childhood phase is characterised by inflammation in 
flexural areas, sides of the neck, wrists and ankles with depigmentation and the first 
signs of lichenification. Marks of the adult phase are flexural inflammation, hand and/
or foot dermatitis, periorbital erythema and lichenification of the anogenital area.184
Histological changes in AD are a matter of controversy. Many authors tend 
to regard the histological findings as nonspecific. Histological findings in AD can be 
classified as acute, subacute and chronic, according to the various stages of clinical 
evolution. Epidermal changes in early lesions are spongiosis, intercellular oedema 
with vesiculation, irregular hyperplasia. Dermal changes include oedema and 
perivascular and intervascular inflammatory infiltrates consisting of lymphocytes, 
macrophages, occasional by neutrophils, eosinophils and basophils. Long-standing 
lichenified lesions of AD show acanthosis of the epidermis, para- and orthokeratosis 
with little or no intercellular oedema. Dermal changes include papillary fibrosis, 
moderate perivascular and intervascular lymphohistiocytic infiltrate in the upper 
dermis and increase of mast cells.185
AD is generelly accepted as an immunologic disease (inside-outside 
hypothesis). Recent investigations have greatly increased the understanding 
of immunological mechanism involved in the pathogenesis of AD. A major 
immunological abnormality is the skewing, within the secondary immune organs of 
ThO cells towards Th2 lymphocytes, upon allergenic challenge. As a result, Th2 cells 
dominate the central responses and through their specific cytokine secretion profile, 
induce B cells to produce allergen-specific IgE. These molecules are secreted into the 
circulation and will then sensitize different organs, by binding via Fc R receptors on 
mast cells and dendritic cells (including Langerhans cells). T cells are activated by 
aeroallergens, food antigens, autoantigens and bacterial superantigens.186
The existence of defects in skin barier function in AD is well accepted, but 
the epidermal abnormality generally is viewed as a downstream consequence of the 
inflammatory phenotype.186 Whithout denying the significance of immunological 
phenomena in the pathogenesis of AD, some authors support the outside-inside 
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hypothesis in which barrier dysfunction plays a major role in the pathogenesis in 
AD.187;188 Evidence for this hypothesis is provided by the observation that increased 
TEWL, abnormal lipid composition and changed levels of enzymes involved in lipid 
metabolism, are already present in the clinically uninvolved skin in the absence of 
clinical and histological signs of inflammation.189-193 Furthermore, disease activity 
correlates with the extent of barrier abnormalities as wel as with factors influencing 
SC barrier function (decreased humidity194, season, psychological stress195). Also 
the threefold increase in prevalence of AD over the past 30 years can be explained 
by barrier dysfunction: alteration of life-styles, such as excesive use of soaps and 
shampoos, changes in indoor climate enhance skin barrier dysfunction.91;196;197 It is 
possible that barrier disruption in AD is an etiologic factor for eliciting dermatitis 
following the easy penetration of irritants and antigens.192 Nevertheless, it remains 
difficult to determine whether barrier dysfunction is a primary initiator or only a 
secondary event that participates in the vicious circle. A possible relationship of 
epidermal barrier dysfunction to the pathogenesis of AD is shown in Figure 2.198
Figure 2 Relationship of epidermal barrier dysfunction to the pathogenesis of atopic dermatitis. 
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Several studies on barrier function and lipid composition have been performed 
in patients with AD, and the important findings are: (1) increased TEWL both in clinical 
involved and uninvolved skin199;200 (2) decreased water content 201;202 (3) reduced water 
binding capacity 203 (4) decrease in the total amount of extractable SC lipids 189;204 (5) 
morphological abnormal lamellar bodies.205 The best investigated lipid fractions in AD 
epidermis are ceramides as they represent the main lipid component of permeability 
barrier.206 Although the results vary in the different studies, the total ceramide amount 
in involved and uninvolved skin of AD patients is significantly reduced.189;190;207 
Among the ceramide fractions, ceramide 1 and 3 are most significantly reduced.126 
The biologic basis of the ceramide deficiency may include abnormal expression of the 
enzymes involved in sphingomyelin metabolisme 191-193, the colonisation of AD skin 
by ceramidase-secreting bacteria208 or a disturbed extruding mechanism of LB’s. As 
ceramides are important determinants involved in the water-holding properties209;210 
and barrier function of SC211;212, the insufficiency of ceramides provide an etiologic 
bassis for the barrier-disruption in AD patients. For some authors, the ceramide-
deficiency in AD make a strong basis to explain some parts of pathogenesis in terms 
of biochemical mechanisms involved in lipid metabolism.192 
The relevance of superantigens in the induction of dermatitis in AD patients 
has recently been underlined.213 AD is known to be associated with a high prevalence 
of skin infections, particularly with Staphylococcus aureus (S. aureus).214 Disease 
severity has been associated with the presence of S. aureus in the skin of children 
with AD215;216 and with the presence of IgE to superantigens.217 The important role 
of S. aureus is supported by observation that even in patients with AD whithout 
bacterial superinfection, the severity of the disease is more reduced by a combination 
of antistaphylococcal antibiotics and topical corticosteroids as compared to topical 
corticosteroids alone.218;219 The mechanisms underlying the increased colonisation 
of atopic skin with S. aureus is unknown. Impairment of the phagocyte system214, 
specific binding of S. aureus to the inflammation mediated by type 2 helper T cells220, 
sphingosine-deficiency221, decreased secretion of IgA and alkaline pH in the skin of 
patients with AD222 are mentioned to explain the increased incidence of infections in 
these patients. Further, it is known that S. aureus grows in colonies in the upper layers 
of the epidermis between keratinocytes.223 This suggests that increase in S.aureus 
could be the result of failure of the innate immune defense system of atopic skin to 
restrict the growth of the organisms. Recently it was shown, that epidermis of AD 
patients expresses low levels of the antimicrobial proteins LL-37 and β-defensis-2, 
compared to psoriasis patients. It was speculated that a insufficiency in the expression 
of inflammation-induced antimicrobial peptides may explain the susceptibility of 
patients with AD to skin infection.224 In this thesis (chapter 3) we extended this 
observation to three other known host defence proteins (SKALP, SLPI and MRP8) to 
further investigate this phenomenon.
Therapeutic agents for AD are limited. Topical corticosteroids are the 
mainstay of the treatment of AD, but their use in a chronic and relapsing condition is 
32
Chapter 1
33
General Introduction
unsatisfactory due to potential toxicity, particularly in small children. A large variety 
of topical steroids is available. The potency of these corticosteroids ranges from mild 
to very potent.225 Recently new therapies has been introduced in the management of 
AD.226 Tacrolimus and pimecrolimus are new macrolide-type inflammatory cytokine 
inhibitors, with a mechanism of action similar to cyclosporin. In contrast to cyclosporin 
A, they are effective in the topical treatment of AD due to their relatively small size. 
Both compounds are effective against itch, one of the most prominent problems of 
patients with AD. In contrast to topical corticosteroids, these compounds seems to 
have a more favorable side-effect profile.129;158;160;227 Topical phosphodiesterase (PDE) 
inhibitors are also used experimentally in the therapy of AD.228;229 PDE inhibitors are 
cAMP-elevating agents as they block the PDE enzymes that convert cAMP to 5’AMP, 
leading to the intracellular acumulation of cAMP. It is known that intracellular 
elevation of cAMP has anti-inflammatory properties. The role of the cyclic nucleotide 
phosphodiesterases (PDE) in the pathogenese of AD was proposed more than 20 
years ago as a possible explanation for the rapid enzymatic breakdown of cAMP 
found in leucocytes from AD patients. PDE 4 inhibitors act as anti-inflammatory 
agents by blocking the increased PDE activity found in AD. Besides the blocking, 
other pathways of the anti-inflammatory activity of PDE inhibitors should be taken 
into consideration. This includes IFN-γ which has been detected in chronic phase and 
bacterial infections, which through the production of superantigens may play a role in 
AD pathogenesis.230 
1.2.3 Psoriasis 
Psoriasis is a chronic, non-infectious, inflammatory disease of the skin. The 
prevalence ranges between 1 and 3% of the population.231;232 The course of the 
disease is unpredictable : it may last from a few weeks to a whole lifetime. Psoriasis 
is considered to be a polygenic and multifactorial disease. A hereditary component 
plays a role, but the mechanism of inheritance remains unclear.233 A family history for 
psoriasis is present in one third of the patients. There is a high association between 
psoriasis and certain HLA-types.234 In addition, a variety of external factors has been 
accepted as triggering factors in predisposed patients.235;236 It is known that local 
irritation or injury to the skin can result in the induction of a new psoriatic lesions 
(Köbner phenomenon).237
The cutaneous lesions in psoriasis are well-defined, elevated and erythematous 
plaques. There is a silvery, non-coherent scaling, which differs in intensity in the 
various patterns of psoriasis. The morphology of psoriasis shows a considerable 
variation. Clinical presentations are: guttate psoriasis, annular psoriasis, pustular 
psoriasis, erythrodermic psoriasis and chronic plaque psoriasis. The last one is the 
most common form of psoriasis, making up 90% of the cases.238 In addition to the 
skin lesions, extracutaneous manifestations can develop: in 30-50% of the patients 
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nail abnormalities are present and a minority of the patients also suffers from psoriatic 
arthropathy.239
Increased proliferation, altered differentiation and cutaneous inflammation 
are the histopathologic changes that characterise psoriasis lesions. The histological 
aspects may vary considerably, depending on the stage of the lesion. The early 
plaque shows polymorphonuclear leucocytes penetrating into the stratum spinosum 
and corneum, forming Munro microabcesses and Kogoj pustuls, respectively. In a 
fully developed psoriatic lesion the histopathological features consist of ortho- and 
parakeratosis, disappearance of the granular layer, elongated rete ridges, oedematous 
papillary dermis and dilated and tortuous capillaries.240;241
Despite many investigations, the exact pathogenesis of psoriasis is still not 
known. It is beyond the scope of this thesis to discuss all different hypotheses on the 
pathogenesis of psoriasis. It is clear that both epidermis and dermis are needed for the 
appearance of psoriatic lesions.
In psoriasis, dysfunction of water holding properties of epidermis has been 
observed. Water barrier function is impaired causing an increase in TEWL and these 
observations are consistent with disturbances in lipid metabolism. Since there is a close 
relationship between lipid metabolism and keratinocyte differentiation, these changes 
in lipid metabolism are probably a direct consequence of epidermal hyperproliferation 
and abnormal differentiation. In psoriatic scale, the same relative content of ceramides 
as in normal SC were found, however, chromatographic separation of ceramide 
species displayed a different pattern of ceramides distribution.35;242-244 In psoriatic 
scales, cer 1, cer 3 and cer 6 show a statistically significant decrease vs. normal 
SC, while some ceramides (cer 2 and cer 5) are increased. A comparable pattern of 
ceramide distribution has not been observed in atopic dermatitis. These biochemical 
changes correlate with ultrastructural studies on psoriasis where an extremely narrow 
intracellular space of SC and pathological lamellae has been found. Likewise, these 
morphological findings are psoriasis-specific and could not be observed in atopic 
dermatitis.245
Also covalently bound lipids, which have principal functions in the formation 
of a lipid envelope on the outer surface of keratinized cells, show different proportion 
from those found in normal SC. An elevated level of bound linoleic acid associated 
with alterations in the covalently-bound ceramides has been described. However, the 
psoriatic scale contains a similar total concentration of the covalently bound lipids.52 
This different pattern of ceramide fraction and covalent bound lipids is possible linked 
specifically to the abnormal differentiation in psoriasis. Although the relative free 
fatty acid content is decreased remarkably (46%) in psoriatic scales, compared with 
normal human SC 242, psoriatic scale shows increased levels of bound linoleic acids 
and other esterified derivates of linoleic acid. 
One can divide the treatment of psoriasis in topical therapy and systemic 
treatment. Examples of topical therapy are vitamin D3-analogues (calcipotriol, 
tacalcitol and calcitriol), corticosteroids, coal tar and dithranol. In case of more 
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widespread psoriasis, phototherapy and photochemotherapy are indicated. In severe 
cases systemic treatment with for example methotrexate, retinoids or cyclosporin is 
indicated.246;247 One purpose of this thesis is to investigate aspects and the management 
of dithranol induced irritation, which is a common side effect of dithranol therapy. 
Hence, a short description of dithranol therapy in psoriasis will be provided.
Dithranol, a synthetic analogue of chrysarobin, has been used for over 80 
years in the treatment of chronic plaque psoriasis. Dithranol is a yellow powder that 
can be incorporated in a cream, ointment, paste or stick. Dithranol application can 
be carried out according to many different regimes for instance the Ingram regime. 
The time honoured 24 hour dithranol appliactions are supposed to be most effective 
but it requires hospitalisation. Short contact applications and cream formulations 
have simplified dithranol treatment. Dithranol has two drawbacks: skin irritation 
and temporary discoloration of the skin and permanent discoloration of garments, 
furniture and sanitary. To avoid this permanent discoloration, precautions have to be 
taken to avoid contact between dithranol and these materials.95;248 Dithranol irritation 
is discussed as a part of irritant contact dermatitis.(see page 21).
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1.3 METHODOLOGY
1.3.1 Experimental human models of ICD
In this thesis the effect of topical treatment on ICD was studied in four different 
established models of experimentally induced skin irritation.
1.3.1.1 Sodium dodecyl sulphate (SDS)
In experimental dermatology, the anionic detergent, sodium dodecyl sulphate, 
is commonly used as irritant in models for ICD. SDS meets the requirements of an 
irritant for experimental use because it causes no systemic toxicity, no cosmetic 
inconvenience to the exposed subjects and it is not a carcinogen nor sensitiser.98 
Guidelines regarding the SDS exposure test have been established and described 
by Tupker et al.249 Barrier dysfunction occurs after exposure to SDS as assessed by 
TEWL as a parameter for barrier function impairment.250;251 This barrier impairment 
is associated with cell biological changes. The cell biological response of the 
keratinocytes include (1) an increased proliferative rate as measured by Ki-67 positive 
cells (2) an induction of involucrin and (3) an upregulation of E-FABP.50
The effect of topical treatment in this thesis was studied in two different 
established models of SDS- induced skin irritation.50;252 Firstly we used a single 
exposure of 1% sodium dodecyl sulphate. We used a 1% dilution of SDS (w/v). An 
aliquot of 150 μl of SDS was pipetted on the patches, consisting of a 1,5 cm2 piece 
of absorbent, non-woven fabric on a 4.0 cm2 piece of impermeable plastic foil. 174 
The subjects were patch tested on investigating sites on the lower back for 24 hours. 
After removal of the patches, the tested ointment was applied daily over the area of 
previously SDS exposed skin, dried at room temperature for 30 minutes. 
To mimic the development of ICD in daily life we used repetitive application 
of 0.2% SDS. 150 μl of SDS (0.2%) (w/v), was pipetted on the patches which of a 
1.5 cm2 piece of absorbent, non-woven fabric on a 4 cm2 piece of impermeable plastic 
foil. The SDS patches were daily fixed at the investigation site to the lower back 
during 4 h for 4 consecutive days. After removal of the patches, the tested ointment 
was applied daily on the area of previous SDS exposed skin. 
1.3.1.2 Tape stripping
We used as another model for barrier disruption tape stripping. After tape 
stripping an increase in TEWL4 and induction of a hyperproliferative/inflammatory 
responses was observed, which include (1)epidermal proliferation as measured by 
Ki-67 positive cells, (2) upregulation of cytokeratin 16, (3) expression of SKALP and 
(4) an increase of density of epidermal Langerhans cells.253-255 Also lipid abnormalities 
after tape stripping have been described.256 As such it offers a suitable method to study 
influence of therapy on barrier dysfunction associated with epidermal cell biological 
changes. 
We used adhesive tape (Tesafilm) which was applied with gentle pressure to 
38
Chapter 1
39
General Introduction
the exposed areas and then removed. This procedure was repeated until the skin was 
glistening.
1.3.1.3 Models of dithranol irritation
Recently, two human experimental models (single and repetitive application) 
of dithranol irritation have been developed. The dynamics in epidermal changes after 
repeated challenge are comparable with those after single application, involving (1) an 
induction of the cornified envelope precursor protein involucrin (2) the cross-linking 
enzyme transglutaminase I and (3) an increase of epidermal proliferation. Uninvolved 
skin of patients with psoriasis is recommended to perform studies on the interference 
of dithranol irritation by various therapeutical agents.6
In our experiments we studied the response of topical treatment after repeated 
applications of dithranol cream on uninvolved skin of psoriasis patients. We applied 
the cream on 2 cm Ø of the lower back for 1 hour, after which the dithranol cream was 
removed with water. We repeated it once daily during 4 consecutive days. 
1.3.2 Measurement of water barrier function: TEWL 
Transepidermal water loss (TEWL) is the constitutive steady state water 
vapour loss from the skin, theoretically excluding sweat gland activity. It is considered 
to be the result of passive diffusion through the skin, the diffusional flux obeying the 
physicochemical laws of passive transport through a membrane.257
TEWL measurement is a frequently used method to asses the function of skin 
barrier. An evaporimeter (Courage & Khaza, Germany) is used in this study. (see 
Figure 3) 
 
Figure 3 Tewameter TM 210
Its operating principle is based on the method of gradient estimation. The 
measuring probe head of this instrument contains two sensor units, placed in in the 
enclosure of an open cylinder. Each sensor unit consist of a humidity transducer and 
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a thermistor. The probe head is applied parallel to the skin, the sensor units being 
positioned af a different distance to the skin surface (3 and 9 mm). Thus, the signals 
of the humidity transducer and thermistors can be used to compute the partial pressure 
of the water vapour and the temperature at these positions above the skin surface. The 
partial pressure gradient and water vapour loss rate can thus be calculated.258 (see 
Figure 4)
Figure 4 The measuring principle. The law of diffusion is 
discovered by Adolf Fick : dm/dt = -D.A.dc/dx. The diffusion 
flow dm/dt indicates the mass per cm2 being transported in a 
period of time. It is a proportional to the area A and the change 
of concentration per distance dc/dx. D is the diffusion coefficient 
of water vapour in the air. This law is only valid within a 
homogenious diffusion zone, which is approximately formed 
by a hollow cylinder. The resulting density gradient is measured 
indirectly by two pairs of sensors (temperature and relative 
humidity) and is analysed by a microprocessor.
TEWL is by definition diffusional water loss through the epidermis. Therefore 
sweat gland activity should be eliminated as much as possible by measuring under 
neutral environmental conditions. In order to avoid thermal sweating and emotional 
sweating subjects should be put at ease for 15-30 minutes in a room with a constant 
temperature of 20-22 °C and a relative humidity of about 40%.259 In case there is 
still sweating despite these recommondations sweating can be blocked by a 1-hour 
occlusive application of scopolamine hydrobromide.260 In order to measure pure 
diffusional water loss one should avoid desorption (loss of excessive unbound water), 
for example by measuring not too early (< 1 hour) after removing patches in irritancy 
testing.261
Many environment-related variables influence water diffusion through the 
horny layer. The most important variables are environmental factors like (i) ambient 
air temperature which influences skin temperature and consequently the horny layer 
barrier function, (ii) air humidity which influences the water vapour gradient over the 
skin and the barrier function characteristics of the SC horny layer and (iii) seasonal 
variation. The latter is a very important variable, since the skin is often dehydrated by 
low indoor relative humidity in the winter in many parts of the world. Low relative 
humidity has a strong effect on skin hydration and consequently on barrier function. 
Also personal factors including age, sex, skin colour and anatomical site may be of 
influence.
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To avoid instrument-related disturbance of the microclimate amongst others 
direct light, heat, draft and pressure of the probe should be avoided. Pinnagoda et al 
defined guidelines for accurate and reproducible measurements.259 
1.3.3 Visual grading
Erythema can be assessed by means of colorimetry or visual grading. A 
previous study showed a good correlation between the visual scoring, with colorimetry 
and with other parameter like TEWL. In order to investigate the effect of therapies 
in ICD we used visual grading to determine the erythema. Semi-quantitative grading 
system of erythema, already described in other studies50, was used: 0-no response; 1-
slight, patchy redness; 2-diffuse mild redness, 3-moderate redness, 4-intense redness; 
5-intense redness with oedema.
1.3.4 Immunohistochemistry
Tabel 1 summarizes epidermal markers we used to investigate the cell 
biological effects of therapeutical agents highlighted in this thesis in diverse models 
of ICD. (Chapter 4 and 5)
Tabel 1.Overwiew of used epidermal immunohistochemicals markers
Immunohistochemical markers (target / antibody)
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Chronic (repeated 
dose (0.2%))
+ + + - + -
Tape stripping + + + - - +
Dithranol model 
(repeated dose 2%)
+ - + + - -
1.3.4.1 Epidermal proliferation
Ki-67 antigen is essential for cell proliferation and has therefore been widely 
used as a proliferation marker. It is a protein doublet, consisting of 345 and 395-kDa 
proteins and it accumulates in the cell nuclei from G1 to mitosis, after which is rapidly 
dissociated.262 Ki67 expression, assessed by MIB-staining is a most valuable approach 
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to assess epidermal proliferation263 and we used this marker to investigate the efficacy 
of selected treatments on ICD in the present thesis.
1.3.4.2 Epidermal differentiation
A set of monoclonal antibodies directed against several cellular markers for 
keratinocyte differentiation was selected:
Cytokeratin 16
Keratinocytes in the basal layer of the epidermis express cytokeratin 5, 14 
and a variable amount of cytokeratin 15. In contrast, in suprabasal compartment 
cytokeratins 1, 2, 10 and 11 are expressed. In hyperproliferative epidermis cytokeratin 
6 and 16 are expressed.264 Cytokeratin 16 is found in hyperproliferative skin but also 
in damaged and recovering skin and is thought to be associated with disturbance of 
the epidermal integrity.265-267
In this thesis, the monoclonal antibody that was used is LL025, that is specific 
for the expression of cytokeratin 16.268
Involucrin
The corneocytes possess an envelope of cross-linked proteins surroundings 
a network of keratins. Involucrin is a soluble cytoplasmic protein precursor which 
is synthesised in the stratum granulosum and is cross-linked in the SC under 
influence of the enzyme transglutaminase. It has been demonstrated that involucrin 
is a precursor in the early phase and loricrin in the late phase in the formation of the 
cornified envelope.269 Immunohistochemical studies show upregulation of involucrin 
expression in the suprabasal compartment of the epidermis in numerous skin 
conditions, characterised by impaired barrier function.50;270;271
In this thesis we used well-characterized monoclonal antibody MON-150 to 
study the expression of involucrin.272
1.3.4.3 Langerhans cells
Langerhans cells (LCs) initiate T-cell-dependent immunity against foreign 
antigens. It has been postulated that epidermal exposure to any penetrating substance 
activates the local LC system, including antigen uptake and presentation. Interestingly, 
the epidermal LCs density also correlates with the integrity of the permeability 
barrier. Barrier disruption with tape stripping, SDS, acetone lead to an increase of 
epidermal LCs and the level of increase correlates with the extent of impairment of the 
permeability barrier. Immunohistochemical studies show that LCs are usually located 
in suprabasal cell layers. The dendrites of the LCs are orientated mainly towards the 
stratum granulosum. Using monoclonal antibodies DAKO-T6 (1:100, DAKO A/S, 
DENMARK), we made an analysis of the presence of LCs.
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1.3.4.4 Epidermal Fatty Acid Binding Protein (E-FABP)
E-FABP belongs to a family of low molecular mass (14-15kDa) proteins. In 
1993, epidermal type FABP (E-FABP) with a high affinity for C-18 fatty acid has 
been characterised in human epidermis.48 It is assumed that E-FABP is involved in the 
transport of fatty acids which play an important role in the epidermis at the structural 
and the functional level.273 For detailed description see page 16. A polyclonal rabbit 
antiserum against E-FABP used in this thesis was prepared as previously described.49
1.3.4.5 Host defense proteins
To investigate the expression of host defense molecules we examined 3 
antimicrobial proteins: SKALP, SLPI and MRP8. For detail description see pag 8. The 
dual function proteins SLPI and elafin were stained using polyclonal antibodies that 
we have previously generated. MRP8 was stained with a polyclonal rabbit antiserum, 
kindly provided by dr P. Madsen. Arhus, Denmark.
42
Chapter 1
43
General Introduction
1.4 AIMS AND QUESTIONS OF THIS THESIS
I. To expand the information on the water barrier of the epidermis with respect 
to lipid metabolism
▪ What is the expression of an epidermal fatty acid carrier in skin conditions 
with impairment of barrier function? Can we find evidence for the role of 
this carrier in skin barrier repair?
II. To study the antimicrobial properties of epidermis in inflammmatory skin 
disorders
▪ Are there differences in expression of epidermal host-defence proteins 
between psoriasis and atopic dermatitis?
III. To investigate novel therapies on irritant contact dermatitis (ICD) focusing 
on the improvement of water barrier impairment 
▪ What is the effect of the phosphodiesterase-4 inhibitor (cipamfylline), 
introduced as a new anti-inflammatory modulator, on experimentally 
induced ICD?
▪ What is the effect of topical skin related lipids on experimentally induced 
ICD?
▪ Can we confirm superiority of topical skin related lipids in skin disorders 
with impaired barrier dysfunction? 
IV. Clinical aspects and topical treatment of dithranol irritation as an unique 
form of ICD
▪ What is the optimal treatment of dithranol induced ICD?
▪ Adaptation as a clinical phenomenon in dithranol irritation
▪ Is dithranol-induced skin irritation correlated with clinical outcome? 
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2.1 LACK OF UPREGULATION OF EPIDERMAL FATTY ACID 
BINDING PROTEIN (E-FABP) IN DITHRANOL INDUCED 
IRRITATION
Abstract
The exact role of epidermal fatty acid binding protein (E-FABP) in skin is 
unknown. A restoration of barrier function may be associated with an upregulation of 
E-FABP. Moreover, E-FABP is upregulated in a variety of cells in response to oxidative 
stress. A recent observation that dithranol induced irritation is not associated with 
skin barrier impairment prompted us to investigated the expression of E-FABP in this 
skin condition to elucidate the unknown function of this protein in skin.
This study shows lack of E-FABP upregulation after a single application of 
dithranol on uninvolved skin of patients with psoriasis. The lack of expression of E-
FABP in dithranol irritation correlates with the unimpaired skin barrier function as 
assessed by measurements of TEWL. 
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Introduction
E-FABP has been characterized as a molecule with a molecular weight of 15 
kDA. It is a member of the mammalian intracellular lipid binding protein family (LBP), 
which plays a variety of roles in intracellular fatty acid, retinoid, bile acid and sterol 
trafficking.1 The function of E-FABP in skin has not been elucidated. It is assumed 
that this protein is involved in the transport of fatty acids (FA) which are the most 
important substrates for (1) energy production, (2) formation of phospholipids, i.e the 
maintenance of membrane lipid structures and (3) participation in signal transduction 
pathways.2 The upregulation of E-FABP expression is associated with a continuous 
high fatty acid transport, needed for the restoration of barrier function.3 A study on 
the cell biological alterations during irritant contact dermatitis strongly suggested that 
E-FABP expression is upregulated after barrier disruption.4 However, its function 
only with the respect to skin barrier has been questioned.5;6 The upregulation of the 
E-FABP gene expression in response to oxidative stress and the generation of reactive 
oxygen species has been shown in a variety of cell types.1
The expression of E-FABP in dithranol irritation has not been studied 
before. Dithranol-induced irritation is an unique type of skin irritation. It is caused 
by anthralin free radicals and oxygen radicals.7 Remarkably, a single application 
of dithranol which induces skin irritation, does not compromise the skin barrier as 
assessed by measurement of transepidermal water loss.8 
The aim of the present study was to investigate the expression of E-FABP in a 
well-established model of free radical induced skin irritation. 
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Material and methods
Subjects
Nine patients with chronic stable psoriasis participated in the study (5 females, 
4 males, age range 50-70 years, the mean of age 55,7 years). They had no history of 
other skin disease. None of the patients used any systemic medication. Permission 
of the Ethical Committee and written informed consent from all volunteers were 
obtained. The experiment was conducted from May to June 2002.
Application of dithranol
The dithranol 2% cream (dithranol 69g, cetiol V 660g, cetomacrogol wax 
450g, liquid petrolatum 450g, salicylic acid 30g, sorbic acid 4,5g, ascorbic acid 1,5g, 
demineralised water up to 3000g) was applied once on one selected site of 2 cm Ø 
of uninvolved skin of lower back of patients with psoriasis. The application time 
was 1 hour, after which the dithranol cream was removed with water. This model of 
dithranol irritation was already described and used before.9 Patients were not allowed 
to use any topical medication on the investigated site during the study.
Immunohistochemical assessment
A total of 18 punch biopsies (3 mm diameter) were taken from the investigated-
sites of nine patients after visual reading and TEWL measurements at 48 hours and 
at day 10. After 4 h fixation in formalin the samples were stored in alcohol 70% 
until embedding in paraffin was done. Then the samples were sectioned at 6 μm for 
immunohistochemical staining. The slides were deparaffinized by incubation in a 
histosafe for 2 times 15 minutes, followed by dipping in an ethanol series from 100% 
to 50%. After washing in phosfate-buffer saline (PBS) the sections were pre-incubated 
with normal goat serum (20%) for 15 minutes. Then all sections were incubated for 60 
minutes with the anti-E-FABP (kindly provided by dr. Siegenthaler10) at the dilution 
of 1:100. After washing with PBS, sections were incubated for 30 minutes with 
biotinylated goat-anti-rabbit IgG (dilution 1:200). Another washing step with PBS 
was carried out, and then complexes were formed between biotin and avidin using 
the Vectastain Elite ABC peroxidase kit, according to the manufacturer’s instructions 
(Vector Laboratories, Burlingame, USA). Sections were developed with amino-
ethylcarbazol. All sections were subsequently counterstained with hematoxylin 1%.
Evaluation
Visual scoring. 
The clinical changes at the exposure sites were scored after 48 hours and after 
10 days and rated as follows: 0 = no erythema, 1 = minimal erythema, 2 = moderate 
erythema, 3 = marked erythema and 4 = marked erythema with oedema.
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Transepidermal water loss measurements
TEWL measurements were performed using an evaporimeter (Tewameter 
TM 210, Courage and Khazaka, Koln, Germany). Measurement were performed 
according to the guidelines described by the Standardisation Group of the European 
Society of Contact Dermatitis.11 Room temperature was kept between 20 and 22 °C 
and relative humidity between 40 and 56%. TEWL measurements were performed 
before exposure on day 0 and at 48 hours and at 10 days after exposure to dithranol. 
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Results
Visual assessment and transepidermal water loss measurements
Table 1 summarises the visual scores (mean ± SEM) and the TEWL (mean 
± SEM) measurements following dithranol application (n=9). All patients clearly 
developed erythema after 48 hours of dithranol application which was also observed 
at day 10. In none of the patients oedema or vesicle formation was seen and no 
complains of pain or itching were reported. The baseline values of TEWL of the 
uninvolved skin of psoriatic patients were comparable to the values of the healthy 
skin as reported in the literature.12 There was no significant increase in TEWL at 48 
hour and at 10 days compared to baseline.
The expression of E-FABP
Following single application of dithranol on uninvolved psoriatic skin 
(n=9), strong cytoplasmic staining in the stratum granulosum and the upper spinous 
layer was observed at 48 hours and at 10 days.(Figure 1a) This pattern of E-FABP 
expression is the same as in normal skin (Figure 1b).5 The staining of the untreated 
lesional psoriatic skin that we used as a positive control, showed the expression of this 
protein in all suprabasal cells (Figure 1c) as already observed before.3 No staining 
was observed with the pre-imune serum in normal human skin.
Table 1 Transepidermal water loss (g/m²/h; mean ± SEM) en erythema score (mean 
± SEM) following a single application of dithranol 2% after 48 hours and 10 days. 
(n=9)
TEWL (mean ± SEM) Erythema (mean ± SEM)
Baseline 6,7 ± 1,3 0
48 hours 6,1 ± 0,7 1,7 ± 0,2
10 days 6,6 ± 0,9 1,4 ± 0,2
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Figure 1 Immunohistochemical 
expression of E-FABP. Following 
single application of dithranol, 
cytoplasmic staining in the stratum 
granulosum and the upper spinous 
layer was observed (a) This pattern 
of E-FABP expression is the same as 
in normal human skin (b), whereas 
untreated lesional psoriatic skin 
demonstrated E-FABP expression in 
all suprabasal cells (c).
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Discussion
The expression of epidermal fatty acid binding protein (E-FABP) was 
studied in dithranol induced irritation of uninvolved skin of psoriasis patients using 
immunohistochemical methods. In the present study, after a single application of 
dithranol, we observed a pronounced erythema after 48 hours in line with other 
studies.13-15 As observed also in a previous study8, dithranol did not increase TEWL 
indicating that single application of dithranol does not compromise the skin barrier. 
After dithranol application, we observed epidermal expression of E-FABP equal to 
normal human skin. These results show that the expression of E-FABP in dithranol 
irritation correlates with a normal function of the skin. The upregulation of E-
FABP has been observed in skin conditions associated with the impairment of skin 
barrier like sodium dodecyl sulphate induced skin irritation4, psoriasis3 and atopic 
dermatitis (unpublished data). Furthermore, delayed recovery of TEWL after acetone 
application to the skin of E-FABP-deficient mice has been reported.16 All these studies 
demonstrate that the role of E-FABP is associated with maintaining of the skin barrier 
function although the exact mechanism for this function of E-FABP remains to be 
further elucidated. In contrast, the presence of E-FABP in the non-keratinized oral 
mucosa epithelium and its expression in tissues other than skin suggests that the role 
of E-FABP is not restricted to the skin barrier alone. Our finding that in dithranol 
irritation the epidermal barrier function and E-FABP expression is normal, suggests 
that increase E-FABP expression is linked to barrier function rather than to skin 
irritation.
Recently, a new function of E-FABP as an antioxidant protein has been 
reported.1 E-FABP was identified as a molecular target for 4-Hydroxynonenal (4-
HNE). 4-HNE is the most cytotoxic unsaturated aldehyde that is produced by lipid 
peroxidation that occurs in response to oxidative stress.17 The identification of E-
FABP as a target molecule for a well known end-product of lipid peroxidation could 
indicate that the E-FABP functions as an antioxidant protein by scavenging reactive 
lipids.1 E-FABP is found in cells exposed to high oxidative stress, including the 
retina, lens, lung and tongue.18 The skin is also particularly vulnerable to the oxidative 
stress due to (i) its constant exposure to high oxygen tension, and (ii) the presence of 
considerable amounts of polyunsaturated fatty acid. 19 20 Indeed, E-FABP is observed 
to be upregulated in the skin conditions associated with oxidative stress.21-24Also 
dithranol-induced skin irritation is strongly suggested to be caused by the generation 
of dithranol free radicals and oxygen radicals.25 There is some evidence, that the 
release of active oxygen species from dithranol could initiate lipid peroxidation in 
cellular membranes of the skin. Firstly, dithranol slightly elevates lipid peroxidation in 
mouse skin after topical application, demonstrated by the exhalation of ethane, which 
is produced from gamma-3 polyunsaturated fatty acids26 and by malondialdehyde 
production.27 In addition, singlet oxygen can accelerate lipid peroxidation by directly 
reacting with unsaturated fatty acyl moieties to give hydroperoxides, which was also 
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already demonstrated for dithranol.28 Thus the peroxidative damage to membrane 
lipids after dithranol application is generally believed to be related to its antipsoriatic 
action as well as induction of skin irritation.25;29 Interestingly, the presumed generation 
of free radical following dithranol application does not cause the induction of a 
protective endogenous mechanism such as enhanced expression of E-FABP. 
In the context of oxidative stress, the lack of upregulation of E-FABP 
observed in this study may be due to some reasons. Although 4-HNE was found to 
be responsible for the damaging effects associated with lipid peroxidation in various 
tissues17 including skin,30-33 there are no studies demonstrating that 4-HNE is generated 
by dithranol-induced lipid peroxidation and therefore the enhanced expression of E-
FABP as a target for 4-HNE is not observed. The scavenging of the 4-HNE by other 
skin antioxidant systems like glutathione S-transferase22 or superoxide dismutase34 35, 
both observed to be modified after dithranol application, should be considered. 
In conclusion, in this study the lack of upregulation of the expression of E-
FABP in dithranol irritation correlates with the lack of skin barrier dysfunction as 
assessed by measurements of TEWL, suggesting a role for E-FABP in the maintenance 
of the skin barrier. 
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2.2 EPIDERMAL EXPRESSION OF EPIDERMAL FATTY ACID 
BINDING PROTEIN (E-FABP) DISTINGUISHES ATOPIC 
DERMATITIS FROM PSORIASIS VULGARIS
Abstract
Psoriasis vulgaris (PV) and atopic dermatitis (AD) can usually be clearly 
differentiated. Chronic lesions in atopic dermatitis, however, may sometimes be very 
similar to psoriasis clinically and/or histologically. Various features of psoriatic 
lesions such as increased proliferation rates and altered keratinocyte differentiation 
can be found in chronic AD lesions as well. Here we studied the expression and 
localization of epidermal fatty acid binding protein (E-FABP) also known as psoriasis 
associated fatty acid binding protein (PA-FABP) in chronic AD lesions, and compared 
this with the known expression pattern in chronic PV lesions. E-FABP was highly 
upregulated in both diseases compared to normal skin, but the pattern was markedly 
different. In psoriatic epidermis the entire suprabasal compartment was strongly 
positive, whereas in AD the upper layers of the stratum spinosum were positive 
while the intensity of the staining gradually decreased towards the basal layer. No 
significant differences were found between PV and AD epidermis with respect to 
cellular proliferation (Ki-67 expression). Although the biological significance of this 
difference is not clear at present, our findings suggest that expression of this protein 
might be useful in the differentiation between AD and PV.
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Introduction
Psoriasis vulgaris (PV) and atopic dermatitis (AD) are two well-defined entities, 
which usually can be differentiated clinically.1-3 If the clinical expression is indefinite, 
histology may help. The spongiform pustules of Kogoj and Munro microabscesses, in 
typical cases confluent parakeratosis, suprapapillary thinning and hyperplasia of the 
rete ridges are diagnostic for psoriasis.1 The most characteristic histological features 
of atopic dermatitis are spongiosis, irregular epidermal thickening with accentuation 
of the rete pattern, and a partially parakeratotic and orthokeratotic epidermis.4 These 
histological features are most apparent in acute AD lesions. In chronic lesions like 
e.g. on the palmar side of the hands clinical distinction may be difficult. Histological 
differentiation may also be difficult and sometimes impossible, since in chronic AD 
and PV lesions typical diagnostic histological features may be missing. In chronic 
AD parakeratosis can be found while spongiosis may be lacking. Psoriasiform 
hyperplasia is invariably present with a sparse superficial perivascular lymphocytic 
infiltrate.5 Because the histopathology based on H&E staining is often not helpful in 
cases of uncertain clinical diagnosis, new immunohistochemical markers could be 
useful for differentiation. The epidermis of the psoriatic lesion shows a vast number of 
changes.6 These changes can be visualized by immunohistochemical staining with Ki-
67, a marker for proliferation, and with markers for differentiation-associated proteins 
such as involucrin7, filaggrin8 and transglutaminase.9 In normal skin the expression 
of these markers is restricted to the stratum granulosum. In contrast, involucrin and 
transglutaminase are strongly upregulated in psoriasis, whereas filaggrin is often 
diminished or absent. 
Epidermal fatty acid binding protein (E-FABP) also known as psoriasis 
associated fatty acid binding protein (PA-FABP) was originally described to be 
upregulated in psoriatic epidermis. It is assumed that E-FABP is involved in the 
transport of epidermal lipids with high affinity for C - 18 fatty acids (FA) which play 
an important role in the epidermis at the structural and the function level.10;11 Since 
marked differences in lipid composition of stratum corneum in both diseases has 
been decribed12-14, E-FABP is an interesting molecule to study because this protein is 
involved in distinct pathways of abnormal lipid metabolism. The aim of this study was 
to compare the expression of E-FABP in AD and PV. E-FABP was highly upregulated 
in both diseases compared to normal skin, but the pattern was markedly different. 
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Material and methods
Subjects
Nine patients (5 male and 4 females, mean age 48.1 years, age range 27-68) 
with clinical diagnosis of moderate to severe plaque psoriasis and ten patients (3 male 
and 7 females, mean age 33.8 years, age range 17- 54) with clinical diagnosis of 
moderate to severe atopic dermatitis participated. None of patient received systemic 
therapy, UVB therapy or topical corticosteroids at the time of biopsy taking. Punch 
biopsies were taken from chronic psoriasis plaques and from subacute to chronic 
atopic dermatitis lesions. Care was taken to exclude acute lesions with vesicles. 
Permission of the medical ethical committee and written informed consent of all 
patients were obtained.
Histological methods
Biopsies were fixed in buffered 4% formalin for 4 hours and processed 
for routine histology. Tissues were embedded in paraffin and 5-µm sections were 
cut. Sections were stained with haematoxylin-eosin (H&E) or processed for 
immunohistochemical staining using an indirect immunoperoxidase technique with 
avidin biotin complex enhancement. We studied epidermal proliferation with an 
antibody directed against the Ki-67 antigen (MIB-1, Immunotech, SA, Marseilles, 
France). Anti-E-FABP serum was obtained as previously described.6 Paraffin section 
were deparaffinised, rehydrated and immunostaining was performed. An indirect 
peroxidase technique was used for staining with the antiserum against E-FABP. 
First, the section was pre-incubated with normal swine serum and then incubated 
with anti E-FABP staining at a dilution of 1:100 for 60 min. After incubation with 
peroxidase-conjugated swine-anti-rabbit Ig, the sections were developed with amino-
ethylcarbazol as the chromogenic substrate.
For staining of the Ki-67 antigen sections were pre-incubated with normal 
horse serum. Subsequently, slides were incubated with anti-Ki-67 antibodies in a 
dilution of 1:50 for 60 minutes. After incubation with biotinylated horse-anti-mouse 
IgG (dilution 1: 200) for 30 minutes, complexes were formed between biotin and 
avidin using the Vectastain Elite ABC peroxidase kit. The sections were developed 
with metal-enhanced diaminobenzidin as the chromogenic substrate.
Histological grading
Epidermal proliferation was measured by counting the number of Ki-67 
positive nuclei per mm length of the section. E-FABP staining in the epidermis 
was assessed using a five-point scale: 0=no staining, 1=sporadic staining, 2=weak 
staining, 3=moderate staining, 4=pronounced staining.
Statistical analysis
The Mann-Whitney U-test was used for statistical analysis. Differences with P 
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values <0.05 were considered statistically significant. 
Table 1 Mean value of the marker for epidermal proliferation and EFABP ± SEM. 
Antigen Psoriasis Atopic dermatitis p-value
E-FABP 3.8 ± 0.15 2.1 ± 0.18 < 0.001
Ki-67 89 ±16.0 85 ±10.3 Not significant
E-FABP staining was assessed using a five-point scale: 0=no staining,1=sporadic staining, 2=weak 
staining, 3=moderate staining, 4=pronounced staining. Ki-67 staining was measured by counting 
the number of positive nuclei per mm length of the section.
� �
� �
� �
� �
Figure 1 H&E staining of atopic 
dermatitis lesion (a) and psoriasis 
lesion (b). Immunohistochemical 
localisation od E-FABP in atopic 
dermatitis (c,e) and psoriasis (d,f). 
Note the differences in localisation 
and staining intensity between 
atopic dermatitis and psoriasis. 
Epidermal proliferation as assessed 
by Ki-67 of atopic dermatitis lesions 
(g) and psoriatic lesion (h). 
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Results
Histopathology (Figure 1a,b)
We examined the following histological features of the epidermis in both 
diseases: parakeratosis, orthokeratosis, spongiosis, elongated rete ridges, acanthosis 
and the presence of neutrophils in the SC. Histological examination confirmed that 
AD lesions were of the chronic/subacute type. Parakeratosis was found in all patients 
and in 7/10 AD lesions mostly with a patchwise distribution. Orthokeratosis was 
found in 9/10 AD lesions and 6/9 PV lesions. Spongiosis was clearly present in 
10/10 AD lesions, but was also found in 7/9 PV lesions, although less pronounced. 
Microabcesses with neutrophils were found in 6/9 PV lesions, but in none of the AD 
lesions. Acanthosis was found in all lesions of both diseases. Uniform elongation of 
rete ridges was observed in 6/9 of PV lesions. In AD lesions irregular elongation of 
rete ridges was found. 
Immunohistochemical staining
Semiquantitative data on the staining pattern of Ki-67 (a measure of 
proliferating cells) and E-FABP are presented in Table 1. We observed similar 
patterns of Ki-67 in PV and AD (Figure 1g-h), indicating that in both diseases the 
basal layers of the epidermis were in a hyperproliferative state. We found marked 
differences in intensity and distribution in E-FABP expression between PV and 
AD lesions. In lesional psoriatic skin the well-known pattern of a strong, uniform, 
cytoplasmic E-FABP staining was found in all suprabasal layers of the epidermis, the 
basal layer being completely negative. (Figure 1d,f) In AD lesions the expression 
of E-FABP was increased compared to normal skin and restricted to the stratum 
granulosum. In all AD lesions we found strong staining of the stratum granulosum 
and upper spinous layers, which gradually decreased in intensity towards the basal 
layer. The first suprabasal layers of AD lesions were invariably negative for E-FABP 
in contrast to PV lesions (Figure 1c,e).
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Discussion
We studied the expression of E-FABP in AD and PV. In normal epidermis E-
FABP expression is restricted to trace amounts in the granular layer, but is strongly 
upregulated in psoriatic epidermis15;16. We observed an increased E-FABP expression 
in AD compared to normal skin and we found significant differences in expression 
between AD and PV as well, although the pattern of expression differed. In contrast 
to psoriasis, we observed a diffuse pattern of expression decreasing in intensity to the 
deeper layers. The first suprabasal layers were negative. We did not find differences 
in the number of cycling cells between AD and PV indicating that the expression of 
E-FABP does not unconditionally correlate with epidermal proliferation. We conclude 
that E-FABP expression in lesional skin may discriminate AD from PV.
The interpretation of these differences is limited by the unknown function 
of E-FABP. The animal model of E-FABP deficient mice could be helpful in 
understanding its specific function, however E-FABP deficient mice show normal 
development without metabolic disorders. Apparently other members of the FABP 
family like e.g. H-FABP compensate for the E-FABP deficiency.17 It is assumed that 
E-FABP is involved in the transport of fatty acids (FA) which play an important role 
in the epidermis at the structural and the function level.15 FA are important for energy 
production, phospoholipid formation and signal transduction.18 FA are poorly soluble 
in water and therefore binding to proteins is required to increase solubility. Within 
cells, E-FABP binds FA and has a particularly high affinity to C-18 fatty acids like 
linoleic acid. Therefore, E-FABP may be involved in intracellular FA transport. In 
psoriasis a decrease of free FA has been reported. It is attractive to speculate, that the 
strong over-expression of E-FABP in psoriatic epidermis represents a compensatory 
mechanism to repair this defect. This decrease in free FA appears to be a distinctive 
biochemical feature of psoriasis.19;20 Lesional atopic skin is also characterised by 
changes in the epidermal barrier lipids, but systematic data in FA (i.e. linoleic acid) 
are scarce and controversial. Mustakallio et al. found increased levels of free FA in 
affected atopic epidermis.21 In contrast, in dry non-eczematous atopic skin, the total 
amount of free FA is significantly decreased.22 Recent data show that the total amount 
of free FA is unchanged in lesional skin, but the amount of free very long chain fatty 
acids (>24-C) was remarkably reduced.23
There is a close relationship between lipid metabolism and keratinocyte 
differentiation.24 We speculate that the upregulation of E-FABP in lesional psoriasis 
skin is directly a consequence of prominent epidermal changes characterised by 
hyperproliferation and abnormal differentiation. In atopic dermatitis the upregulation 
of E-FABP may be the result of disease-specific changes in lipid metabolism since 
abnormal lipid composition and changed levels of enzymes involved in lipid 
metabolism are already present in the uninvolved skin.12;25-28 Nevertheless, further 
research on FA metabolism in both diseases is required to confirm this hypothesis.
We conclude that over-expression of E-FABP is associated with both AD 
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and PV lesional skin, however in two different ways. Differences in epidermal lipid 
metabolism in lesional skin may account for the difference. Since the metabolism 
of fatty acid in epidermis of both diseases is not exactly clarified, it is difficult to 
speculate about the metabolic pathways of this epidermal fatty acid carrier. Whether 
the findings of this study can be used to differentiate both diseases when clinical and 
histological findings fail to do so, requires further study.
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3.1 SPECIFIC UPREGULATION OF EPIDERMAL HOST-
DEFENCE PROTEINS IN PSORIASIS COMPARED TO ATOPIC 
DERMATITIS
Abstract
Recently it was shown that lesional epidermis of atopic dermatitis patients 
expresses low levels of the antimicrobial peptides LL-37 and β-defensin-2, compared 
to psoriasis patients. Here we have investigated whether this is a general phenomenon 
for host defence proteins, and how specific it is for this class of molecules. Using 
immunohistochemistry, we examined chronic lesions of atopic dermatitis and psoriasis 
patients with respect to epidermal expression of SKALP/elafin, SLPI and MRP-8, 
three proteins associated with a broad spectrum of biological activity in cutaneous 
host defence. In addition, we examined markers of normal differentiation (involucrin) 
and other markers of the activated/hyperproliferative epidermal phenotype such 
as cytokeratin 16 and Ki-67. We found that chronic lesions of psoriasis and atopic 
dermatitis patients are remarkably similar with respect to cellular proliferation 
(Ki-67 staining) and expression of structural proteins (cytokeratin 16, involucrin). 
In contrast, the dual-function host defence proteins SLPI and SKALP/elafin, which 
have antiproteinase and antimicrobial properties, were found to be strongly expressed 
throughout the stratum spinosum of psoriasis lesions. In atopic dermatitis lesions we 
found only weak, mostly patchy expression of SLPI and SKALP/elafin. MRP8 was 
continuously expressed in the epidermis of both diseases, but staining intensity was 
weaker in atopic dermatitis than in psoriasis. We conclude that psoriatic epidermis 
expresses high levels of host defence proteins compared to atopic dermatitis epidermis, 
and this phenomenon appears to be specific for these proteins as several other 
markers for epidermal activation showed no differences. It remains to be investigated 
whether the difference in expression of these epidermal proteins is caused by genetic 
polymorphisms in cutaneous stress response pathways, or induced by differences in 
the cellular infiltrate in psoriasis compared to atopic dermatitis.
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Introduction
The stratum corneum of normal human epidermis is a crosslinked structure 
of insoluble proteins and lipids and as such represents a barrier against invasion 
by microbial agents. In addition to this physical barrier, human keratinocytes 
express a number of molecules that are part of the innate immune system and 
participate in recognition of “microbial non-self” and subsequent killing of invading 
microorganisms.1 Some of the toll-like receptors (TLR), which are involved in 
recognition of conserved microbial patterns, were recently demonstrated in human 
epidermis.2 The skin appears to be a particularly rich source of effector molecules 
as many proteins with bactericidal or bacteriostatic properties are constitutively or 
inducibly expressed in human epidermis. These include human β-defensin (hBD)-1, 
2, 3 and 4, secretory leukocyte proteinase inhibitor (SLPI), LL-37, SKALP/elafin, 
dermcidin, calprotectin and cystatin A.3-6 Serial analysis of gene expression (SAGE) 
on cultured keratinocytes or human skin biopsies has revealed that some of these 
molecules are found at high levels of expression.7 There is evidence from genetic 
studies in mice that these molecules are vital for maintaining epidermal integrity.8;9 
Elafin, LL-37, hBD-2 and calprotectin are not normally present in human epidermis 
but are highly induced upon barrier disruption or chronic inflammation such as in 
the skin disease psoriasis. In psoriasis the on-switch of these genes appears to be 
part of a stress response also referred to as regenerative maturation, which includes 
hyperproliferation and induction of marker genes such as cytokeratin (CK) 6, 16 and 
17 and psoriasin.
Psoriasis vulgaris and atopic dermatitis are two distinct clinical entities 
characterised by various different histological features depending on the stage of the 
lesion. These histological characteristics are most apparent in fully developed acute 
lesions. In the chronic phase of the disease the histopathological differences are less 
pronounced and both diseases are characterized by acanthosis and a mononuclear 
infiltrate. A striking difference is the high frequency of bacterial colonization 
of non-lesional atopic dermatitis skin and recurrent skin infections by bacterial, 
fungal and viral pathogens in lesional atopic dermatitis skin.10 In contrast, a large 
epidemiological study on disease concomitance in psoriasis revealed that psoriasis 
patients have an increased resistance to bacterial infections compared to controls and 
atopic dermatitis patients.11 Recently, a study was published showing that expression 
levels of two antimicrobial proteins hBD-2 and LL-37 are significantly decreased 
in lesional atopic dermatitis epidermis compared to lesional psoriatic epidermis.12 It 
was speculated that a relative deficiency in expression of innate immunity genes in 
atopic dermatitis patients could account for the susceptibility to skin infection with 
Staphylococcus aureus. Here we addressed the following two questions: (1) Is the 
difference in expression of host defence genes between psoriasis and atopic dermatitis 
patients a general phenomenon?, In other words: are all known host defence genes 
overexpressed in psoriasis? (2) How specific is the observed difference? In other 
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words: is expression of genes not involved in host defence also altered? We therefore 
compared the presence of elafin, SLPI and MIF-related protein 8 (MRP8) in biopsies 
from psoriasis and atopic dermatitis patients. Although the presence of these 
molecules has been demonstrated in psoriasis, no systematic comparison has been 
made sofar.5;13 Elafin and SLPI, originally discovered as inhibitors of leukocyte serine 
proteinases14;15, have antimicrobial activity against a variety of microorganisms.4;16 
MRP8 is a S100 Ca++-binding protein that forms the heterodimeric calprotectin 
complex together with MRP14. Calprotectin is active against C.albicans and 
intracellular bacteria presumably via binding of Zn++ ions.17 Our data indicate that 
in psoriasis and atopic dermatitis, expression patterns of these proteins are different 
as shown by immunohistochemistry; other established markers of the regenerative 
phenotype (Ki-67, involucrin, CK16) show equal distribution and expression levels.
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Materials and Methods
Subjects
The study participants included 9 patients with a clinical diagnosis of moderate 
to severe chronic plaque psoriasis (5 male and 4 females, mean age 48,1, range 27-
68) and 10 patients with clinically moderate to severe atopic dermatitis (3 male and 
7 females, mean age 33,8, range 17- 54). All patients were eligible for systemic 
treatment, UVB-treatment or hospitalisation. None of the patients received systemic 
therapy or UVB-therapy at the time of biopsy taking. Punch biopsies were taken from 
chronic psoriasis plaques and from subacute to chronic atopic dermatitis lesions. Care 
was taken to exclude acute lesions or lesions with crusts or vesicles. Biopsies from 
normal skin were obtained from healthy volunteers. The study was approved by the 
medical ethical committee and all patients gave written informed consent. 
Histological methods
Biopsies were fixed in buffered 4% formalin for 4 h and processed for routine 
histology. Tissues were embedded in paraffin and 5- m sections were cut. Sections 
were stained with haematoxylin-eosin (H&E) or processed for immunohistochemical 
staining using an indirect immunoperoxidase technique with avidin biotin complex 
enhancement. For the immunohistochemical stainings a panel of monoclonal and 
polyclonal antibodies was used: an antibody directed against the Ki-67 antigen was 
used to investigate epidermal proliferation, (MIB-1, Immunotech, SA, Marseilles, 
France). To assess epidermal differentiation we used monoclonal antibodies 
against involucrin (MON-150), cytokeratin 16 (LL025, Novocastra Laboratories 
Ltd, Newcastle upon Tyne, UK). The dual function proteins SLPI and elafin were 
stained using polyclonal antibodies that we have previously described.5 MRP8 was 
stained with a polyclonal rabbit antiserum, kindly provided by dr P.Madsen, Aarhus, 
Denmark.
Grading of immunohistochemical staining
Epidermal proliferation was measured by counting the number of Ki-67 
positive nuclei per mm, by an observer who was unaware of the patient history 
(average of 3 measurements per section). Expression of elafin, SLPI, involucrin, 
CK16 and MRP8 was assessed in two ways. First the distribution was scored on a 
3 point scale: 0: absent, 1: patchy, 2: continuous. All markers with the exception of 
SLPI and elafin showed a continuous distribution in all samples studied. An additional 
parameter was the positively stained area of the epidermis, which was assessed by 
calculating the average ratio of positive cell layers/total cell layers of the epidermis 
between two dermal papillae (mean of 3 measurements). 
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Results
Histopathology
Biopsies taken from chronic lesions of both patient groups were analysed for 
parakeratosis, orthokeratosis, spongiosis, elongated rete ridges, acanthosis and the 
presence of neutrophils. Histology confirmed that atopic dermatitis lesions were of 
the chronic/subacute type. Acanthosis and elongation of rete ridges was observed 
in nearly all biopsies. Regular elongation of rete ridges, however, was found in 6/9 
psoriasis patients and in none of the atopic dermatitis patients. Parakeratosis was 
found in all psoriasis patients, and in 7/10 atopic dermatitis patients mostly with a 
patchwise distribution. Spongiosis was clearly present in 10/10 atopic dermatitis 
patients, but was also found in 7/9 psoriasis patients, although less pronounced. 
Microabcesses with neutrophils were found in 6/9 psoriatic patients, but in none of 
the atopic dermatitis patients. 
Host defence proteins 
To investigate if overexpression of host defence molecules as reported for 
hBD-2 and LL-37 is a general phenomenon, we examined 3 other antimicrobial 
proteins: elafin, SLPI and MRP8. SLPI staining in normal skin revealed a weak 
presence in the stratum granulosum (Figure 1a), whereas in psoriasis a strong 
staining throughout the upper layers of the stratum spinosum was found (Figure 1c). 
In epidermis of atopic dermatitis patients SLPI staining was variable (Figure 1b). 
In some biopsies it showed a discontinuous distribution and in others it resembled 
normal skin. In some cases a few layers of the stratum spinosum were stained. Semi-
quantitative scoring for distribution and intensity indicated a significant difference 
between the two diseases (see Table 1). Elafin was absent in normal human epidermis 
(Figure 1d) but is highly expressed in psoriatic epidermis as shown in Figure 1f. In 
the epidermis of atopic dermatitis patients we observed a similar pattern as found 
for SLPI; the distribution was often discontinuous, and the intensity as measured by 
the ratio of positive cell layers over the total number of cell layers was significantly 
different between the two diseases (Figure 1e and Table 1). Staining for MRP8 was 
absent in normal skin (Figure 1g) but showed a continuous staining of the suprabasal 
compartment in both diseases (Figures 1h and 1i). Staining intensity, however, was 
more intense in psoriasis, and often extended to the first suprabasal layer (Figure 1i). 
The difference was of borderline significance (Table 1).
Differentiation related proteins
We now asked whether other epidermal proteins that are not known to 
be associated with host defence showed similar patterns. The structural protein 
involucrin is present in the stratum granulosum of normal epidermis (not shown), and 
is highly expressed throughout the stratum spinosum of psoriatic epidermis (Figure 
2b). Figure 2a and 2b show that the staining pattern is similar between psoriasis and 
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atopic dermatitis. No significant difference was found (Table 1). The cytoskeletal 
protein CK16 is absent from normal epidermis (not shown) but is highly induced 
in psoriasis as shown previously by others. As such it has been one of the earliest 
recognized markers for the regenerative differentiation pathway in epidermis. Figure 
2 and Table 1 show that there is no significant difference in CK16 staining between 
the two diseases. 
Epidermal proliferation
It could be argued that the observed difference in expression level of host 
defence proteins is a consequence of gross differences in epidermal structure, the 
number of cell layers or proliferative status of the tissues. Although histopathological 
differences exist, features such as parakeratosis, acanthosis and spongiosis were 
observed in both conditions (see above). To investigate cellular proliferation we 
performed Ki-67 staining which is a marker for cycling cells. Figures 2e and 
SLPI
Elafin
MRP8
Normal skin Atopic dermatitis Psoriasis
Figure 1 Kucharekova et al
Figure 1 Host defense proteins in human skin
Immunohistochemical staining of normal skin (a-d-g), atopic dermatitis skin (b-e-h) and psoriatic 
skin (c-f-i) for SLPI (a-c), elafin (d-f) and MRP8 (g-i). Note the difference in elafin and SLPI 
localization and staining intensity, between psoriasis and atopic dermatitis. Bar: 50 μm
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Table 1 Semi-quantitative scoring of immunohistochemical staining
Protein Score Psoriasis Atopic dermatitis
Elafin distribution 2.0 + 0.0* 0.8 + 0.4
ratio 0.48 + 0.14* 0.23 + 0.11
SLPI distribution 2.0 + 0.0$ 1.1 + 0.6
ratio 0.49 + 0.10# 0.28 + 0.16
MRP8 distribution 2.0 + 0.0 2.0 + 0.0
ratio 0.78 + 0.12¶ 0.50 + 0.30
Involucrin distribution 2.0 + 0.0 2.0 + 0.0
ratio 0.59 + 0.11 0.64 + 0.05
CK16 distribution 2.0 + 0.0 2.0 + 0.0
ratio 0.85 + 0.14 0.84 + 0.10
Ki-67 positive cells per mm 89 + 45 85 + 45
Immunohistochemical staining was quantified as indicated in the Method section Figure s 
represent mean +/- standard deviation of 10 atopic dermatitis patients and 9 psoriasis patients. 
Values for elafin, SLPI and MRP8 staining were significantly different between psoriasis and 
atopic dermatitis: *p<0.001, $p<0.01, #p<0.02, ¶p<0.05. No significant differences were found for 
involucrin, CK16 and Ki67. Mann-Whitney U-test
Involucrin
CK16
Ki-57
Atopic dermatitis Psoriasis
Figure 2 Kucharekova et al
Figure 2 Differentiation and 
proliferation in psoriasis and atopic 
dermatitis
Immunohistochemical staining of 
atopic dermatitis skin (a-c-e) and 
psoriatic skin (b-d-f) for involucrin 
(a-b), CK16 (c-d) and Ki-67 (e-f). 
Note the similar localization and 
staining intensities of these markers 
in the two diseases. Bar: 100 μm
Involucrin
16
i-67
   t        Psoriasi
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2f, and Table 1 show that the epidermis of atopic dermatitis patients is equally 
hyperproliferative as is the case in psoriasis.
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Discussion
A recent study by Ong et al has raised the intriguing possibility that the 
increased susceptibility of atopic dermatitis patients for bacterial infections may 
be related to low expression levels of antimicrobial peptides (when compared to 
psoriasis patients).12 In our present study we have extended their observations to three 
other host defence proteins, and we show that this phenomenon is not found for two 
other differentiation related proteins without a known function in host defence. It 
should be noted, however, that there is at least one other epidermal protein (E-FABP) 
not associated with host defence, which also shows a differential expression pattern 
between psoriasis and atopic dermatitis (see chapter 2 of this thesis). How could we 
interpret the remarkable finding that there appears to be a difference in cutaneous 
innate immunity between these two diseases? First, one could ask whether expression 
of epidermal host defence genes is low in atopic dermatitis or high in psoriasis. A 
comparison with healthy individuals has not been performed in either study, for the 
obvious reason that it is not easy to obtain a suitable chronic inflammatory T-cell 
mediated control lesion in otherwise healthy volunteers. It is conceivable to address 
this experimentally, using the induction of antimicrobial proteins in response to 
standard injury of normal skin, or uninvolved skin of psoriasis and atopic dermatitis 
patients. The tape-stripping model would be an interesting option in this respect. This 
would, however, not address the question whether it is a cell-autonomous process or 
not, in other words: is the difference in epidermal innate immunity governed by the 
inflammatory infiltrate, or is it an intrinsic property of the keratinocyte? This could 
be investigated in keratinocyte cultures following stimulation with the appropriate 
factor to induce innate immunity genes in vitro. Previous studies have shown that 
serum, TNF-alpha and detergents can induce elafin gene expression in cultured 
keratinocytes.18;19 These studies and reports on elafin induction in other cellular 
systems have indicated that its expression is dependent on p38 MAPkinase and NFκB 
signalling.20 hBD2 and LL37 were shown to be induced by various agents including 
IL-1, TNF-α, IL-6 and bacterial products. 21;22 Taken together these data suggest 
that several of these antimicrobial proteins may be expressed following Toll-like 
receptor (TLR) signaling or in the context of a Th1 immune response, where TNF-
α is a dominant cytokine. Interestingly, an active TLR-4 receptor has recently been 
described in keratinocytes.23 It remains to be investigated whether the actual tissue 
levels of TNF-α or activity of TLR signalling pathways are higher in psoriasis than in 
atopic dermatitis lesions. Alternatively, keratinocytes from psoriatic patients could be 
genetically programmed to respond earlier (at lower thresholds) or more vigourously 
to stimuli such as TNF-α or microbial products. In this case, one would expect that the 
psoriasis loci that have been identified in extensive linkage studies performed over the 
last years, would yield candidate genes associated with innate immunity. The NOD2 
gene would be a good candidate but this has been recently excluded for psoriasis.24 It 
is interesting to note that, in culture, differences in chemokine production have been 
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found between psoriasis and atopic dermatitis keratinocytes.25 This study suggests 
that psoriatic keratinocytes intrinsically produce more IL-8, MCP-1 and IP-10 than 
cells from atopic dermatitis patients. 
It could be argued that a comparison between any two diseases would reveal 
differences in immunolocalization of host defence genes, because of the differences 
in disease stage and severity, and the specific architecture of the affected epidermis 
in a particular disease. When, for instance, an acute lesion of atopic dermatitis is 
compared with a psoriatic lesion, the comparison would be less meaningful because 
of the reasons mentioned above. We took care, however, to study chronic lesions 
of both patient groups. Although the clinical diagnosis of the patients was clear-cut, 
the lesions showed a number of histopathological similarities, as indicated above. 
Some of the biopsies (5/19) could not be unambiguously classified on the basis of 
histopathology alone. Cellular proliferation and acanthosis measured as the number 
of epidermal cell layers were not different between the two diseases. A remarkable 
finding was that CK16, an established marker of keratinocyte activation in the context 
of hyperproliferaton, was not differentially expressed.
It is conceivable that psoriasis and atopic dermatitis patients represent the 
extremes of a population. Psoriasis patients may have a genetic background that 
predisposes towards a Th1 dominated T-cell population in response to microbial 
stimuli and they might carry polymorphisms in TNF-α and NFκB signaling that 
favour expression of epidermal host defence genes; on the other hand atopic dermatitis 
patients favour a Th2 response26 and could possibly carry genetic polymorphisms 
conferring a poor epidermal innate immune response towards environmental 
microbial stimuli. The fact that psoriasis and atopic dermatitis are very common 
diseases, strongly suggests that these predisposing genes confer a certain evolutionary 
advantage. A large population based study by Henseler et al has shown that psoriasis 
patients have an increased resistance to cutaneous bacterial infections.11 In this light, 
psoriasis could be the evolutionary cost of having too many, otherwise favourable 
genetic polymorphisms.
To summarize, we think that the observations made by Ong et al12 and the 
data presented here together with the recently proposed interaction between innate 
and adaptive immunity, can provide new insights in the immunobiology of common 
inflammatory skin diseases. The notion that polymorphisms in genes dealing with 
environmental (microbial) stimuli play a role in these conditions may enable us 
to gain greater insight in the pathogenesis of these diseases and even lead to more 
specific therapeutic avenues.
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contact dermatitis:
Experimental and clinical studies
This chapter was based on the following publications:
The effect of a PDE-4 inhibitor (Cipamfylline) in two human models of irritant contact dermatitis
M. Kucharekova, M. Hornix, T. Ashikaga, S. T’kint, G.J. de Jongh, J. Schalkwijk, P.C.M. van de Kerkhof, 
P.G.M. van der Valk
Arch Derm Res;2003;295(1):29-32
Effect of a lipid-rich emollient containing ceramide 3 in an experimentally induced skin barrier 
dysfunction
M. Kucharekova, J. Schalkwijk, P.C.M. van de Kerkhof, P.G.M. van der Valk
Contact Dermatitis;2002;46(6):331-338
A randomized comparison of an emollient containing skin-related lipids with a petrolatum-based 
emollient as adjunct in the treatment of chronic hand dermatitis
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4.1 THE EFFECT OF A PDE-4 INHIBITOR (CIPAMFYLLINE) 
IN TWO HUMAN MODELS OF IRRITANT CONTACT 
DERMATITIS
 
Abstract
The treatment of irritant contact dermatitis (ICD) is a major problem in 
clinical dermatology. New therapeutic approaches have to be considered. Recently, 
phosphodiesterase 4 (PDE-4) inhibitors have been introduced as non-steroidal, anti-
inflammatory agents. These agents inhibit the secretion of the cytokines, which are 
thoughts to be involved in the pathogenesis of ICD. We investigated the effect of a new 
selective PDE-4 inhibitor (cipamfylline), in human models using single and repeated 
exposures to an irritant in a blind, randomized pilot study with healthy volunteers. 
We compared the effect of cipamfylline-ointment with a strong corticosteroid 
(betamethasone -17-valerate) and with a placebo-ointment. 
Ten volunteers were patch tested at four investigation sites with sodium 
dodecyl sulfate (1%) for 24 hours. In a model that simulates chronic damage, eleven 
volunteers were patch tested with sodium dodecyl sulphate (0.2%) for 4 hours a 
day for 4 consecutive days. The investigation sites were treated once a day with the 
above mentioned agents. One site was left untreated. We used erythema scoring, 
measurements of transepidermal water loss (TEWL) and several immunohistochemical 
markers for epidermal proliferation and differentiation. 
Repetitive application revealed that betamethasone-17-valerate caused a 
statistically significant reduction of erythema and TEWL compared to cipamfylline 
and placebo. Furthermore, we observed a significant suppression of proliferating 
cells and cytokeratin 16 expression at the site treated with betamethason compared 
to the other sites. In the model for acute ICD no significant differences were seen 
between the investigated sites.
Our data shows that betamethasone-17-valerate may be modulating the 
response in ICD. In these human models of ICD we could not confirm the efficacy of 
cipamfylline. Clinical studies are needed before refuting of PDE-4 inhibitors in ICD 
with certainty. 
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Introduction
Irritant contact dermatitis (ICD) has been defined as a non-immunological 
inflammatory response of the skin due to one or more external factors.1 ICD may 
be classified into two main types. 1. Acute irritant contact dermatitis may develop 
from a single exposure of the skin to a strong irritant in a relatively short time. 2. 
Chronic irritant contact dermatitis is thought to be caused by repeated exposures to 
various irritant factors by a repetition of one or more impairing external factors. ICD 
is a major cause of occupational disability, it results in loss of productivity, medical 
expenses and disability payment.2 Various therapies have been tried but treatment 
remains unsatisfactory. New therapeutic approaches, therefore, still need to be 
considered.
Recently, phosphodiesterase-4 (PDE-4) inhibitors have been introduced 
as anti-inflammatory agents. Phosphodiesterases (PDEs) are a family of enzymes 
responsible for the hydrolysis of the intracellular messengers, cyclic AMP (cAMP) and 
cyclic GMP (cGMP) causing their inactivation. The PDE-family consists of at least 9 
isoenzymes with different selectivity for tissue of localisation. PDE-4 is localised in 
all inflammatory cells.3 The inhibition of PDE-4 and the subsequent increase in cAMP 
levels may be of significant value in controlling inflammatory disorders. In this way, 
PDE-4 inhibitors are able to inhibit inflammatory cytokine production and modulate 
immune and inflammatory responses.4 Clinical and preclinical studies with PDE-4 
inhibitors have shown that these agents reduce inflammation in atopic dermatitis 4;5 
and in models of immunological inflammation.6-8 
These promising results in atopic inflammation prompted us to study the effect 
of PDE-4 inhibitors in ICD. PDE-4 inhibitors may be potential therapeutic agents in 
ICD because of several reasons. Upon skin irritation enhanced production of cytokines 
has been reported.9-11These cytokines may act as mediators to elicit an inflammatory 
response and/or coordinate metabolic responses for barrier repair. Thus, cytokines 
may be important candidates controlling irritant contact reaction and inhibition of 
their function may diminish an ensuing inflammatory response.12 In particular, the 
proinflammatory cytokine, tumor necrosis factor - alpha (TNF-α), is thought to be 
critical in ICD responses.2;10;13-15The expected effects of PDE-4 inhibitors on ICD 
could be due to their ability to inhibit TNF-α6 and the production of other cytokines 
as IL-123, IL-4.6 Such a non-steroidal, anti-inflammatory approach is a promising 
therapy of ICD and may be even superior to dermatocorticosteroid therapy because it 
may not only modulate the inflammatory response, but is also not likely to induce skin 
atrophy and barrier impairment. 
In the present study we investigated the effect of cipamfylline, a new 
selective inhibitor of phosphodiesterase-4 enzyme in human models using single 
and repeated exposures to a detergent (SDS) in a blind, randomized pilot study with 
healthy volunteers. We compared the effect of cipamfylline ointment with a strong 
dermatocorticosteroid (betamethasone-17-valerate) and with a placebo ointment. 
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Barrier function disruption occurs after exposure to detergents as SDS and this 
impairment may be relevant to ICD. Therefore, we investigated repair of skin barrier 
function by measuring transepidermal water loss. We also performed clinical erythema 
scoring. The development of erythema and increasing of TEWL in SDS induced 
irritation, is associated with increased number of cycling cells16 and upregulation 
of differentiation-associated proteins (e.g. involucrin, epidermal fatty acid binding 
protein).17 These aberrations can be visualised by immunohistochemical staining of 
different marker proteins. We used these immunohistochemical markers to investigate 
potential cell-biological effects of the above mentioned therapeutical agents. To assess 
the changes on epidermal proliferation, we used an immunohistochemical marker of 
epidermal growth, known as Ki-67 antigen, present in cycling cells. Furthermore, 
we observed the expression of two terminal differentiation proteins (involucrin, 
epidermal-fatty acid binding protein) and the expression of cytokeratin 16 which is 
present in hyperproliferative conditions.18;19
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Material and Methods
Subjects
21 healthy volunteers with no history of skin diseases (6 male, 15 female, 
mean age 48.1, ranging from 24 to 69 years) participated in the study. After approval 
by the Medical Ethics Committee, informed consent was obtained from all subjects. 
The study was conducted in January -March 2002.
Skin exposure to sodium dodecyl sulphate and topical formulations
Experimentally induced skin irritation was studied in two different models. 
Model A consisted of a single exposure of 1% sodium dodecyl sulphate. We used a 
1% dilution of SDS (w/v). An aliquot of 150 μl of SDS was pipetted on the patches, 
consisting of a 1,5 cm2 piece of absorbent, non-woven fabric on a 4.0 cm2 piece of 
impermeable plastic foil.20 10 subjects were patch tested on 4 investigating sites on 
the lower back for 24 hours. After removal of the patches, the ointment was applied 
daily over the area of previously SDS exposed skin, dried at room temperature for 30 
minutes. The ointment was applied for 3 consecutive days from day 1 to day 3, once 
a day.
Model B consisted of repetitive application of 0.2% SDS for 4 consecutive 
days.150 μl of SDS (0.2%) (w/v), pipetted on the patches, consisting of a 1.5 cm2 
piece of absorbent, non-woven fabric on a 4 cm2 piece of impermeable plastic foil, 
which was daily fixed at the same site to the back of 11 subjects during 4 h for 4 
consecutive days from day 0 to day 3. After removal of the patches, the ointment was 
applied daily over the area of previous SDS exposed skin, dried at room temperature 
for 30 minutes. The ointments were applied for 4 consecutive days from day 0 to day 
3, once a day. 
The following formulations were used for both models: cipamfylline ointment 
(cipamfylline 2.5 mg/g, macrogol-2 stearyl ether, white soft paraffin, liquid paraffin, 
and propylene glycol), placebo ointment (macrogol-2 stearyl ether, white soft paraffin, 
liquid paraffin, propylene glycol) and betamethason-17-valerate ointment (1mg/g). 
One site was untreated. Applications were performed according to the randomisation 
code.
Clinical scoring and transepidermal water loss (TEWL) measurements
For both models visual grading and TEWL were assessed at day 0 to day 4. 
TEWL was measured with a Tewameter TM 210, according to standard guidelines.21 
Room temperature varied from 18º C until 22º C and relative humidity from 38% 
to 56%. Semi-quantitative grading system of erythema, already described in other 
study17, was used: 0-no response; 1-slight, patchy redness; 2-diffuse mild redness, 3-
moderate redness, 4-intense redness; 5-intense redness with oedema.
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Biopsy procedures
A total of 80 punch biopsies (3 mm diameter) were taken from each of the 
patch-test sites of 20 volunteers after visual reading and TEWL measurements at 
day 4. After 4 h fixation in formalin the samples were stored in alcohol 70% until 
embedding in paraffin was done. Then the samples were sectioned at 6 μm for 
immunohistochemical staining.
Immunohistochemical methods
Biopsy sections were evaluated light microscopically using haematoxylin-
eosin staining according to Mayer and immunohistochemical staining. For the 
immunohistochemical staining a panel of monoclonal and polyclonal antibodies 
was used. To assess epidermal proliferation, an antibody directed against the Ki-67 
antigen was used (MIB-1, DAKO A/S Denmark). To assess epidermal differentiation 
three markers were used: a monoclonal antibody against involucrin (MON-150)22 a 
monoclonal antibody against cytokeratin 16 (LL025, Novocastra, Newcastle, United 
Kingdom), and a polyclonal antibody against the epidermal-fatty-acid-binding-
protein (anti-E-FABP).23 
The slides were deparaffinized by incubation in histosafe for 2 times 15 
minutes, followed by dipping in an ethanol series from 100% to 50%. After washing 
in phosfate-buffer saline (PBS) the sections were pre-incubated with normal horse 
serum (20%) for MIB-1, LL025, MON-150; and with normal goat serum (20%) for 
anti-E-FABP for 15 minutes. Before this pre-incubation the sections were pre-treated 
with citrate buffer in case of MIB-1, LL025 and MON-150. Furthermore, an antigen 
retrieval method in a microwave oven was necessary for MIB-1, LL025 and MON-
150. Then all sections were incubated for 60 minutes with the following primary 
antibodies: MIB-1, anti-E-FABP, LL025 and MON-150 at the dilution of 1:50, 1:
400, 1:10 and 1:40, respectively. After washing with PBS, sections were incubated for 
30 minutes with biotinylated horse-anti-mouse IgG or goat-anti-rabbit IgG (dilution 
1:200). Another washing step with PBS, and then complexes were formed between 
biotin and avidin using the Vectastain Elite ABC peroxidase kit, according to the 
manufaturer’s instructions (Vector Laboratories, Burlingame, USA). Sections were 
developed with amino-ethylcarbazol as the chromogenic substrate or metal-enhanced 
diaminobenzidin. All sections were subsequently counterstained with hematoxylin 
1%.
Histological grading
Semiquantative assessment of the histology was carried out by two observers 
who were unaware of which sections accounted for which treatment. Epidermal 
proliferation was measured by counting the number of Ki-67 positive nuclei per 
mm length of the section. Of every section 3 fields were counted, and we calculated 
mean ± SEM. Involucrin staining was assessed by calculating the ratio of positively 
stained cell layers, compared to the total number of cell layers, at a representative 
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interpapillary and papillary area. The expression of E-FABP was scored as already 
mentioned before on page 77. CK-16 was graded: 0- no staining, 1- sporadic staining, 
2- minimal staining, 3- moderate staining, 4- moderate/pronounced staining, 5- 
pronounced staining.
Statistical analysis
Data are reported as means ± SEM. The differences were analysed with 
statistica 5.0 using ANOVA/MANOVA. In case of a significant difference further 
analysis was performed by use of the Duncan-test. A p-value < 0.05 was supposed to 
be statistically significant. 
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Results
Clinical response and TEWL measurements
Single exposure of human skin to SDS (1%) resulted in an erythematous 
reaction and increase of TEWL on all investigated sites, gradually decreasing to day 
4. No significant differences in erythema or TEWL was found between the treated and 
untreated sites. 
Repetitive exposure to SDS (0.2%) induced an increase of erythematous 
reaction and TEWL values, enhancing in intensity up to day 4. There was a significant 
smaller increase of erythema and TEWL values in the betamethason-17-valerate 
treated sites compared to the cipamfylline and placebo, but not compared to the 
untreated site. (Figure 1a,b)
Histology and immunohistochemistry 
H&E staining
At day 4 we observed in both models mild to moderate parakeratosis, 
spongiosis and acanthosis and a mild to moderate perivascular infiltrate. No apparent 
differences were seen between the various treated sites.
Epidermal proliferation
The MIB-1 antibody was used to stain the Ki-67 antigen in cycling cells. 
Keratinocytes with positively stained nuclei were located in the basal and the first 
suprabasal layers of the epidermis. Skin exposed to SDS in the acute and chronic 
model is characterised by an increase in the number of MIB-1 positive nuclei. In 
the acute model no significant differences were found in cycling cells/mm between 
the various investigated sites (data not shown). Repetitive exposure of SDS (0,2%) 
resulted in untreated skin in an increase in the number of cycling cells/mm to a 
maximum of 48,9 ± 8,3 (mean ± SEM). A marked, significant decrease in the cycling 
cells/mm was observed in the betamethasone-17-valerate treated sections compared 
to the sites treated with cipamfylline, placebo and not treated site . (Figure 2a)
Epidermal differentiation
In both models, exposure to SDS, caused an increased expression of 
involucrin, E-FABP and cytokeratin 16. None of the treatment affected cytokeratin 16 
expression in the acute model. (data not shown) In the chronic model, the expression 
of cytokeratin 16 after treatment with betamethasone differed significantly from 
cipamfylline treated site, placebo and not treated site, respectively (Figure 2b).
In both our models we did not find any significant differences between the 
investigated sites with respect to expression of involucrin and epidermal fatty acid 
binding protein. (data not shown) 
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Figure 1 (a) Erythema score in 
model of repetitive application of 
SDS (0.2%). Erythema was assessed 
using a five-point scale: 0-no 
response; 1-slight, patchy redness; 
2-diffuse mild redness, 3-moderate 
redness, 4-intense redness; 5-intense 
redness with oedema. * Significant 
difference between the site treated 
with betamethasone compared to 
the sites treated with cipamfylline 
(p=0.013) and placebo (p=0.015), 
but not compared to the not treated 
site.
(b)TEWL values (g/m2/h) in model 
of repetitive application of SDS 
(0.2%). * Significant difference 
between the site treated with 
betamethasone compared to the sites 
treated with cipamfylline (p=0.017) 
and placebo (p=0.01), but not 
compared to the not treated site.
Figure 2 Immunuhistochemical 
staining. (a) The number of 
proliferative cell (Ki-67) per mm 
length of the section after repetitive 
application of 0.2% SDS. The values 
are mean ± SEM. * Significant 
difference between the sites treated 
with betamethasone compared to 
the sites treated with cipamfylline 
(p=0.02), placebo (p=0.006) and not 
treated site (p=0.031).
(b) Cytokeratin 16 after repetitive 
application of 0.2% SDS. The 
expression of CK 16 in epidermis 
was assessed using a five-point 
scale: 0- no staining, 1- sporadic 
staining, 2- minimal staining, 
3- moderate staining, 4- moderate/
pronounced staining, 5- pronounced 
staining. * Significant difference 
between the site treated with 
betamethasone compared to the sites 
treated with cipamfylline (p=0.006), 
placebo (p=0.018) and not treated 
site (p=0.023).
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Discussion
In the present study, the induction of irritant reactions by single and repetitive 
exposure to SDS and the repair with or without treatment was studied using visual 
scoring, TEWL and markers of epidermal proliferation and differentiation. Single 
exposure to SDS resulted in an erythematous reaction and an increase in TEWL 
values on all investigated sites after 24 hours, gradually decreasing till day 4. The 
repetitive model showed an increase in erythematous reaction and TEWL, increasing 
in intensity up to day 4. The acute and repetitive exposure to SDS not only induced 
histological changes in the epidermal cell compartment, but also upregulated the 
expression of markers for epidermal differentiation and proliferation in line with a 
previous study.20 
Treatment of skin irritation with cipamfylline ointment, placebo and 
betametasone-17- valerate after single, 24 hour exposure of SDS, did not significantly 
decrease erythema, TEWL and also did not significantly modulate epidermal 
proliferation assessed by Ki-67 and epidermal differentiation assessed by the 
expression of involucrin, E-FABP and cytokeratin 16. Therefore, it can be concluded 
that these treatments did not modulate SDS damage in this model. The present study 
confirms a study by Levin who also failed to show an effect of corticosteroids in 
the acute model of ICD.24 Repetitive exposure to SDS, however, provides a model 
which is more similar to irritant contact dermatitis. The validity of single and repeated 
application of SDS as a model for ICD has been discussed before.20 In contrast to 
one single application, repetitive application revealed that betamethasone-17-valerate 
caused a statistically significant reduction of erythema and TEWL values compared to 
cipamfylline and placebo and a tendency of a reduction as compared to the untreated 
site. 
In order to elucidate the potential of a corticosteroid and cipamfylline 
in ICD we studied epidermal proliferation and differentiation parameters using 
immunohistochemical markers. An inhibition of Ki-67 and cytokeratin 16 was shown 
following betamethasone-17-valerate treatment compared to cipamfylline treated, 
placebo treated and untreated sites. However, again cipamfylline did not show any 
effect on the expression of these markers. Previously, several authors reported a lack 
of efficacy of topical corticosteroids on skin irritation, whereas others clearly showed 
such an effect.20;24-27 However, there are considerable differences between the designs 
of these studies with regard to corticosteroid potency, the duration and site of the 
irritation, open or closed application, the concentration of the irritant, which apparently 
may influence the outcome of the study. Acute and repetitive open application testing 
on the hands of volunteers with several irritant and corticosteroid formulations are 
recommended in order to establish the efficacy of corticosteroids in ICD.28 Consistent 
with the study of Le 20, who studied the effect of mild corticosteroid (triamcinolon 
acetonide cream) in the repetitive model of ICD, we found betamethasone-17-valerate 
to reduce the number of cycling cells significantly. But in contrast to this study we also 
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find a significant decrease in erythema, TEWL and cytokeratin 16 expression. Such 
might be due to the fact that betamethasone-17-valerate is more potent compared to 
triamcinolon acetonide.
In various entities of dermatitis (e.g. radiation dermatitis29, dithranol irritation30, 
nickel contact dermatitis31) a beneficial clinical effect of topical corticosteroids 
has been observed. Schmutz et al suggested that the positive effect of topical 
corticosteroids on barrier function in radiation dermatitis is caused by a reduction in 
the inflammatory response.29 In ICD barrier dysfunction precedes inflammation and 
therefore damage to the skin barrier may only be partly a reflection of an inflammatory 
response. This may explain the modest or absent efficacy of a topical corticosteroid or 
other anti-inflammatory treatment in some models of ICD, since barrier dysfunction 
is considered to play a role in its pathogenesis.32
In contrast to a mild effect of betamethasone-17-valerate on the clinical 
severity and the pronounced antiproliferation effect of betamethasone-17-valerate 
in the repetitive model of ICD, cipamfylline proved to have no effect on erythema, 
TEWL and epidermal proliferation and differentiation. On the other hand in atopic 
dermatitis, PDE 4 inhibitors have been shown to be effective.4;8 In this respect there 
are pronounced differences between ICD and atopic dermatitis. Indeed, costicosteroids 
and more recently tacrolimus are effective treatments of atopic dermatitis 33-35 but 
have a limited or no efficacy in ICD at all. In contrast, tacrolimus has been shown to 
enhance experimentally induced contact dermatitis.36 
The rationale for the potential use of PDE-4 inhibitors in ICD was based 
on the ability of PDE-4 to inhibit TNF-α and the production of other cytokines 
which are enhanced in ICD. 9;10;15;37 However, some animal studies demonstrated 
that neither TNF-α nor IL-1 alone are essential for cutaneous pathology induced by 
barrier perturbation. In these studies it is suggested that cytokines do not mediate 
any of the responses induced by barrier disruption and their modulation would not 
be likely to result in significant alteration in skin barrier response.38 Therefore, it is 
most likely, that the effect of cipamfylline in irritant skin reaction is limited to the 
anti-inflammatory action. 
In summary, this present study supports our view that effective topical 
treatment of skin irritation is arduous. Our data shows that betamethasone-17-valerate 
may be modulating the response in ICD. However, we could not confirm any action 
of cipamfylline on SDS induced irritation. 
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4.2 EFFECT OF A LIPID-RICH EMOLLIENT CONTAINING 
CERAMIDE 3 IN EXPERIMENTALLY INDUCED SKIN 
BARRIER DYSFUNCTION
 
Abstract
In the present study we compared the effect of a ceramide 3-containing emollient 
(Locobase® Repair) with a control emollient (vaselinum album/cremor lanette ana) 
and untreated damaged skin using clinical, bioengineering and immunohistochemical 
methods in two different models of experimentally induced skin barrier dysfunction. 
In model A (n=13) skin barrier dysfunction was inflicted at three investigation 
sites by tape stripping. In model B (n=13), the volunteers were patch tested at three 
investigation sites with sodium dodecyl sulfate (0.2%) for 4 h a day for 4 consecutive 
days. The investigation sites were treated once a day with the above-mentioned 
agents. Daily, irritant reaction was assessed by erythema scoring and measurements 
of transepidermal water loss (TEWL). After 5 days punch biopsies were taken from 
all sites. Immunohistochemical assessment was carried out with respect to epidermal 
proliferation, epidermal differentiation and Langerhans cells. 
Tape stripping resulted in an erythematous reaction and an increase of 
TEWL associated with upregulation of cycling cells, involucrin and expression of 
cytokeratin 16. Ceramide 3 - containing emollient significantly decreased at day 
4 the erythema score compared to the untreated site. TEWL and cycling cells are 
significantly decreased in comparison with the untreated site and the site treated 
with control emollient. Repetitive exposure to SDS induced a variable degree of 
erythema, gradual increase of TEWL, an increase of cycling cells, and upregulation of 
involucrin, cytokeratin 16, E-FABP and SKALP/elafin. The treatment with the control 
emollient significantly prevented erythema, increase of TEWL and cycling cells at day 
4 compared to the untreated site. 
In summary, the present study demonstrated that, both tested emollients 
improve skin barrier in different conditions compared to the untreated skin and that 
there is some indication that formulations containing skin- related lipids might be of 
benefit in barrier disruption following tape stripping. Different models and clinical 
trials are needed to establish in specific conditions the usefulness of emollients 
containing skin-related lipids. 
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Introduction
Emollients have been used in the treatment of dry, scaly skin conditions for 
over 2000 years.
Although we are starting to understand how emollients work, only a few trial 
data have been published demonstrating their efficacy. 1-4
Theoretically, emollients may act on three different levels of the epidermis: 
1. an immediate effect by adding a lipid mixture to the skin surface (occlusion) 
2. an intermediate effect by adding a lipid mixture to the intercellular spaces 
3. a delayed effect by providing lipids to the epidermal cells, enabling these to 
enhance the natural lipid production and lipid release. 5
Most emollients act on the first two levels listed. An ideal emollient would be 
one that possesses all three of these qualities. A promising approach in this respect 
may be the incorporation of lipids chemically related to the physiological content of 
the intercellular domain of the horny layer in a topical formulation.
Recently, findings on the composition of intercellular lipids and the effects of 
well-defined preparation of these lipids on the skin barrier have made this approach 
feasible. Firstly, it was shown that the topical application of an equimolar three-
component system of ceramides, cholesterol and fatty acid allows normal barrier 
repair in acetone-treated murine skin as compared to delayed barrier repair by lipids 
alone or by other combinations. In these animal studies it has also been demonstrated 
by fluorescence and electron microscopy that the mixture of cholesterol, fatty acid 
and ceramides rapidly traversed the SC with subsequent uptake into the epidermal 
nucleated layers.6;7 Secondly, it was shown that acceleration of barrier repair can 
be achieved if the relative contribution of any of these ingredients is increased.8 
Finally, it has been suggested that cholesterol, ceramides, palmitate and linoleate in 
the composition of 4.3 : 2.3 : 1 : 1.08 is the most optimal ratio for barrier recovery. 
This lipid formulation causes a markedly accelerated skin barrier recovery following 
barrier disruption in mice.9 To correlate animal data with human skin, different lipid 
formulations containing varying molar ratios of these lipids were tested in limited 
numbers of patients. In some combinations a noticeable improvement in skin 
suppleness was observed.10 
These experimental studies showed evidence that emollients containing certain 
combinations of key physiologic lipids may have therapeutic benefits in conditions 
involving skin barrier dysfunction.11 However, studies that document the efficacy of 
such lipid compositions in barrier disturbance in humans either clinically or in models 
are scarce. The limited number of available human studies, using bioengineering 
methods to assess barrier function, is contradicting.10;12-17 In the present study we 
investigated the efficacy of a ceramide 3-containing emollient (Locobase® Repair). 
It is claimed to be a formulation which contains an optimal composition of skin-
related lipids in barrier recovery. We studied this claim by comparing Locobase® 
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Repair with vaselinum album/cremor lanette I ana (control emollient) and untreated 
damaged skin in barrier recovery capacity. We investigated skin barrier function by 
measuring transepidermal water loss. We also performed clinical erythema scoring 
and (immuno)histological studies of experimentally induced skin barrier dysfunction. 
The skin barrier dysfunction was inflicted by tape stripping or exposure of the skin 
to a low concentration of sodium dodecyl sulfate (SDS) in a cumulative exposure 
model. 
Beneficial effects of both emollients using clinical, bioengineering and 
immunohistochemical methods were observed depending on the type of injury.
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Materials and methods
Subjects
A total of 26 healthy volunteers without past or present history of skin diseases 
(11 male, 15 female, mean age 38, ranging from 20 to 61) were included in the study. 
Written informed consent was obtained from all participants and the study was 
approved by the local Ethics committee. The study was conducted in January 2000.
Methods
Experimentally induced barrier dysfunction was studied in two different 
models: 
A. single tape stripping 
B. repetitive exposure to low concentration of sodium dodecyl sulfate (SDS) 
Model A: Mechanical irritation by single tape stripping: On baseline (day 0) a 
plastic template with three windows (2,5 cm diameter) was applied to three sites of the 
lower back of 13 participants. The exposed areas were at least 2.5 cm apart. Adhesive 
tape (Tesafilm ) was applied with gentle pressure to the exposed areas (site 1, 2, 3) and 
then removed. This procedure was repeated until the skin was glistening.
Model B: 13 participants were patch tested with 0.2% SDS once daily for 4 
hours on each of 4 consecutive days from Monday to Thursday (days 0-3). 150 µl of 
SDS was applied to our self-made patches consisted of a 1.5 cm2 piece of absorbent, 
non-woven fabric fitted into a flat round silver chamber with an internal diameter of 
30 mm. The chambers were applied on the three sites of the lower back (min. distance 
2,5 cm) and hold in place with tape (Fixomull stretch, Beiersdorf AG, Hamburg). 
After the removal of all SDS chambers, the skin was washed with cold running water 
and gently patted dry with a paper towel.
Topical application of the emollients 
The exposed areas were treated once daily for 7 days in model A and for 5 days 
in model B according to the following scheme:
Site 1 control emollient (vaselinum album/cremor lanette I ana, Dutch 
pharmacopoeia)
Site 2 untreated 
Site 3 ceramide 3-containing emollient (Locobase® Repair, Yamanouchi Pharma 
B.V.) 
Evaluation
Clinical assessment and Transepidermal Water Loss (TEWL) measurements
Erythema was evaluated by the investigator daily according to the scoring 
system: 0-no response; 1-slight, patchy redness; 2-diffuse mild redness, 3-moderate 
redness, 4-intense redness; 5-intense redness with oedema.
TEWL were measured by TEWAMETER TM 210 (Robinson electronic Ltd.) 
118
Chapter 4
119
Novel therapies on irritant contact dermatitis
according to the guidelines from the Standardisation Group of the European Society 
of Contact Dermatitis.18 Measurements were performed following a waiting period of 
30 min. Measurements were taken more than 12 h after application of the emollients. 
Room temperature varied from 19 °C to 22 °C and relative humidity from 40% to 
50%. 
TEWL measurements were performed:
Model A: at day 0 - before (baseline TEWL) and at various moments after tape 
stripping: post-exposure (dag 0), and 24 hours (day 1), 48 hours (day 2), 96 hours 
(day 4), 168 hours (day 7) after barrier disruption. Model B: at day 0 - before SDS 
exposure (baseline TEWL), after 24 hours (day 1), 48 hours (day 2), 96 hours (day 4). 
The measurements at 24 h, 48 h and 96 hours were performed before the following 
exposure of SDS.
Biopsy procedures
Model A: 24 punch biopsies (3mm) were taken under local anaesthesia at 48 
(day 2) and 96 hours (day 4) after tape stripping from all investigated sites of eight 
participants. The biopsy specimens were embedded in Tissue TEK II OTC compound, 
immediately snap-frozen in liquid nitrogen and stored at -80 C until further use. 
Sections of 6 μm were cut and fixed during 10 minutes with acetone-ether (60/
40vol.%) for the MIB-1 staining and for the other staining with cold acetone only.
Model B: 24 punch biopsies (3mm) were taken under local anaesthesia at 96 
hours (day 4) after repetitive application of SDS from all investigated sites of eight 
participants. After 24 h fixation in formalin, the samples were embedded in paraffin, 
sectioned at 6 μm and prepared for staining.
Histological methods
Biopsy sections were evaluated light microscopically using haematoxylin-
eosin staining and immunohistochemical stainings. For the immunohistochemical 
stainings a panel of monoclonal and polyclonal antibodies dependent on model was 
used.
Model A: To assess epidermal proliferation, an antibody directed against the 
Ki-67 antigen was used (MIB-1, 1:50, Immunotech, SA, Marseilles, France). To 
assess epidermal differentiation, monoclonal antibodies against involucrin (MON-
150, 1:15, Dept. Clin. Chem., St. Elisabeth Hospital, Tilburg, The Netherlands) and 
monoclonal antibody against cytokeratin 16 (LL025, 1:10, Novocastra Laboratories 
Ltd, Newcastle upon Tyne, UK) were used. Using monoclonal antibodies DAKO-T6 
(1:100, DAKO A/S, DENMARK), made analysis of the presence of Langerhans cells. 
For all monoclonal antibodies, an indirect immunoperoxidase technique was used.
Model B: All markers except the marker for Langerhans cells have been used. 
Besides that, we used two other differentiation markers. A polyclonal antibody against 
skin-derived-antileukoproteinase (anti-SKALP, 1:500) and a polyclonal antibody 
against epidermal-fatty-acid-binding-protein (anti-E-FABP, 1:100, ) have been used. 
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For all antibodies, except for MIB-1 and anti-E-FABP, an indirect immunoperoxidae 
technique was used. An avidin-biotin immunoperoxidase technique was carried out 
for MIB-1 and anti-E-FABP.
Statistical analysis
The differences were analysed by the Wilcoxon test for erythema score and 
immunohistochemical scoring. P<0.05 was chosen as level of significance. 
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Results
Clinical response and TEWL measurements
Tape stripping of human skin resulted in an erythematous reaction. After tape 
stripping TEWL strongly increased and then gradually decreased to day 7. The time 
course of the visual grading of erythema and TEWL measurements is shown in Figure 
1a and Figure 1b, respectively. The erythema score was significantly decreased at day 
4 on the site treated with ceramide 3 - containing emollient compared to the untreated 
site, but not significantly compared to the side treated with control emollient. TEWL 
value was significantly decreased at day 4 on the site treated with ceramide 3 - 
containing emollient compared to the control emollient and untreated site.
Repetitive exposure of human skin to SDS induced a variable degree 
of erythema. The erythematous response increases in intensity up to day 4 in 9 
participants (Figure 2a). No strong erythematous reactions were observed. Four 
participants did not have any erythematous reaction at all. However, a gradual 
increase of TEWL values with maximum at day 4 was observed in all participants 
(Figure 2b). Treatment with both the ceramide 3-containing emollient and the control 
emollient prevented erythema and the increase of TEWL values. The treatment with 
the control emollient significantly prevented erythema and increase of TEWL value at 
day 4 compared to untreated site.
Immunohistochemistry
Epidermal proliferation 
We observed an increase of the number of cycling cells at 48 and 96 hours after 
tape stripping at all sites (Figure 3a). At the site treated with ceramide 3 - containing 
emollient the number of cycling cells is significantly reduced in comparison to the 
untreated site and to the site treated with control emollient.
Repetitive exposure to SDS induced an increased number of cycling cells after 
4 days at all investigated sites (Figure 3b). The site treated with control emollient 
showed a significant lower number of cycling cells at day 4 in comparison with the 
untreated site.
Epidermal differentiation
In the present study, tape stripping and SDS application induced clear 
expression of cytokeratin 16. However, no significant effect of any of the treatment 
was noticed. Expression of involucrin was slightly upregulated in both models. 
However, treatment with neither of the emollients significantly altered involucrin 
expression (data not shown). With respect to E-FABP and SKALP, we observed 
upregulation of E-FABP and expression of SKALP exclusively in patients with slight 
erythema after SDS application. We did not see any effects of the treatment on these 
markers. 
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Figure 1b TEWL measurements 
(g/m2/h) in tape stripping model
* Significant difference between the 
site treated with Locobase® Repair 
vs. the untreated site 
(p<0.03) and Locobase® Repair vs. 
control emollient (p<0.03)
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Figure 1a Erythema score in tape 
stripping model.
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Langerhans cells (LCs) 
We investigated the expression of Langerhans cells 48 and 96 hours after tape 
stripping. We observed at all sites an increase of epidermal LCs after epidermal injury. 
No significant differences were found in the exposed treated and untreated skin. 
Table s 1, 2 and 3 summarise the responses using various clinical, physiological 
and immunohistochemical parameters.
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Figure 3a Cycling cells (Ki-67) 
48 hours and 96 hours after tape 
stripping
We found a significant effect of 
Locobase® Repair compared to 
control emollient (p<0.03) 
and the untreated site (p<0.01). The 
sampling time was not significant.
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Figure 3b Cycling cells (Ki-67) 96 
hours after repetitive application of 
SDS (0.2%).
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(p< 0.03).
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Table 1 Interference of Locobase® Repair and control emollient with tape stripping 
induced changes
Parameters Locobase®
Repair 
Control 
emollient
(Vaselinum/
cr. Lanette)
P1- value P2-value
Erythema ↓↓ ↓ 0.018
TEWL ↓↓ ↓ 0.012 0.020
Ki 67 ↓↓ ↓ 0.018 0.003
Involucrin ↔ ↔
Cytokeratin 16 ↔ ↔
Langerhans cells ↔ ↔
↓↑ = tendency of an inhibition or stimulation, ↓↓↑↑ = statistically significant inhibition or 
stimulation, ↔ = no effect
P1 is the p value for difference between the site treated with Locobase® Repair and the untreated 
site P2 is the p value for difference between the site treated with Locobase® Repair and control 
emollient
P values only mentioned if significant
 
Table 2 Interference of Locobase® Repair and control emollient with SDS induced 
changes
Parameters Locobase®Repair Control emollient
(Vaselinum/cr. Lanette)
P-
value
Erythema ↓ ↓↓ 0.027
TEWL ↓ ↓↓ 0.032
Ki 67 ↓ ↓↓ 0.013
Involucrin ↔ ↔
Cytokeratin 16 ↔ ↔
SKALP/elafin ↔ ↔
E-FABP ↔ ↔
↓↑ = tendency of an inhibition or stimulation, ↓↓↑↑ = statistically significant inhibition or 
stimulation, ↔ = no effect
P is the p-value for difference between the site treated with control emollient and the untreated site. 
P-values only mentioned if significant
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Table 3 Characteristic clinical, TEWL and immunohistochemical changes
following repetitive application of SDS and tape stripping in our study
Parameters Repetitive application of 
SDS (0,2%)
Tape stripping
Erythema gradual increase ↑↑
TEWL  gradual increase ↑↑
Ki 67 ↑ ↑↑
Cytokeratin 16 ↑ ↑↑
Involucrin ↑ ↑
SKALP/elafin ↑ ND
E-FABP ↑ ND
Langerhans cells ND ↑ in epidermis
ND= not done
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Discussion 
In both models, following a single course of tape stripping and repeated 
applications of SDS, skin barrier repair was accelerated by the two lipid formulations 
(Locobase® Repair and vaselinum album/cremor lanette I ana). In the acute model 
of barrier disruption (tape stripping) Locobase® Repair accelerated repair of barrier 
damage significantly. In the cumulative SDS-model, vaselinum album/cremor lanette 
I ana recovered significantly the repair of damaged skin barrier. In the tape stripping 
model we observed a significant suppression of proliferating cells at the site treated 
with Locobase® Repair, whereas in the SDS models we observed a significant 
suppression of proliferating cells on the site treated with the emollient-control. The 
decrease of proliferating cells correlated with suppression of erythema score and 
TEWL. We did not observe any modulation of cytokeratin 16, involucrin, E-FABP, 
SKALP and Langerhans cells after the application of both emollients.
The results are in line with the results of an animal study using a comparable 
lipid mixture. In the animal experiment, the tested lipid mixture accelerated barrier 
recovery after tape stripping but not after SDS related damage.9 Several different 
mechanisms can explain the discrepancy of results between the models. 
Firstly, horny layer damage after detergent application differs from tape 
stripping induced injury. Tape stripping disrupts barrier function by removing the SC 
mechanically, detergents disrupt barrier function by removing and rearranging SC 
lipids. It is suggested that the quantity and spectrum of lipids removed from the SC, 
is detergent - specific. It is possible that detergents such SDS, may cause damage to 
the nucleated layers of the epidermis, which cannot be corrected by providing lipids 
alone. The difference in efficacy of tested emollients between the tested models 
supports the hypothesis that the ability of the lipid mixture to accelerate barrier repair 
depends on the specific damage, requiring damage-specific correction.9 
Secondly, the limited efficacy of Locobase® Repair in SDS model compared 
to control emollient could be matter of ratio of the lipid components. It is known that 
not all types of topical formulations, which contain lipids chemically related to the 
physiological content of the intercellular domain of the SC, are effective. Out of a 
number of preparations, those with a lipid ratio most comparable to that present in the 
human skin barrier, is considered to be effective.16 It is unknown whether lipid ratio 
of Locobase® Repair, which consists of cholesterol, semisynthetic ceramide 3, oleic 
acid and palmitic acid, mimics the lipid ratio in the human skin. Furthemore, ceramide 
3 is the exclusive ceramide that is incorporated in Locobase® Repair. Ceramides 
represent a unique, heterogeneus group of at least six ceramides that differ from each 
other by the head group architecture and by the mean fatty acid chain length. Other 
ceramides in the SC are probably needed to provide the SC with a water-resistant 
lipid multilayer. It is assumed that especially ceramide 1 is of major importance for 
proper SC barrier function.19 Because of its unusual structure, which contains linoleic 
acid linked to the long chain (C>30) omega hydroxy fatty acid, ceramide 1 is of great 
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importance for the formation of the lateral lipid packing as well as the long range 
lamellar ordering in SC.19;20 Studies of lipid composition of atopic skin showed a 
lowered level a ceramides, especially ceramide 1, suggesting its important role in 
barrier function.21-23 Concerning SDS-induced irritation, only a few references can be 
found with respect to the correlation between SC abnormalities and SDS irritation.24;25 
Nevertheless, the data imply that ceramide 1 is an important ceramide, and it is 
unknown whether emollients with ceramide 3 could sufficiently replace the role of 
ceramide 1 and other natural occuring ceramides. 
 In human studies the beneficial effect of emollients on the barrier function 
in SDS-induced skin irritation and tape stripping using clinical and bioengineering 
methods has been established.15-17;26 In one of these studies the effect of a ceramide 
3 -containing emulsion was investigated in which no additional positive effect was 
observed on barrier repair in SDS induced skin irritation. However, the authors did 
found positive effects on TEWL when damaged skin is treated with o/w emulsions 
enriched with mixtures of ceramides, cholesterol and fatty acids.16 In two other 
studies, a lipid mixture containing ceramide 3, cholesterol and fatty acids (Locobase® 
Repair) was compared with different emollients which contain non-physiological 
lipids on SDS induced skin irritation. In these studies, Locobase® Repair was 
of no advantage compared to non-physiological lipids containing emollient with 
respect to acceleration of barrier recovery after SDS application, which is in line of 
our results.15;17 To the best of our knowledge there is only one clinical study on the 
beneficial effect of emollients containing skin-related lipids on tape stripped human 
skin.17 In this study Locobase® Repair was not superior to petrolatum in contrast with 
our results. Probably the methods used to inflict barrier dysfunction were not similar. 
In our study the barrier dysfunction after tape stripping was more severe which may 
explain the lack of the superior effect of Locobase® Repair in their study. 
In addition to the clinical assessment and TEWL measurements, we 
investigated cell biological changes using markers for epidermal proliferation 
(MIB-l) epidermal differentiation (LL025, MON 150, anti-E-FABP, anti-SKALP) 
and Langerhans cells (T6). The disturbances in epidermal proliferation, epidermal 
differentiation and Langerhans cells can be associated with impaired skin barrier 
function in some skin diseases and experimentally induced skin barrier irritation. 27-33 
Using these immunohistochemical markers which are supposed to be associated with 
skin barrier dysfunction, we wanted to compare the cell biological effects of emollient 
treatment on experimentally induced skin barrier dysfunction. In our models of skin 
barrier dysfunctions we observed differences in the dynamics of proliferating cells 
after treatment with emollients. With regards to the other markers, we observed 
downregulation after skin barrier dysfunction, but we did not see any significant 
differences in the expression of these markers after application of the investigated 
emollients. 
According to some authors the accelerated recovery of barrier disruption after 
emollients could be due to a semiocclusive effect of the emollient, which restricts 
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water evaporation from the skin thereby allowing the skin to recover.(15) However, 
the role of occlusion has been questioned.34;35 We hypothesise that the limited efficacy 
of Locobase® Repair as compared to other more occlusive emollient may not be 
related to limited barrier recovery but rather to limited protection against repeated 
exposure to a detergent. The fatty components of the emollient - control may form 
a better physical barrier than the components of Locobase® Repair. These results 
support the hypothesis that the optimal barrier repair therapy should be based on 
understandings of the specific damage and recovery.17;36 We suggest that an ideal 
emollient does not exist and that a specific emollient will not be appropriate for all 
clinical purposes. 
In summary, the present study demonstrates that emollients improve skin 
barrier in different conditions compared to untreated skin and that there is some 
indication that formulations containing skin-related lipids might be of benefit in 
barrier disruption by tape stripping. To demonstrate a beneficial effect of emollients 
containing skin-related lipids, clinical studies are mandatory. An emollient protecting 
against all kinds of physical and chemical injuries is probably not realistic.
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4.3 A RANDOMIZED COMPARISON OF AN EMOLLIENT 
CONTAINING SKIN-RELATED LIPIDS WITH A 
PETROLATUM-BASED EMOLLIENT AS ADJUNCT IN THE 
TREATMENT OF CHRONIC HAND DERMATITIS
 
Abstract
Hand dermatitis is a multifactorial skin disorder in which skin barrier 
impairment is involved in the pathogenesis. The development of topical agents that 
improve skin barrier function is therefore a promising approach for the management 
of hand dermatitis. Topically applied lipids may interfere with skin barrier function, 
and emollients containing skin-related lipids have been suggested to facilitate repair 
of the skin barrier. However, evidence for the superiority of emollients containing 
skin-related lipids over the more traditional emollients is still lacking. 
The aim of this study was to compare an emollient containing skin-related 
lipids (Locobase® Repair) with a traditional petrolatum-based emollient for the 
management of hand dermatitis. Adult males and females (n=30) with mild to 
moderate chronic hand dermatitis were treated twice daily for 2 months either with 
an emollient containing skin-related lipids or with a petrolatum-based emollient. In 
the case of exacerbation, the patients of both treatment groups were allowed to use 
a mild corticosteroid according to instructions. Both treatment regimes significantly 
improved clinical symptoms of hand dermatitis as assessed by the investigator global 
assessment and hand eczema area and severity score. We did not observe significant 
differences in the improvement of clinical signs, itching, the patients’ assessment of 
efficacy, cosmetic acceptability or the usage of topical corticosteroids between both 
treatment groups. 
In conclusion, this study confirms that the frequent use of emollients may be 
useful in the therapy of hand dermatitis. However, we could not demonstrate the 
superiority of this particular emollient containing skin- related lipids in patients with 
chronic hand dermatitis.
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Introduction
Emollients may have various effects on the skin. They may form a covering 
film, which acts as a barrier for chemicals from the exterior and which restricts the 
loss of water and other essential substances from the interior.1 The product can be 
designated as a barrier cream if the primary goal is prevention of penetration.2;3 If the 
emollient restricts water loss, the stratum corneum is hydrated and the emollient can 
be designated as a moisturizer.4 If ingredients of the emollient penetrate the skin, these 
ingredients may interact with the lipids in the intercellular domain. Finally, ingredients 
of an emollient may enter corneocytes, eventually be metabolized and modify lipid 
secretory machinery of the SC.5;6 Recently, emollients containing skin-related lipids 
have been introduced. This new generation of emollients is believed to improve the 
skin barrier dysfunction by being incorporated into the multi-layered structure of the 
intercellular space or in cells of the SC. 
Chronic hand eczema is a common skin problem affecting approximately 2 
to 10 % of all patients seen by dermatologists.7 It is a multifaceted disease in which 
both endogenous and environmental influences are often relevant.8 The impact of the 
function of the skin barrier in this disorder should be emphasized. A good skin barrier 
helps to avoid the penetration of both allergens and irritants. One of the putative 
goals in the treatment of this disease, therefore, may be improvement of skin barrier 
function by well-selected emollients.
Animal studies have shown that topical mixtures of three key stratum corneum 
(SC) lipids, including ceramide, cholesterol and free fatty acid, when applied in 
optimized proportions accelerate barrier repair following a variety of external, acute 
or sustained perturbations.6;9;10 Human studies report the efficacy of different mixtures 
of these physiological lipids in experimentally induced skin barrier dysfunction 11-15 
and in clinical conditions involving skin barrier disturbances.16-18 However, evidence 
for the superiority of emollients with a specific lipid profile over the more traditional 
emollients is still lacking. 
In a previous report we reported on the effects of an emollient containing skin-
related lipids (Locobase® Repair) in experimentally induced skin barrier dysfunction. 
In that study, Locobase® Repair significantly accelerated repair of barrier damage 
in the acute model of barrier disruption (tape stripping) as assessed by clinical, 
bioengineering and immunohistochemical methods.14 This paper reports on a pilot 
study with Locobase® Repair in chronic hand dermatitis. We compared the effects 
of this emollient containing skin-related lipids with a petrolatum - based emollient 
(cremor vaselini lanette FNA). Here we studied clinical effects, cosmetic acceptability 
and the usage of topical corticosteroids. 
 
134
Chapter 4
135
Novel therapies on irritant contact dermatitis
Materials and Methods
Patient selection
32 patients with bilateral chronic hand dermatitis entered the study after 
informed consent was obtained. The patients were recruited from a university hospital 
outpatient clinic between January 2002 and May 2002. Chronic hand dermatitis was 
defined as an eczematous eruption present for longer than 6 months. 
Patients meeting the following criteria were included: 
• mild to moderate disease (according to the investigator global assessment) 
• good response to class I or class II topical corticosteroids 
Exclusion criteria were:
• clinically relevant allergic or irritant contact dermatitis and the inability to avoid 
exposure 
• severe and very severe hand dermatitis (according to the investigator global 
assessment)
• severe vesiculation or bullae 
• history of contact urticaria and pustular diseases
• recent therapy with potent topical corticosteroids (class III or IV)
• recent systemic therapy or phototherapy 
Methods
This pilot study compared the efficacy of an emollient containing skin-related 
lipids (Locobase® Repair; Yamanouchi Pharma BV; contains ceramide 3, oleic 
and palmitic acid in a fatty cream base with petrolatum, aqua, paraffin, paraffinum 
liquidum, glycerin, sorbitan oleate, carnauba, cholesterol, carbomer, tromethamine 
in unknown ratio; lipid content 63%) and a traditional petrolatum-based emollient 
(Vas/Lan; Cremor vaselini lanette FNA, Bipharma, BV, The Netherlands; contains 
petrolatum, lanettewax, paraffinum liquidum, propylenglycol). On entry to the study 
all patients were interviewed regarding previous course and duration of the hand 
dermatitis, contact factors in their work and/or hobbies, atopy and current use of 
emollients and topical corticosteroids. We provided information on proper skin care 
related to personal circumstances. 
Patients were asked to discontinue the use of topical prescriptions and 
emollients for a wash-out period of 1 week. Patients were randomized into 2 groups: 
17 participants were asked to use Locobase® Repair twice daily, 15 participants were 
asked to use petrolatum-based emollient twice daily. In the case of active dermatitis 
all patients were allowed to use mild corticosteroid (unguentum triamcinoloni 0.1 % 
FNA, Dutch pharmacopoeia) according to the following instructions. 
• In case of exacerbation of the dermatitis the patients were allowed to use the 
topical corticosteroid twice daily for a maximum of 1 week. After this week the 
use was tapered to once daily for a maximum of 4 days a week. 
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• In the case of clearance the patient stopped the use of the topical corticosteroid 
and continued only with the emollient.
• Patients were asked to record the use of the topical corticosteroid and emollients 
in a diary. 
Besides the study medication, no other topical treatment was allowed.
Clinical evaluation
The following variables were used to monitor the efficacy of the treatment. 
The same study investigator blindly assessed the dermatitis at various time-points: 
at baseline, after 1 month and after 2 months. To this end we used the hand eczema 
area and severity score (HEAS) as described and used before 19: the hand was divided 
into 7 areas: the palm and the back of the hand and the 5 digits, each area having its 
own correction factor based on the relative size (palm and back of the hands 0.25 and 
the digits 0.1) Each area was evaluated for area on a scale of 0-4 (0=0%, 1=1-25%, 
2= 26-50%, 3=51-75%, 4=76-100%). We scored each area for intensity of erythema, 
vesicles, papules, scaling, fissures, excoriations and hyperkeratosis on a 0-3 scale 
(0=none, 1=slight, 2=moderate, 3=severe). We calculated a score for each area by 
multiplying the % of the affected area with the correction factor and with the sum of 
the intensities of the symptoms. Finally, we calculated the sum score by adding up the 
scores of each area.
Investigator global assessment (IGA): This assessment was made on a scale 
of 0-520:
• Clear (0): no residual visible dermatitis
• Almost clear (1): minimal erythema and/or scaling 
• Mild disease (2): clearly visible signs of dermatitis (erythema, scaling), with no 
hyperkeratosis, oedema, fissures or functional impact
• Moderate disease (3): moderately severe signs of dermatitis, with a few fissures 
and moderate functional impairment.
• Severe disease (4): marked signs of dermatitis, with oedema, fissures or functional 
impairment.
• Very severe disease (5): marked signs of dermatitis with exdutation/crusting and 
very severe functional impairment.
Patients’ evaluation
A questionnaire assessed the patient’s opinion on the course of the disease 
after treatment (1=worse, 2=no change, 3=minimal improvement, 4=moderate 
improvement, 5=marked improvement, 6=clearing or almost clearing). Patients 
assessed the cosmetic acceptability of the study-emollients and rated the products as 
‘very poor’, ‘poor’, ‘acceptable ’, ‘good’, ‘excellent’ and compared this with past and 
current emollients.21 In this questionnaire, we also enquired about habits before and 
during the study in order to investigate the effect of the study protocol.
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The use of topical corticosteroids
We asked the patient to specify when topical corticosteroids were used in a 
diary. The tubes of corticosteroids were collected for weighing to determinate the 
amount of medication used. At the end of the study patients were questioned regarding 
the use of corticosteroids.
Statistics
We used the Mann-Whitney U test to test the differences in the HEAS and 
IGA between both treatment groups at baseline, at 1 month and at 2 months. For 
the differences in results between baseline and the end-of-the-study results for 
each treatment group, we used the Wilcoxon matched pairs test. For the patients’ 
assessment of efficacy, itching, cosmetic acceptability and the usage of corticosteroids 
we used the chi-square test of a contingency table. 
Table 1 Demographics of randomized patients.
Subjects baseline demographics and characteristics
Patients (n) 32
Sex (n) 10 males, 22 females
Age (years) 19-65, mean 39.15 
Duration of dermatitis (years) 0.5 to 31, mean 10.10 
Subject baseline disease characteristics
Hand eczema area and severity score 3.9
Baseline IGA (0-5) 2.3
Atopy (n) 23
Atopic dermatitis 18
Bronchial asthma 7
Hay Fever 8
Hand surface involvement (n)
Dorsum 1
Palms 2
Digits 4
Palms and digits 13
Dorsum and digits 9
Palms, dorsum and digits 3
Use of emollients 4 weeks before the study
Twice or more per day 3
Daily 9
Sporadically 11
No use 9
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Results
Efficacy
The profile of randomized patients (n=32) is shown in Table 1. 2 patients 
were lost to follow-up after the baseline visit due to unknown reasons. We used only 
their baseline characteristics. 2 patients from each group discontinued therapy during 
the study. One Locobase® Repair patient dropped out of the study at visit 1 due to 
deviation from the protocol. This patient was not able to use the emollient twice daily. 
The second dropout patient in the Locobase® Repair group and both dropout patients 
of the Vas/Lan group had to stop because of exacerbation of the hand dermatitis, 
which made it necessary to treat with a strong potency topical corticosteroid. The 
analysis at the end-of-treatment as assessed by the IGA and the HEAS involved 
30 patients including the 4 dropout patients. We observed a statistically significant 
reduction in the IGA from baseline to end-of-treatment for both treatments (p=0.005 
Locobase® Repair, p=0.007 Vas/Lan). We also observed a significant improvement in 
the HEAS in both groups (p=0.002 Locobase® Repair, p=0.02 Vas/Lan). We did not 
see any statistically significant difference between the group treated with Locobase® 
Repair and the group treated with Vas/Lan (Figures 1 and 2)
Patients’ assessment of efficacy
Assessment by patient of the treatment response at the end of treatment is 
shown in Figure 3a. Approximately 2/3 of patients of both groups (67.7% Locobase® 
Repair, 69.2% Vas/Lan) indicated improvement or clearance of the hand eczema. 
There were no significant differences between the groups. The patients’ assessment 
of itching is shown in Figure 3b. At the end of treatment, itching improved or even 
disappeared in 75% of Locobase® Repair users and 69% of Vas/Lan users. There 
were no significant differences between the groups.
Cosmetic assessment
All patients tolerated the emollients well. Evaluation of the patients opinion 
on cosmetic acceptability of the study-emollients showed that both groups rated the 
study-emollients as acceptable , good or excellent (1-5). Most patients (43.7%) using 
Locobase® Repair considered this product as good (score 4), while most patients 
(38.4%) using Vas/Lan considered it as acceptable (score 3). There was no significant 
difference in the patients’ assessment on the cosmetic acceptability between the 
groups (Figure 4). 12 % of Locobase® Repair users and 7.6% of Vas/Lan users rated 
the emollient as poor. 81 % considered Locobase® Repair as helpful in treating their 
skin condition, in comparison to 69% of patients using Vas/Lan. 53 % percent of both 
groups stated that the study-emollient was superior to their current emollient and most 
of them were likely to continue the use of the emollient (94% Locobase® Repair, 85% 
Vas/Lan). We found no significant differences between the groups.
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Figure 1 IGA - investigator global 
assessment. 0= clear 1= almost 
clear 2= mild disease 3= moderate 
disease 4= severe disease 5= very 
severe disease. * Significant decrease 
of IGA in the group treated with 
corticosteroid and Locobase 
Repair at visit 2 (end-of-treatment) 
in comparison to baseline.(p=0.005) 
** Significant decrease of IGA in 
the group treated with corticosteroid 
and Vas/Lan at the visit 2 (end-of-
treatment) in comparison to baseline. 
(p=0.007) No significant differences 
between the treated groups were 
found.
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Figure 2 Hand eczema area and 
severity score. For more details see 
Methods. * Significant decrease 
of IGA in the group treated with 
corticosteroid and Locobase 
Repair at visit 2 (end-of-treatment) 
in comparison to baseline. (p=0.002) 
** Significant decrease of IGA in 
the group treated with corticosteroid 
and Vas/Lan at the visit 2 (end-of-
treatment) in comparison to baseline 
(p=0.02). No significant differences 
between the treated groups. 
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Figure 3 Patients’ assessment of 
(a) the response of hand eczema 
(b) itching after 2 months of 
treatment with Locobase Repair 
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The use of emollients and corticosteroids
It appeared that 9 of the patients (28%) did not previously use emollients, 
whereas the remainder (72%) had used emollients with varying frequency. During the 
study most patients (56.2 % of Locobase® Repair group, 61.5 % of Vas/Lan group) 
used more of the emollient than in the period of 4 weeks before the study. 
As to the use of topical corticosteroids, the questionnaires showed that 62.2% 
of the Locobase® Repair group used less corticosteroids during the study than before 
the study, in comparison with 38.4% of Vas/Lan group. Almost half of the patients 
of the Vas/Lan group (46.1%) stated that they had had to use more corticosteroids 
during the study (Figure 5). An analysis of the diaries, in which patients recorded the 
use of corticosteroids, showed that the Locobase® Repair group used corticosteroids 
1.78 days and the Vas/Lan group 1.72 days per week. On average, the amount of 
corticosteroids used during the study was 10.7 g for the Locobase® Repair group and 
9.7 g for patients treated with Vas/Lan. These differences are not significant.
The effect of the protocol
To elucidate the effect of the protocol of the study, we asked whether certain 
changes in daily life occurred during the study. The time the patients took over the 
care of their hands before the beginning of the study was for most patients (93%) 15 
min per day. During the study 56.2% of the Locobase® Repair users spent more time 
on the care of their hands than before the study. The care-time of 37.5% of the patients 
remained unchanged. In the Vas/Lan group, 2/3 of the patients (69.2%) stated that the 
time did not change, while 37.5% of them spent more time than before the study. At 
the beginning of the study 88.9 % performed daily wet work activities, of whom 14 % 
spent even more then 2 h daily. The questionnaires showed that 22.3 % of all patients 
decreased wet work activities and also the frequency of washing of their hands during 
the study. 78 % of all patients did not change such habits at all.  
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Discussion
In the present study, an emollient containing skin-related lipids (ceramide 
3, cholesterol and free fatty acids) was compared with a traditional petrolatum-
based emollient. Active lesions were treated with a mild topical corticosteroid. Both 
treatment regimens significantly improved clinical signs as assessed by the IGA 
score and the HEAS. However, there were no statistically significant differences in 
improvement between both study arms. Furthermore, we did not observe significant 
differences in the improvement of itching, the patient’s assessment of efficacy and 
cosmetic acceptability and the usage of topical corticosteroids between both treatment 
groups.
Thus, the study shows that both emollients are effective in the therapy of hand 
dermatitis and both are cosmetically acceptable . The efficacy of traditional emollients 
containing petrolatum has already been confirmed in various skin conditions.22-26 
Because of its hydrating properties, petrolatum has been considered as a standard 
emollient against which other moisturisers should be compared.27 In this study, 
the efficacy of Locobase® Repair was comparable with a petrolatum-containing 
emollient. Because of a lack of significant differences and a lack of statistical power 
due to small sample size, we cannot conclude whether Locobase® Repair is a more 
appropriate choice than the other emollient. 
The superiority of emollients containing skin-related lipids remains a point 
of discussion. Previous studies have shown that the ratio and the concentration of 
the skin-related lipids in the emollient are crucial to the rate of barrier recovery.28 It 
is known that not all types of topical formulations that contain skin related lipids are 
effective. Out of a number of preparations, those with a lipid ratio most comparable to 
that present in the human skin barrier are considered to be effective. 29 It is unknown 
whether the ratio and the concentration of lipid component of Locobase® Repair, 
which consists of cholesterol, semisynthetic ceramide 3, oleic acid and palmitic acid, 
is optimal for barrier repair in chronic hand dermatitis. Further, ceramide 3 is the 
only ceramide that is incorporated into Locobase® Repair. Research data indicate 
that ceramide 1 is also an important ceramide in skin and it is unknown whether 
ceramide 3 can sufficiently fill the need for ceramide 1 and other natural occurring 
ceramides.30 
Furthermore, the effect of the application of skin-related lipids has varied 
depending on the method of barrier disruption. A promising effect of skin-related lipids 
was seen in experimental models of barrier dysfunction inflicted by tape stripping or 
an organic solvent. When the barrier was disrupted by treatment with detergents such 
as sodium dodecyl sulfate or ammonium lauryl sulfosuccinate, skin- related lipids did 
not accelerate barrier repair.9 This may indicate that the ability of the lipid mixture 
to accelerate barrier repair depends on the specific external damage, suggesting the 
need for damage-specific correction.31 In this study, we applied emollients in patients 
with chronic hand dermatitis, a skin condition characterized by a multifactor origin in 
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which the skin barrier may be variably relevant. There is evidence that a barrier repair 
strategy should not only meet specific demands depending on the type of external 
damage, but should also be adjusted to endogenous deficiencies.17;32-34
In conclusion, this study confirms that, related to the methodological strategies 
applied, the frequent use of emollients may be useful in the therapy of hand dermatitis 
and that patients should be encouraged to use them. However the results of this pilot 
study do not support the concept of superiority of an emollient containing skin-related 
lipids in a heterogeneous group of patients with chronic hand dermatitis. Since the 
composition of emollients is important, it should be further investigated whether 
emollients with another composition of skin-related lipids have more efficacy in 
different clinical conditions. 
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5.1 THE EFFECTS OF TOPICAL CORTICOSTEROIDS AND 
A COAL TAR PREPARATION ON DITHRANOL INDUCED 
IRRITATION IN PATIENTS WITH PSORIASIS
 
Abstract
Since more than 80 years dithranol is a mainstay in the treatment of psoriasis. 
Although a safe approach, the irritation of the clinically uninvolved perilesional skin 
remains a major limitation of this treatment. Corticosteroids and coal tar solution 
have an anti-inflammatory potential. The aim of the present study was to investigate 
the clinical and cell-biological effects of two topical corticosteroids and a coal tar 
preparation on dithranol irritation. 
During four consecutive days, dithranol 2% cream was equally applied to six 
uninvolved skin sites on the lower back of 9 patients with psoriasis. Dithranol was 
left on the skin for one hour, after which it was removed with water and soap and the 
skin was dried with a towel. Subsequently site one was treated with 0.05% clobetasol-
17-propionate ointment (CP), site two with unguentum cetomacrogolis (vehicle 1), 
site three with 0.005% fluticasonpropionate ointment (FP), site four with 10% coal 
tar solution in lanettewax cream (CTS), site five was left untreated (control) and site 
six was treated with lanettewax cream (vehicle 2). Every day erythema, oedema and 
vesicle formation was scored. On day 5, punch biopsies were taken from the six sites. 
The expression of epidermal proliferation, differentiation and inflammation markers 
and the clinical irritation scores indicate that the application of a strong potency 
corticosteroid (CP) is the best approach to minimalize dithranol irritation whereas 
CTS had virtually no effect on dithranol irritation using a 4 day experimental model.
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Introduction
Dithranol has been a main therapeutic agent for the topical treatment of 
psoriasis since 1916. Although it is a well-know irritant of the symptomless skin, it 
is a frequently applied treatment for almost a century. Although corticosteroids and 
coal tar solution (CTS) have been used to treat dithranol irritation, controlled studies 
on their effect are contradictory. Previously, it has been shown that pre-treatment 
with CP1 and betamethasone-valerate2 results in a reduction of the inflammatory 
reaction. On the other hand, Misch et al. suggested that dithranol erythema represents 
a betamethasone-17-valerate resistant form of inflammation.3 Puschman concluded 
that dithranol irritation is a hydrocortisone 1% and clobetasol-17-propionat resistant 
form of irritation.4 Juhlin observed no effect of betamethasone, while fluocinolone 
augmented the irritative response.5 Van de Kerkhof and Timmerman studied the effect 
of CP and crude coal tar on dithranol irritation in uninvolved skin: both agents did 
not influence dithranol-induced erythema, but in contrast had a synergistic effect on 
the induction of alkaline phosphatase (ALP) as a direct reflection of the metabolic 
activity of endothelial cells. The authors concluded that CP and crude coal tar are 
not indicated for the treatment of dithranol irritation but rather suggested that both 
agents aggravate dithranol irritancy.6 The aim of the present study was to investigate 
the clinical and cell biological changes in uninvolved skin of psoriatic patients after 
modulating dithranol irritation in an experimental model with topical corticosteroids, 
coal tar solution and their vehicles.
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Materials and methods 
Nine patients with psoriasis affecting more than 5% of the body surface 
participated in the present study. The patients had no signs or a history of other 
diseases of the skin or keloid-forming scars. Unstable psoriasis, oral anti-psoriatic 
medication, antihistaminic’s, NSAID’s and immunosuppressiva were exclusion 
criteria. The group consisted of two females and seven males. Their ages were 
between 42 and 82 years. Approval of the medical ethical committee was obtained 
and informed consent forms were signed.
Preliminary investigations in five subjects revealed a marked clinical response 
to 2% dithranol after one hour of application, while being well tolerated after repeated 
applications. In the present study the following model was applied to study dithranol 
irritation. For four consecutive days, dithranol 2% cream was equally applied to six 
uninvolved skin sites (Ø 3 cm) on the lower back of the nine patients. Dithranol was 
left in situ for one hour, after which it was removed by water and soap, and the skin 
was dried with a towel. Subsequently, site one was treated with 0.05% clobetasol-17-
propionate ointment (CP), site two with unguentum cetomacrogolis approaching the 
ointment base of CP and 0.005% fluticasonpropionate ointment (FP) (vehicle 1), site 
three with FP, site four with 10% coal tar solution in vaselinum album cremor lanette 
I ana partes (CTS), site five was left untreated (control) and site six was treated with 
vaselinum album cremor lanette I ana partes (vehicle 2). During day 0, 1, 2, 3, before 
dithranol application and at day 4, 24 hours after the fourth dithranol application, 
just before taking the biopsies, clinical scoring was performed. On day 4, 3 mm 
punch biopsies were taken from the six sites. For detailed information on the biopsy 
procedure see previous publications.7 
Clinical assessment
Erythema, oedema and vesicle formation were scored on a five point scale: 0 = 
absent, 1 = minimal, 2 = moderate, 3 = marked and 4 = pronounced.
Immunohistochemical assessment
The monoclonal antibody MIB-1 for nuclear expression of Ki-67 was chosen 
to assess epidermal proliferation. 
We used two differentiation markers: a monoclonal antibody against 
involucrin (MON-150) and a mouse monoclonal antibody anti-human keratinocyte 
transglutaminase. 
Three inflammation markers were used. Anti-elastase, as a monoclonal mouse 
antibody to human neutrophil elastase, was used to visualise polymorphonuclear 
leukocytes (PMN). T11 was used as a monoclonal antibody against T-lymphocytes. 
WT14 was used as a monoclonal antibody against CD14-positive cells, which 
represent monocytes and macrophages. 
An indirect peroxidase technique was used for MIB-1, MON 150, anti-
152
Chapter 5
153
Clinical aspects and topical treatment of dithranol irritation
transglutaminase and anti-elastase. For the T11 and WT14 staining the avidin-biotin 
method (ABC method) was used. 
For detailed information concerning immunohistochemistry, histological 
examination and statistical analysis we would like to refer to previous publication.7 
Table 1 Mean clinical erythema scores ±(SEM) P-value (between different 
treatments on day four) 
Treatment Day 1 Day 2 Day 3 Day 4 P-value
CP 0 ± (0) 0.4 ± (0.29) 1.1 ± (0.45) 1.6 ± (0.41) *
Vehicle 1 0 ± (0) 1.3 ± (0.33) 2.1 ± (0.26) 2.7 ± (0.33) 0.001 
FP 0 ± (0) 1.2 ± (0.27) 1.8 ± (0.43) 2.2 ± (0.32) 0.01 
CTS 0.3 ± (0.23) 1.8 ± (0.32) 2.4 ± (0.29) 2.9 ± (0.26) < 0.001 
0.01
Control 0.1 ± (0.11) 1.4 ± (0.29) 2.3 ± (0.23) 2.9 ± (0.26) < 0.001 
Vehicle 2 0 ± (0) 1.3 ± (0.28) 2.0 ± (0.37) 2.4 ± (0.29) < 0.01 
*At day 4 erythema scores at CP test sites were significantly decreased compared to the other 
5 test sites.
Table 2 mean value ±(sem) of proliferation and differentiation markers 24 hours 
after the fourth dithranol application.
Treatment
K
i-67
P
-value
Involucrin 
Interpapillary
Involucrin 
P
apillary
P
-value
T
G
M
 
Interpapillary
T
G
M
 P
apillary
CP 5 ± (1.8) 0.28 ± 
(0.06)
0.42 ± 
(0.06)
0.30 ± 
(0.05)
0.47 ± 
(0.07)
Vehicle 1 19.2 ± 
(6.8)
0.26 ± 
(0.04)
0.46 ± 
(0.05)
0.05 
(CTS)
0.27 ± 
(0.03)
0.47 ± 
(0.04)
FP 13.7 ± 
(4.0)
0.28 ± 
(0.04)
0.49 ± 
(0.05)
0.30 ± 
(0.04)
0.55 ± 
(0.05)
CTS 26.8 ± 
(6.5)
< 0.01 
(CP)
0.30 ± 
(0.04)
0.55 ± 
(0.05)
0.01 
(CP)
0.32 ± 
(0.03)
0.55 ± 
(0.04)
Control 23.3 ± 
(5.1)
0.02 
(CP)
0.30 ± 
(0.03)
0.51 ± 
(0.04)
0.04 
(CP)
0.31 ± 
(0.02)
0.46 ± 
(0.04)
Vehicle 2 12.9 ± 
(4.2)
0.26 ± 
(0.05)
0.46 ± 
(0.05)
0.05 
(CTS)
0.26 ± 
(0.04)
0.51 ± 
(0.05)
p-value (between different treatments) only mentioned if significant.
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Results
Clinical results 
Table 1 summarises erythema scores. In none of the volunteers oedema or 
vesicle formation were noticed. 48 hours after the first dithranol application all 
volunteers showed an erythematous reaction on the control site which increased 
up to day 4. 96 hours after the first dithranol application we noticed a maximum 
of irritation. P-values of the statistical analysis of the responses at day 4 of the six 
different test sites are given in Table 1. The erythematous reaction on the vehiculum 
1 and the vehiculum 2 site were comparable to that on the control site on all days. CP 
suppressed the erythematous response in the majority of the volunteers on day 2. Two 
patients showed pronounced irritation. Even on day 3, there were still 5 volunteers 
who did not show any irritation, and on day 4 eight out of nine volunteers showed mild 
irritation while the ninth did not show irritation at all. On day four CP significantly 
reduced of erythema scores as compared to all other treatments. At the FP treated site 
irritation started on day 2 increasing further on day 3 in eight volunteers. However, on 
day 4 in none of the volunteers a significant reduction of the erythematous response 
to FP was observed as compared to the control site. At the CTS treated site we already 
observed pronounced irritation in 2 volunteers at day 1. On day 2, eight volunteers 
showed irritation and on day 3 all volunteers showed pronounced irritation. On day 4, 
we noted a significant increase of the erythematous response compared to the CP and 
the FP treated site. 
Remarkably, in one patient we observed sharply demarcated annular islands of 
normal appearing skin, even on day 4, within the erythematous test sites. 
. 
Cell biological results 
The cell biological results 24 hours after the fourth dithranol application (96 
hours after the first) have been summarised in Table 2 and 3.
The staining for epidermal proliferation (Ki67 staining) revealed less cycling 
epidermal cells on the CP treated site in comparison with the control site (p = 0.02) 
while the CTS treated site showed a significant higher number of cycling cells, in 
comparison with the site treated with CP (p < 0.01). 
Evaluating the epidermal differentiation markers we found a significant 
difference of the papillary involucrin ratio between the CP treated site and the control 
site (p = 0.04). The CTS treated site showed a significant higher ratio in comparison 
with the site treated with CP (p = 0.01), but also compared to the site treated with 
vehicle 1 (p = 0.05) and the site treated with vehicle 2 (p = 0.05). Transglutaminase 
expression revealed no statistically significant differences.
With respect to inflammation, epidermal T cell accumulation at the CP 
treated site was found to be significantly reduced compared to the sites treated with 
vehicle 1, vehicle 2 and the control site (p = 0.02). The occurrence of monocytes 
and macrophages at the CP treated site was significantly reduced in the epidermis (p 
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= 0.02) and diffuse in the dermis (p < 0.01) in comparison to the sites treated with 
vehicle 1, vehicle 2 and the control site. Anti-elastase (PMN) staining did not reveal 
significant differences between the test sites.
 
Table 3 Mean value ±(sem) of inflammation markers in the six treated sites 24 
hours after the fourth dithranol application. 
Treatment T-lymphocytes Monocytes And 
Macrophages
Polymorphonuclear 
Cells
E
piderm
al
D
iffuse 
D
erm
al
P
eri-
Vascular 
E
piderm
al
D
iffuse 
D
erm
al
P
eri-
Vascular 
E
piderm
al
D
iffuse 
D
erm
al
P
eri-
Vascular 
CP 0.7 ± 
(0.2)
1.1 ± 
(0.1)
1.9 ± 
(0.2)
0.7 ± 
(0.17) 
1.2 ± 
(0.15) 
2.0 ± 
(0)
0.0 ± 
(0)
0.9 ± 
(0.11)
0.3 ± 
(0.17)
Vehicle 1 1.0 ± 
(0)
1.3 ± 
(0.2)
2.4 ± 
(0.2)
1.0 ± 
(0)
1.8 ± 
(0.15)
2.1 ± 
(0.11)
0.0 ± 
(0)
0.8 ± 
(0.15)
0.4 ± 
(0.17)
FP 0.9 ± 
(0.1)
1.1 ± 
(0.1)
2.0 ± 
(0)
0.8 ± 
(0.17)
1.7 ± 
(0.17)
2.2 ± 
(0.15)
0.1 ± 
(0.11)
0.7 ± 
(0.17)
0.0 ± 
(0)
CTS 1.0 ± 
(0)
1.3 ± 
(0.2)
2.8 ± 
(0.3)
1.0 ± 
(0)
2.0 ± 
(0.17)
2.6 ± 
(0.24)
0.2 ± 
(0.15)
0.9 ± 
(0.11)
0.4 ± 
(0.17)
Control 1.0 ± 
(0)
1.4 v 
(0.2)
2.7 ± 
0.2)
1.0 ± 
(0)
1.9 ± 
(0.11)
2.7 ± 
(0.23)
0.1 ± 
(0.11)
0.8 ± 
(0.15)
0.2 ± 
(0.15)
Vehicle 2 1.0 ± 
(0)
1.2 ± 
(0.2)
2.4 ± 
(0.3)
1.0 ± 
(0)
1.9 ± 
(0.11)
2.2 ± 
(0.15)
0.0 ± 
(0)
0.9 ± 
(0.11)
0.4 ± 
(0.17)
Only significant p-values are mentioned.
Semiquantitative T-lymphocytes scores: CP scores were significantly different compared to 
the sites treated with vehicle.1,2 And the control site: epidermal (p = 0.02 )
Semiquantitative monocytes and macrophages scores: cp scores were significantly different 
compared to the sites treated with vehicle.1,2 And the control site: epidermal (p = 0.02 ) And 
diffuse dermal (p < 0.01).
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Discussion
We investigated the clinical and cell biological changes after influencing 
dithranol irritation by topical corticosteroids, a coal tar solution and their vehicles in 
uninvolved skin of patients with psoriasis. Clinical observation showed that, although 
the majority of patients (eight out of nine) demonstrated an inflammatory reaction 48 
hours after the first dithranol application, dithranol irritation was already manifest 
after 24 hours (1 patient). The maximal irritation was observed at day 4 (24 hours 
after the fourth dithranol application). The appearance of irritation 24-48 hours after 
dithranol application is in correspondence with literature.1;8 The response to dithranol 
is dependent on the concentration, application time and frequency of application. The 
sharply demarcated annular islands of normal appearing skin within a pronounced 
erythema of test sites even on day 4 in one patient is intriguing. It is attractive to 
speculate that previous psoriatic lesions or initial psoriatic involvement below the 
clinical threshold was present causing resistance to dithranol. 
CP treatment significantly suppressed the erythematous response to dithranol, 
whereas CTS seemed to have no effect. In a pilot study (n = 10) with the same design 
we found no effect of CTS, confirming the present findings. In an earlier study we 
investigated the influence of CP 0,05% ointment on dithranol short contact therapy 
showing a reduction of perilesional irritation at the cellular level although this 
effect was not expressed by reducing dithranol erythema.9 In the present study, coal 
tar solution had no inhibitory effect on dithranol irritation, confirming findings in 
several previous studies.6;10;11 Other authors found that combined therapy of dithranol 
and coal tar augmented the rate of clearance of psoriasis and diminished dithranol 
irritancy12;13 and explaining its widespread and long-established clinical use.14-18 It has 
been suggested that this effect is caused by the inactivation of dithranol by coal tar.19 
The addition of coal tar results in a rapid oxidation of dithranol into its ineffective 
oxidation products, danthron and dithranol dimmer.20 The contradictory results 
may be explained by the fact that crude coal tar preparations and coal tar solution 
preparations are not identical concerning the described effects.
Ki-67 is a suitable marker of dithranol irritation. De Zwart et al. observed a 
significant increase of Ki-67 positive cells after 48 hours of dithranol application.21 
Epidermal proliferation, Ki-67staining, revealed less cycling epidermal cells on the 
site treated with CP in comparison with the control site (p = 0.02), while the site treated 
with CTS showed a significant higher number of cycling cells, in comparison with site 
1 (p = 0.005). Evaluating the epidermal differentiation markers we found a significant 
difference of the papillary involucrin ratio between the site treated with CP and the 
control site (p = 0.04). The site treated with CTS showed a significant higher ratio 
in comparison with the site treated with CP (p = 0.01), the site treated with vehicle 
1(p = 0.05) and the site treated with vehicle 2 (p = 0.05). Concerning inflammation, 
epidermal T cells, monocytes and macrophages and diffuse dermal monocytes and 
macrophages were found to be significantly reduced on the site treated with CP. Those 
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effects underline the clinical results and confirm strong potency corticosteroids (CP) 
as the best treatment for dithranol irritation. 
The present study, using a model of 4 days short contact dithranol challenge of 
the uninvolved skin of patients with psoriasis, suggests that CP is effective in reducing 
dithranol erythema, whilst CTS is not. The role of CP and CTS in reducing dithranol 
irritation during treatment of psoriatic plaques remains controversial. 
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5.2 DITHRANOL IRRITATION IN PSORIASIS TREATMENT: A 
STUDY IN 68 INPATIENTS 
Abstract
The irritative response of perilesional skin is a serious limitation of dithranol 
therapy in psoriasis. No data are available on the actual prevalence and severity 
of irritation during 24 hours dithranol treatment in an inpatient setting. Using a 
retrospective analysis of 68 patients with psoriasis visiting our inpatient department 
for dithranol treatment, the occurrence of dithranol irritation was studied. We found a 
relatively high frequency of dithranol irritation. Most irritation occurs at the start of 
the therapy with relatively low concentrations.
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Introduction
Dithranol (1,8-dihydroxy-9-anthrone), also known as cignolin or anthralin, 
has been a mainstay in the treatment of psoriasis for more than eight decades.1 It may 
be used in different formulations (ointment, paste, cream or stick) and application 
schemes. Dithranol can be applied for 24 hours, in paste Lassar or stiff paraffin on 
the psoriatic lesions, or in white petrolatum on the involved and the uninvolved 
skin (diffuse application). Application for 24 hours is practically impossible in an 
outpatient setting because of irreversible staining of garments and furniture. Although 
dithranol treatment is safe, the irritative response of perilesional and uninvolved skin 
is a serious limitation.2;3In case of irritation, application has to be withdrawn for 
several days and may result in a prolongation of the treatment. Alternative application 
schedules with a cream formulation in a short contact exposure seems to reduce the 
disadvanrage of staining of the classical 24 hours dithranol application.1;4 Because 
of short contact times, staining of clothes can be avoided and patients can be treated 
at home. Comparing different vehicles and treatment schedules of dithranol, 24 
hours application of dithranol in a paste or ointment appears to be most effective. 
Inpatient treatment results in a significant faster clearance as compared to outpatient 
treatment.1
At our inpatient department of dermatology we routinely use dithranol 
ointment which is diffusely applied for 24 hours. So far, the information on the 
duration of dithranol irritation and the relationship of dithranol irritation with the 
duration of treatment has not been documented. Therefore, we set out to study the 
occurrence of irritation in our inpatient department. In particular we investigated 
the frequency and threshold concentration for irritation during treatment with 24 h 
application of dithranol ointment. In the present study we analyzed retrospectively 
the characteristics of dithranol irritation and interpreted the irritation in the light of 
available information on the characteristics of responses to other irritants.
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Material and methods
The present study is based on a retrospective analysis of data from records 
of patients visiting our in-patient department for psoriasis treatment during the 
period January 1999 until March 2001. In total 68 patients with generalised psoriasis 
were included and evaluated. These patients were treated with a dithranol ointment 
(dithranol in white petrolatum) as monotherapy for 24 hours. Dithranol ointment was 
applied diffusely over the skin (both involved and uninvolved skin) below the head 
and neck, except flexures. Tube-bandages were used to cover the dithranol application 
sites and to protect the patient’s clothes and environment. Dithranol was applied daily 
by trained nurses. The treatment was started with 0.1 % dithranol and if no irritation 
occurred the concentration was increased stepwise every three-four days (maximum 
concentration 5.0%) according to a written protocol used at our centre. Dithranol 
ointment was prescribed in the following concentration: 0.1%, 0.25%, 0.3%, 0.4%, 
0.6%, 0.8%, 1.0%, 2.0%, 3.0%, and 5.0%. In case of irritation, physician decided to 
remain at the same concentration or to interrupt the dithranol treatment for a few days. 
The use of emollients was recommended during the cessation of treatment. Physicians 
were also the persons who determinate the re-introduction of dithranol therapy which 
wasusually started with a lower concentration. The treatment was continued until 
total clearance was reached or a considerable improvement had occurred which was 
acceptable for the patient. Patients who have used systemic therapy, phototherapy and 
topical treatments of corticosteroids and vitamin D3 analogues were excluded from 
the analysis. 
Information was collected concerning frequency of hospitalisation during the 
study period, the frequency and duration of “irritation-episodes” and the concentration 
which caused irritation. In this study an irritation-episode was defined as an episode 
of skin irritation, which required temporary cessation of dithranol therapy as assessed 
by a physician.
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treatment interruption (days). 
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Results
We evaluated 68 patients with psoriasis who received at least one course of 
monotherapy with dithranol ointment during the period January 1999 until March 
2001 at our inpatient department. 34 were male and 34 were female, ranging in age 
from 17 to 92 years. 64 were of Caucasian origin and 4 of Asian origin.
The average number of hospitalisations per patient was 1.4 during the 26 
months observation period. In total 172 irritation episodes were recorded during 96 
hospitalisations. The average number of irritation episodes per hospitalisation was 1.9 
and the mean duration requiring discontinuation of dithranol was 2.36 days. Table 1 
summarises the hospitalisation data. Figure 1 shows the number of days patients were 
not treated because of irritation per episode. Mostly the irritation was short lasting. In 
73% of the patients the irritation was 2 days or less. The percentage of patients who 
had to discontinue dithranol for 4 days or longer was 13%. Most patients (85.3%) 
experienced skin irritation at least once during the treatment, while 14.7% patients 
did not have skin irritation and completed the dithranol treatment without interruption 
(Figure 2).
The frequency of irritation-episodes in relation to the concentration of dithranol 
in the vehicle is shown in Figure 3. Most episodes of irritation occurred at the start of 
the therapy with relatively low concentrations (0.1%- 0.2%).
Table 1 Data on hospitalisation and irritation
Number of patients 68
Total hospitalisations (from January 1999 until March 
2001)
96
Hospitalisations per patient (mean ± SEM) 1.41 ± 0.08
Days of treatment period (mean ± SEM) 37.26 ± 1.84 
Total irritation-episodes 172
Irritation-episodes per hospitalisation (mean ± SEM) 1.92 ± 0.18
Stop days per irritation-episode (mean ± SEM) 2.36 ± 0.71 
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Discussion
In the analysis of 68 inpatients we observed in 85,3 % of the patients experienced 
skin irritation. Most of the patients had only one episode of dithranol irritation and the 
irritation was mild and caused only a short cessation of the therapy (up to 2 days). This 
is in line with our impression, that extreme irritation during this regime is rare. Only 
13 % of the patients had to discontinue dithranol treatment for 4 days or longer for 
reasons of irritation. As may have been predicted, the number of patients experiencing 
irritations in this study is higher compared to available data on skin irritation taken 
from clinical trials where dithranol crème in short contact regime in outpatients was 
applied (48% - 72%).5-7 Short application time of dithranol relatively increases the 
bioavailability in the psoriasis plaque compared to the healthy skin. This phenomenon 
makes it possible to treat the patients with high concentration of dithranol, while side 
effects remain modest.8 The other possibility for the high prevalence of dithranol 
irritation in our study might be due to the high number of our patients with severe and 
instable disease. The sensitivity to dithranol in these patients is likely to be increased. 
Furthermore, most episodes of dithranol irritation occur at the start of the therapy 
with relatively low concentrations (0.1 - 0.2 %). Subsequently with further dosage 
increments episodes of irritation were less frequent. These results have confirmed the 
well known clinical experience that in the course of treatment with dithranol, the skin 
adapts and will be less susceptible to the irritant effects of dithranol. This adaptive 
effect is also responsible for the decrease of antipsoriatic potency of dithranol during 
prolonged treatment which requires increasing concentrations of dithranol.9
Such an adaptation is in striking contrast to e.g. sodium dodecyl sulphate 
irritation, where repeated challenges cause summation of the irritant response.10-
12 In case of dithranol irritation the possibility of a delayed type hypersensitivity 
should be reconciled.13-16 Differentiation between an irritant response or a delayed 
type hypersensitivity may be a problem as dithranol irritation occurs at low 
concentrations. Adaptation following repeated application is normally not seen with 
subsequent applications of a contact allergen. For example, repeated applications 
of diphenylcyclopropenone is a well known treatment of alopecia areata.17 These 
applications elicit a mild eczema and no tendency of habituation is observed in the 
vast majority of the patients. In fact, one study showed tolerance to the contact allergen 
only in 5.8% of the patients.18 Apparently, the adaptation during repeated applications 
of dithranol discloses an entirely different mechanism which is suggested to be 
specific for dithranol irritation.19 However, the underlying mechanism of this adaptive 
response of the skin has not been elucidated. Brandt and Mustakallio suggested that this 
adaptation may be due to exhaustion of anthrone-induced inflammatory mediators.20 
Lawrence and Shuster hypothesised that this phenomenon may be caused by an 
unknown active adaptive mechanism. They found that tape stripping and a very low 
dose of dithranol induced tolerance of the skin to dithranol.21 Farkas et al. investigated 
repeated treatment with dithranol in a hyperproliferative human keratinocyte line. 
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Their results indicated that the keratinocytes experienced tolerance (tachyphylaxis) 
to the antiproliferative effects of dithranol due to a selective elimination of the most 
dithranol-sensitive cells.9 Kemeny et al. recently demonstrated that a low dose of 
dithranol significantly suppressed dithranol induced mouse ear oedema, whereas 
it had no effect on croton oil- or dinitrofluorobenzene (DNFB)-induced dermatitis. 
Superoxide dismutase treatment cancel this tolerance-inducing effect of low dose 
dithranol, indicating that superoxide anion radicals are involved in the triggering the 
adaptive mechanism of dithranol.22 Further studies are needed to elucidate the exact 
mechanism of adaptation of the skin to dithranol which may be helpful in finding 
optimal therapeutic schedules with dithranol for the treatment of psoriasis.
In conclusion, dithranol irritation is a phenomenon which occurs preferentially 
in an early phase of dithranol treatment. This habituation to dithranol irritation is in 
contrast with the response to other irritants. 
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5.3 SKIN IRRITATION DURING TREATMENT OF CHRONIC 
PLAQUE PSORIASIS WITH SHORT CONTACT DITHRANOL 
VERSUS CALCIPOTRIOL OINTMENT
Abstract
The efficacy of topical treatment with dithranol and calcipotriol in psoriasis is 
well-established. In an open randomized trial we studied aspects of skin irritancy of 
both treatments. 105 patients with chronic stable plaque psoriasis were included. 52 
patients were treated with short contact dithranol and 53 patients were treated twice 
daily with calcipotriol ointment once daily. All patients were treated at the day-care 
centre.
Skin irritation was observed in 48.1% of patients treated with dithranol and 
in 18.9% of patients treated with calcipotriol. We did not observe any significant 
correlation between Psoriasis Area and severity Index (PASI) on the entry of the study 
and frequency of skin irritation in both treatments. No significant correlation was 
observed between skin irritation and PASI-scores at the end of treatment.
In conclusion, skin irritation during dithranol and calcipotriol treatment 
is probably not very relevant to the efficacy of these treatments in the studied 
population.
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Introduction
Treatment with dithranol has been a time-honored principle in the topical 
treatment of psoriasis, characterized by high efficacy and safety. However, staining 
and irritation are serious limitations of this treatment.1 In the majority of patients, skin 
irritation occurs during dithranol treatment when dose increasments are carried out. 
Irritation during dithranol has been suggested to be a prerequisite for efficacy. 
Topical treatment with calcipotriol has become a mainstay in the treatment 
of mild to moderate psoriasis. Calcipotriol is generally well tolerated although skin 
irritation is a side effect, which occurs in 10-25% of the patients if treated twice daily 
with calcipotriol ointment.2-6 So far, no studies have been reported suggesting that 
irritation due to calcipotriol is followed by enhanced or decreased efficacy.
The aim of the present study was to characterize irritation during dithranol 
and calcipotriol treatment in order to find out (I) whether the frequency of irritation 
depends upon the severity as assessed by PASI before treatment and (II) whether 
patients with irritation have a more-or less favorable clinical response to calcipotriol 
and dithranol compared to patients without irritation.
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Materials and methods
Study design
The trial was a multi-center, randomized; open, prospective, parallel-group 
comparison of two treatments and was performed in the Netherlands. Patients were 
instructed and treated at day-care centers in order to reach optimal compliance.
Subjects
Out-patients, of both sex and aged 18 or over, with a minimum PASI score for 
extent of  2 in at least one body region, were recruited. Medical Ethics Committee 
approval was obtained prior to recruitment and all patients gave informed consent. 
Patients with guttate, pustular, erythrodermic or exfoliative psoriasis, patients who 
have received systemic antipsoriatic treatment or phototherapy within the last 6 
weeks, patients with changes in their concurrent medication that could affect their 
psoriasis during the study period, patients with known or suspected hypercalcaemia, 
patients who are hypersensitive to components of either calcipotriol ointment or 
dithranol cream and females who were pregnant or not using adequate contraception 
were excluded.
Randomization
Randomization was by computer-generated random numbers.
Study visit schedule
Subjects attended a screening visit at which all treatments for psoriasis were 
discontinued except for emollients and/or descaling agents (5% salicylic acid in white 
petrolatum). After a 2-week washout period subjects attended for a baseline visit. 
Those who met all entry criteria were randomly allocated to one of two treatment 
groups. Subjects were seen at study visits by the same clinical investigator at 2, 4, 8 
and 12 weeks of active treatment.
Treatment protocol
A labor- and time intensive treatment concept for both treatments has been 
chosen that combines treatment of the patient in a day-care center with home 
treatment, aiming to improve self-treatment and treatment compliance. During the 
first week, the patients were treated and instructed at the day- care center daily. 
After this week patients were treated at the day-care center twice a week and treated 
themselves at home the other five days of the week. 
Calcipotriol ointment (50 g/g, Daivonex ointment, Leo Pharma BV) was 
applied twice daily to all lesions below the head and neck, not exceeding a maximum 
of 100 g per week.
Dithranol cream (dithranol, cetiol V, cetomacrogol wax, liquid petrolatum, 
salicylic acid, sorbic acid, ascorbic acid, demineralized water) in appropriate 
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concentrations (0.05%-0.1%-0.2%-0.3%-0.4%-0.6%-0.8%-1%-2%-3%) was applied 
to lesional and perilesional skin. Dithranol preparations were manufactured, certified 
and supplied by Tiofarma, the Netherlands. Dithranol was applied according to a 
short-contact treatment regime. We used a three days short contact application scheme 
starting with 15 minutes of application, followed by 30 to 45 minutes application 
time. After each application dithranol was washed off. After three days of 45 minutes 
application time the therapy was continued with a 15 minutes application of a one 
step higher concentration. Individual adjustments were allowed, according to the 
individual patient’s susceptibility. Patients who were intolerant to 0.1% dithranol 
cream, started their treatment with 0.05% dithranol cream. Face and scalp were 
excluded from this treatment. In case of irritation the treatment time was shortened or 
dithranol concentration was lowered. The duration of treatment in this study was 12 
weeks. Because of the differences in the treatment schedules, it was not possible to 
blind the study. 
Compliance Checks
During the first week daily and subsequently twice a week the patients were 
treated at the day-care centre, which guaranties 100% compliance at these visits. 
The patient’s study compliance at home was monitored by asking the patient at all 
study visit if he/she had used the meditation as prescribed. If not, the degree of non-
compliance was recorded.
Clinical Assessments
At baseline, 2, 4, 8 and 12 weeks of treatment the severity was assessed using 
the modified PASI. The extent of psoriatic involment was recorded for each of the 
three areas: upper extremities, trunk and lower extremities (which correspond to 20, 
30 and 40% of the body area, respectively) using the following 7-category scale: 0=no 
involment, 1=<10%, 2=10-29%, 3=30-49%, 4=50-69%, 5=70-89%, 6=90-100%. The 
head and neck were not assessed. The severity of the psoriasis lesions was recorded 
with respect to each of the following three clinical signs: redness, thickness, scaliness 
using the 5-category scale below: 0=no cutaneus involment,1=slight involment, 
2=moderate involment,3=severe involment, 4=severest possible involment.
Skin Irritation
In case of skin irritation the duration of irritation, the intensity (mild, moderate 
or severe) was recorded.
Statistics
Patients with irritation and without irritation were compared with respect to the 
decrease in PASI-score during treatment using a student t-test. 
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Tabel 1: Treatment duration (in days) before the first period of skin irritation
Calcipotriol (n=53) Dithranol (n=52)
Mean 30.7 26.3
SD 18.7 17.3
Minimum 8 0
Maximum 57 56
Tabel 2. The number and percentage of patients in each category of number of skin 
irritation episodes
Calcipotriol (n=10) Dithranol (n=25)
Number of 
skin irritation 
episodes
Number of 
patients
% Number of 
patients
%
1 10 100 13 52
2 0 0 5 20
3 0 0 5 20
4 0 0 1 4
5 0 0 1 4
Tabel 3: Baseline PASI. No significant correlation was found between severity of 
psoriasis at the entry of the study and skin irritation in both treatments groups
Calcipotriol (n=53) Dithranol (n=52)
Skin irritation 
(n=10)
No skin 
irritation
(n=43)
Skin irritation
(n=25)
No skin 
irritation
(n=27)
Mean 11.2 9.4 10.5 9.7
Median 9.8 8.6 10.7 9.0
SD 5.3 5.2 2.6 4.9
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Results
In total 52 patients were randomized in the dithranol treatment group and 53 in 
the calcipotriol group. Twenty-five (48.1%) of the 52 patients in dithranol group and 
ten (18.9%) of the 53 patients in the calcipotriol group experienced at least one episode 
of irritation. The treatment duration before the first episode of skin irritation for both 
treatments is shown in Table 1. Treatment duration before the occurrence of skin 
irritation was comparable in both groups. The Table 2 shows the number of episodes 
with skin irritations in calcipotriol and dithranol treated patients. During calcipotriol 
treatment only one single episode of irritation occurred and in the dithranol group 
12 out of 25 patients had multiple episodes of irritation. In the calcipotriol group the 
average number of days with skin irritation was 2.3 days, in dithranol group 7.2 days. 
In four patients of the calcipotriol group skin irritation was the reason of withdrawal. 
In the dithranol group, three patients withdrew due to skin irritation. Regarding 
severity of irritation, two patients of the calcipotriol group experienced irritation as 
mild, seven patients as moderate and one patient as severe. In the dithranol group, 
twelve patients experienced the skin irritation as mild, eleven patients as moderate 
and one patient as severe. The severity had not been assessed in one patient.
Table 3 and Table 4 show the baseline PASI-scores and the end of treatment 
PASI-scores of these patients with and without skin irritation, respectively. No 
significant differences were found with respect to the baseline PASI-scores and end 
of treatment PASI-scores between the treatment groups and between patients with or 
without skin irritation.
Table 4 End of treatment PASI. No significant correlation was found between 
severity of psoriasis at the end of study and skin irritation in both treatments 
groups
Calcipotriol (n=53) Dithranol (n=52)
Skin irritation 
(n=10)
No skin 
irritation
(n=43)
Skin irritation
(n=25)
No skin 
irritation
(n=27)
Mean 5.3 3.2 3.8 3.2
Median 4.8 2.2 2.7 2.6
SD 3.4 3.5 3.1 3.1
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Discussion
In the analysis of 53 out-patients treated with short contact dithranol was 
observed that 48.1% of these patients experienced irritation. Half of these patients 
(52%) had only one episode of dithranol irritation and the irritation was mild. 
Occurrence of skin irritation during short contact dithranol considerably varies in 
literature (48% to 72 %).7-9 The frequency of skin irritation by calcipotriol ointment 
in this study was 18.9% and is in line with literature (10-25%).10-12 Although skin 
irritation was observed more often in the dithranol group, such was not reflected in 
a higher number of patients (n=3) who stopped compared to the calcipotriol group 
(n=4). 
Skin irritation during dithranol treatment is a major limitation of this time-
honored treatment. Many unsuccesful attempts have been made to reduce the side 
effect of dithranol by changing the duration of the application or the vehicle, or by 
a combination of dithranol with other drugs. A marked irritation to dithranol may 
require stopping the treatment for one or more days. Previously, a significant negative 
correlation between the duration of cessation of treatment for reason of irritation and 
treatment days needed to achieve a clearance of skin in a population of patients with 
moderate to severe plaque psoriasis has been observed.13 However, in the present 
study we did not observe a correlation between PASI-scores at the end of treatment 
period and skin irritation. Therefore, although the duration of treatment required for 
clearing may be longer in patients with severe irritation, the efficacy assessed at the 
end of treatment was similar. 
Skin irritation during treatment with calcipotriol is the most frequent reported 
adverse event. Although the skin irritation during calcipotriol treatment is often mild, 
it may impair compliance and eventually result in the decreased efficacy. In literature 
some patients experienced deterioration of psoriasis accompanied by skin irritation of 
the uninvolved skin.7 In the present study, we did not observe a significant correlation 
between skin irritation and PASI-scores at the end of the treatment, although a 
tendency was observed that patients without skin irritation reached better results.
The exact underlying pathogenic mechanism of the calcipotriol- and dithranol 
- induced skin irritation has not been elucidated. Both of them do not affect the 
skin barrier (non-corrosive type of skin irritation).14-16 It is generally assumed that 
dithranol irritation is caused by the formation of super-oxide radicals due to the loss of 
a hydrogen atom from the methylene group at position C-10.17 Regarding calcipotriol, 
recent studies have shown that the irritant profile of calcipotriol is dominated by 
vascular reactions. The special ointment, which is needed to keep calcipotriol stable 
, may be in part responsible for the skin irritation. Furthermore, in individual patients 
the possibility of allergic contact dermatitis should be reconciled.18-24 
It has been suggested that patients with unstable relapsing psoriasis are more 
sensitive to dithranol irritation. PASI-scores, reflect severity of the disease and not 
necessarily indicate instability of the disease. However, in this study, the severity of 
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the disease before treatment as assessed by PASI-scores did not correlate significantly 
with the frequency and the severity of irritation. In the calcipotriol group we did not 
observe a significant correlation between baseline PASI-scores and the frequency of 
irritation either. These results indicate that PASI-scores has not a predictive value for 
dithranol and calcipotriol induced skin irritation.
In conclusion, skin irritation following dithranol and calcipotriol are common 
limitations to these treatments. In this study, irritation during these treatments showed 
a limited impact on the clinical efficacy. A baseline PASI-score does not have a 
predictive value for the development of skin irritation during these treatments in the 
population studied. 
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This thesis addresses several aspects of the epidermal barrier. The primary 
role of the epidermis is to form an efficient barrier for chemical, physical and 
microbiological threats. Epidermal growth takes care of the continuous adaptive 
formation of the stratum corneum (SC). The SC is a very efficient defence line against 
the penetration of chemicals, ultraviolet light and microorganisms. The barrier is not 
perfect and penetration of external agents may harm the viable layers of the epidermis. 
Also, external agents and environmental circumstances may cause direct harm to the 
SC. The injuries to the skin, both to the SC and the deeper layers, normally lead to 
regeneration and adaptation of the epidermal compartment. However, if the injury is 
severe or the epidermis is diseased, repair may be delayed or incomplete. If this is the 
case, disturbed epidermal differentiation will lead to sub-optimal barrier formation. 
Increased susceptibility to external agents may be the result and a vicious circle may 
ensue. 
Many skin diseases are associated with the impairment of epidermal barrier 
function. In this thesis we focused on three chronic skin disorders, irritant contact 
dermatitis (ICD), atopic dermatitis (AD) and psoriasis vulgaris (PV), more or less 
associated with skin barrier impairment. Since curative therapy of these diseases is 
still needed, the disturbed skin barrier is an attractive target for the development of 
new therapies. Therefore, new insights in the involvement of the impaired skin barrier 
in the pathogenesis of these diseases are necessary.
In this final chapter we will discuss epidermal barrier function in these three 
disorders, in relation to our findings described earlier.
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6.1. BARRIER REPAIR STRATEGIES IN THE TREATMENT 
OF IRRITANT CONTACT DERMATITIS
Irritant contact dermatitis (ICD) may be caused by external factors directly 
influencing the barrier function of the SC. Occlusion and high ambient humidity may 
over-hydrate the skin, low ambient humidity may dry the skin and chemicals may 
damage the cellular and intercellular domain e.g. by washing out lipids. All these 
factors have an impact on the function of the SC, which may, per se, lead to skin 
irritation. External toxins may also penetrate the skin and give rise to damage to the 
viable layers of the epidermis with or without interaction with the SC. Damage to 
these deeper layers will lead to disturbed differentiation and SC formation.
Skin irritation is under most circumstances quickly reversible. However, 
ICD may be very chronic and the question rises why healing takes often so much 
time despite strong reduction in skin exposure to irritants. Sustaining factors may 
involve persistent inflammation and/or persistent barrier disturbance. Therefore, anti-
inflammatory therapy may be useful in accelerating the cure of the irritant dermatitis. 
Especially anti-inflammatory treatments which may have a beneficial effect on the 
function of the SC, or at least do not cause atrophy of the epidermal compartment 
such as dermatocorticosteroids, are good candidates. The development of such anti-
inflammatory agents is hampered by the fact that more target sites could be relevant in 
the skin barrier repair. Furthermore, in most cases the interaction between target sites 
is unknown or debatable. Therefore, the elucidation of the relationship between anti-
proliferative effects of such drugs and the skin barrier repair requires further studies. 
In most hyperproliferative conditions (e.g. psoriasis) the beneficial effect of the 
anti-proliferative and anti-inflammatory agents like dermatocorticosteroids has been 
shown.1 Contrary, in ICD associated with barrier impairment, the anti-proliferative 
effects of dermatocorticosteroids has been suggested to cause recovery delay of the 
skin barrier. 2;3
6.1.1. Cytokines as a therapeutical target
An attractive target for new anti-inflammatory agents is the modulation of 
cytokines, since up-regulation may both play a role in the pathogenesis of ICD and 
on repair processes after barrier disruption. The inhibition of their production may 
diminish the inflammatory response accompanying ICD.4 However, the interaction 
between cytokines, (especially TNF-α) and barrier repair remains to be clarified. 
Some animal studies show a marked increase in epidermal cytokines in response to 
barrier disruption suggesting their major role in skin barrier repair.5;6 In contrast, the 
development of TNF receptor type I and IL-1 receptor deficient mice, as a decisive 
model, raises doubts about the role of TNF-α and IL-1 in barrier repair. Since a normal 
phenotype and normal recovery after barrier disruption in these knock-out mice has 
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been observed, some authors suggested that TNF-α is probably not essential in the 
process of skin repair.7 Therefore, the modulation of TNF-α and other cytokines 
has probably no effect on repair. This implies that the development of new anti-
inflammatory agents targeting the improvement of the skin barrier, should be based 
on more precise insights in the pathogenesis of ICD.
In this thesis, we investigated a new anti-inflammatory agent (cipamfylline), 
which by inhibition of phosphodiesterase-4 (PDE-4) is able to suppress cytokines.8 
We know that PDE-4 inhibitors are able to suppress the production of cytokines (e.g. 
TNF-α) in keratinocytes. 9;10 PDE-4 inhibitors have been used successfully in the 
treatment of atopic dermatitis as well.11 Therefore, we considered a PDE-4 inhibitor 
as a good candidate for the treatment of ICD, also because this principle is unlikely to 
cause skin atrophy, the well-established side effect of topical corticosteroids.
In our study described in paragraph 4.1, we could not confirm a clinical effect 
of cipamfylline in an acute and a cumulative exposure model using applications 
of a detergent (SDS). In contrast, a positive control (betamethasone-17-valerate) 
showed a beneficial effect on erythema scores and on barrier repair as assessed by 
transepidermal water loss (TEWL) in the cumulative exposure model. We observed 
an inhibition of the number of proliferating cells and an inhibition of the expression 
of cytokeratin 16 in betamethasone-17-valerate treated sites compared to the control 
sites. Again cipamfylline did not show any effect on these immunohistochemical 
parameters.
In addition to the potential dual relation between cytokines and skin barrier 
repair, some methodological reasons for the lack of effect in our study can be taken 
into consideration:
(1) The bioavailability of cipamfylline from the selected vehicle may be sub-
optimal. In our study it was not possible to assess tissue-levels of the drug. 
(2) Therapeutic agents may suppress an inflammatory response, but do not repair 
cellular or architectural damage. The inflammatory response, although causing 
short-term clinical effects (symptoms) may be essential for long-term recovery. 
Anti-inflammatory drugs may suppress short-term effects, but aggravate 
the condition in the long run. In neither of these models we prolonged our 
observation until erythema cleared and baseline values of TEWL were reached. 
It may be very interesting to find out how many days are needed until complete 
recovery of the skin occurs upon different therapeutical agents and whether 
long term therapy with PDE-4 inhibitor can cause increased skin susceptibility 
to irritants as observed by some authors after long term use of dermato 
corticosteroids. 
(3) Since exposure to irritants can lead to specific cutaneous reactions depending on 
the nature of irritants we cannot exclude any efficacy of PDE-4 inhibitors in skin 
irritation caused by another irritant stimulus. 
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(4) The difference in the course of SDS-induced skin irritation (complete healing 
in 1-2 weeks) and chronic ICD (healing in weeks to months) points out the 
limitations of these models and indicate that results of intervention in these 
models should be interpreted with caution until verified in clinical conditions. 
In conclusion, PDE-4 inhibitors are not likely to induce skin atrophy, 
tachyphylaxis and rebound phenomena. Therefore, despite the negative results of our 
pilot study, it is still the possible that cipamfylline might be effective in the treatment 
of ICD and further clinical studies are recommended. Whether the therapeutic effects 
both in vivo models and in clinical trials will be beneficial or not, will be dependent 
on its intrinsic pharmacodynamic effect and its bioavailability.
6.1.2. Lipid metabolism as a therapeutical target 
SC lipids play a crucial role in skin barrier and its water-holding capacity.12 
The positive effect of topical lipids on the reinforcement of skin barrier in ICD has 
been documented in experimental studies.13 For long we considered lipids as part of 
the vehiculum with only physical effects on the SC. Lipids are occlusive and therefore 
may form a barrier for water, resulting in hydration of the skin and alteration of barrier 
characteristics.14 
In recent years is became clear that lipids may penetrate the intercellular 
domain of the SC and may have specific effects on the composition of the lipid domain 
and on epidermal differentiation.15 A new generation of emollients with a specific lipid 
profile and a specific lipid content approaching the physiological situation is under 
development, but evidence for superiority in human to the traditional emollients 
remains to be provided.
Based on the studies described in chapter 4, we can conclude that the 
application of topical lipids on ICD associated with skin barrier impairment is 
advisable. However, in our pilot clinical study where we investigated the efficacy of 
the emollients in heterogeneous group of hand dermatitis, we could not confirm the 
superiority of treatment with skin related lipids as we observed earlier in the in vivo 
models for ICD. We cannot rule out that long term treatment of ICD with skin related 
lipids may have some superior effects especially when investigated in a large number 
of patients with more clearly defined presentations of ICD. 
In the context of the results described in this thesis (chapter 4) some 
recommendations could be made concerning the use of topical lipids in ICD. It is 
very likely that an ideal emollient, effective in all clinical situations, does not exist. 
The pathogenesis-based barrier repair therapy should be based on understanding of 
the specific damage and recovery.16 Therefore, initially the purpose of application of 
emollients should be defined in an individual patient. If protection of healthy skin 
against a detergent is intended, an emollient with a high content of lipids before 
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the exposure to irritants seems to be appropriated. Such emollients may provide a 
relative sufficient protection against cumulative exposure to a weak irritant. However, 
emollients with a high content of lipids are not convenient to use in all occupational or 
environmental settings. An emollient with less fat may suffice, although strong drying 
effects should be avoided. Of course, during the short exposure to a strong irritant, 
such an emollient is failing and some other kind of protection or a combination of 
protective measures should be considered. If emollients accelerate the skin barrier 
repair in already damaged skin, the correction with a three-component formulation of 
skin related lipids (cholesterol, ceramide, free fatty acid) in an optimized ratio could be 
of benefit. The results of our experimental study (paragraph 4.2) support the concept 
of supplementation with skin related lipids after mechanical damage. One should 
realize that such a recommendation is not applicable for all formulations consisting of 
skin related lipids, because of considerable variations of the ratio, concentration, and 
structuring between such products.
This thesis does not provide enough evidence for the superiority of the 
formulation with skin related lipids, so their use cannot generally be recommended. 
It is still unknown whether formulation with skin related lipids can prevent irritant 
and allergic reactions of the skin and also whether they can enhance the therapeutical 
activity of other pharmacologically active agents. Some key questions regarding 
topical lipids still remain to be answered. Does an exchange between exogenous 
and endogenous lipids exist in human skin? Does incorporation of skin related 
lipids in epidermal cells exist? Is incorporation of skin related lipids in epidermal 
cells possible? Does the extent of occlusive effect influence the efficacy of the 
product? Further research should focus on these questions and on the development of 
standardized test models for topical lipids. 
6.1.3.  Development of new agents targeting skin barrier repair in ICD
New treatment modalities focusing on the improvement of barrier function 
should be based on new insights in homeostatic repair response in ICD. As described 
in chapter 1, lipids play a key role in the formation of skin barrier. In this thesis, 
topical application of suitable lipids as one method for skin barrier repair was 
investigated. Skin barrier repair can be accelerated not only by the topical application 
of lipids but also by regulation of nonlipid factors such as enzymes and ions. Lipid 
metabolism is regulated by a series of enzymes in the epidermis and each of them 
has its optimal pH and optimal ion balance.17 Calcium, magnesium and potassium in 
human epidermis play an important role in the lipid metabolism of the epidermis. It 
has been shown that the topical application of calcium or potassium impairs barrier 
repair, whereas magnesium or a mixture of calcium and magnesium salts accelerates 
the repair process.18 
From the observation described in chapter 4 it is evident, that the treatment 
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of ICD does not have one single mode of action. An important role of the nuclear 
hormone receptor PPAR-α (peroxysome-proliferator-activated receptor-α) on the 
formation and maintenance of epidermal lipid barrier has been demonstrated.19-22 It 
has also been shown that topical application of PPAR-α activators (clofibrate, linoleic 
acid) accelerate barrier recovery after tape stripping or acetone treatment.23 Regulation 
of the nuclear hormone receptor could open a new possibility for improvement of the 
skin barrier function. In this respect, the elucidation of the function of epidermal fatty 
acid carriers can possibly provide an intervention target, since the interaction between 
epidermal fatty acid carriers and PPAR-α has been demonstrated.24 Furthermore, the 
relationship between the skin barrier function and the histamine H1 and H2 receptor 
has been reported. The topical application of histamine H1 and H2 receptor antagonist 
accelerated the barrier repair. Histamine itself delayed the barrier repair.25 Although 
the mechanism of the relationship between the histamine receptors and the barrier 
repair process has not been clarified, these findings provide another perspective target 
for treatment of ICD.
In general, topical treatment is preferable above systemic treatment in ICD, 
because systemic (immunosuppressive or immunoregulatory) treatment may cause 
severe side effects. On the other hand, the potential irritancy of a topical formulation 
and/or its ingredients is possibly a considerable disadvantage of topical treatment. In 
highly irritable skin and/or in vesicobullous diseases systemic treatment should be 
considered for breaking a vicious circle. To date, no sufficient systemic treatment of 
ICD is available. 
In this context, modulation of retinoid X receptors (RXR’s) could be an 
alternative since an important role of retinoid X receptors (RXR’s) for the SC has 
been suggested.26 From the therapeutical agents, 9-cis-Retinoid Acid (9-cis-RA) has 
a particular pattern of binding and activating retinoid X receptors (RXR’s). Oral 9-
cis-RA has already been investigated in the treatment of chronic hand dermatitis with 
promising results.27;28 Whether oral 9-cis-RA can really accelerate the barrier repair is 
unknown and could be the focus of further experimental and clinical studies. 
In conclusion, different signaling pathways could be targets in the development 
of effective treatment. Replenishing of suitable lipids is one of the possibilities. But 
also the pharmacological regulation of the endogenous homeostatic process of 
the epidermal inflammation, proliferation and differentiation may be effective in 
the improvement of the skin barrier. Further studies on the pathogenesis of ICD 
and further insights in the mode of action of potential pharmacological agents are 
important investments for patients of tomorrow. 
6.1.4. Prevention
Topical therapy of ICD is unsatisfactory and arduous. Not only the 
disappointing results of the pharmacological agents, but also a risk of skin irritation 
from the topical formulations prompt us to look for other approaches. ICD is one 
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example of skin diseases where sufficient primary and secondary prevention could 
significantly decrease the prevalence of this disease with a major social impact. 
Therefore, preventive measurements in ICD are required and should be a main 
interest of further research. 
Preventive measurements include (1) identification of individuals with a 
higher risk of ICD and (2) identification and avoidance of potential irritants. 
(1)Identification of individuals with a higher risk of ICD
Individuals with an atopic dermatitis or a history of atopic dermatitis have an 
increased susceptibility to irritants.29 However, increased responsiveness to irritants 
is not only restricted to such susceptible phenotypes but can be extended to the 
healthy, nonatopic population. In the non-atopic population it is difficult to identify 
individuals with a predisposition to over-response to irritants, because reliable 
prospective data for such risk persons are scarce. Many investigators have attempted 
to identify factors, which affect reactivity to irritants, as summarized in the Table 
4 of chapter 1. Possible underlying biological mechanisms should be considered. 
Among them, a genetic predisposition to inflammation is under current attention 
since gene polymorphisms seem to play an important role.30-32 Since cytokines have 
been implicated in the pathogenesis of ICD, it is not unreasonable to speculate that 
interindividual variations in the level of their production give rise to variations in the 
intensity of an inflammatory response. Recently the first description of a nonatopic 
genetic marker for irritant susceptibility in normal individuals has been published. 
A polymorphisms at position-308 of the TNF-α gene has been associated with 
susceptibility to experimentally induced ICD in response to SDS.33 Such suggests that 
cytokine genotyping may be an important screening method for use in occupations 
associated with high risk of ICD in the future. In chapter 1 we already introduced 
oxidative stress as a component involved in ICD, especially in dithranol induced skin 
irritation. There is evidence that polymorphisms in genes encoding several of the 
antioxidant enzymes, have an influence on the extent of cellular damage associated 
with oxidative stress.30 The genetic variability of the capacity of an individual’s skin 
to scavenge free radicals may also be responsible for variation in dithranol induced 
skin irritation. 
(2) Identification and avoidance of potential irritants 
Although complete avoidance of contact with irritants is usually not needed, 
strict reduction may be necessary and could lead to improvement of chronic ICD. 
This reduction can be achieved by appropriate use of gloves and protective clothing. 
For household tasks, rubber or PVC gloves should suffice. When protective gloves 
are used for more than 10 minutes, cotton gloves should be worn underneath. It is 
important to take off the gloves on a regular basis, because sweating may aggravate 
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existing dermatitis.34 The gloves can create an occlusive environment, which is an 
irritant situation in itself and may impair the barrier function.35;36 If an irritant gets into 
the glove, the occlusive milieu leads to an increased penetration and stronger irritant 
reactions.37 In an occupational setting, the most appropriate glove for prevention will 
depend upon the nature of the irritant stimuli, because penetration of chemicals differs 
strongly between different materials.38;39 Substitution of non-irritating agents could 
be another protective measure. The most common example is a soap substitute.40 
Theoretically, a barrier cream often called ‘invisible gloves’ may protect against 
well-defined chemical substances. Since ICD is only rarely caused by one substance 
and stimulus41, barrier cream must protect against a wide spectrum of irritant stimuli 
during the entire period of exposure. Until now, barrier creams are usually not tested 
sufficiently in vivo against a combination of different irritants.42;43 Therefore, their 
use is limited and cannot be generally promoted, because of a false sense of security 
is offered.44 Furthermore, it has to be kept in mind that barrier creams may have an 
irritant potential on their own, therefore their use cannot be generally recommended.
Summarizing we can state that the prevention by avoidance of skin contact to 
irritants is a rewarding approach. Because patients or employees in high-risk jobs are 
often not aware of the exposure and/or the nature of irritant, education in preventive 
action and instruction in proper skin care should be offered.
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6.2. BARRIER REPAIR STRATEGIES IN THE TREATMENT 
OF ATOPIC DERMATITIS
Most treatment strategies for atopic dermatitis (AD) such as corticosteroids, 
calcineurin-inhibitors (tacrolimus) are targeted primarily at the immunopathogenesis 
of AD. These approaches result in secondary improvement of the barrier function 
that parallels the clinical response. The involvement of skin barrier impairment in 
the pathogenesis of AD is unambiguous. The skin barrier for chemicals, physical 
influences and micro-organisms is perturbed. (For more details see chapter 1) 
Involved and uninvolved skin of AD patients exhibit a barrier deficit which correlates 
with a reduction in the ceramide fraction of the intercellular lipid domain.45;46 This 
abnormality is so prominent that some authors consider AD as a ceramide-deficient 
disease.47 Although emollients are mainstays in the management of AD, currently 
available emollients do not correct this prominent SC lipid abnormality. Ceramide-
dominant formulation of skin related lipids may represent a rational intervention.16 
Preliminary trials with a ceramide-dominant formulation significantly reduced 
clinical symptoms in children with recalcitrant AD.48;49 Further controlled studies are 
needed to validate this approach in the therapy of AD.
In addition, from a number of studies it can be concluded that bacterial 
superantigens contribute to the pathogenesis and exacerbation of AD.50-52 The 
mechanisms underlying the increased bacterial colonization of atopic skin are poorly 
understood. As mentioned in chapter 1, the skin is the first line of defence against 
invasion of microbial agents. The failure of the innate immune defence system of 
atopic skin against bacterial invasion should be considered. 
Recently, it was speculated that insufficient expression of antimicrobial 
peptides, as elements of the innate immune system, may be involved in the 
pathogenesis of the increased susceptibility to bacterial infection in atopic patients.53 
In this thesis (chapter 3) we extended this observation to other antimicrobial 
peptides (SKALP, SLPI and MRP8). Consistent with the study by Ong et al we 
found a decreased level of several of these peptides in AD versus psoriasis, although 
expression of differentiation markers involucrin and keratin 16 was comparable in 
both conditions. This finding provides a strong evidence for a significant role of host 
defence proteins in superinfections in AD. Identification of the molecules involved 
in the process of enhanced bacterial colonization may have important implications in 
the approach to manage and develop new therapies for AD. Whether keratinocytes in 
AD have an intrinsic defect in the control of bacterial colonization by polymorphisms 
in genes encoding antimicrobial peptides or driving their expression, may become a 
fascinating new field of research.
The possibility that bacterial overgrowth can exacerbate acute AD provides a 
rationale for the use of antibacterial therapy in patients with AD. Topical anti-septic 
may be of value, but may irritate the skin.54 Topical antibiotics such as 2% mupirocine 
ointment or 2% sodium fusidate ointment may be considered.55 Due to increased 
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risk of bacterial resistance, it is important to combine antimicrobial therapy with 
effective skin care since it is well established that the excoriated inflamed skin of AD 
predisposes to S. aureus colonization. Therefore the use of antibiotic therapy must 
be carried out with good skin hydration to restore skin barrier function and effective 
anti-inflammatory therapy to reduce skin inflammation.56 From this point of view 
the combination of topical corticosteroids with antibiotic in an optimal vehiculum 
can be recommended.57 Regarding the vehiculum, a non-irritative basis should be 
guaranteed. Recently, it has been demonstrated that levels of sphingosine (as a natural 
antimicrobial agent) are significantly reduced in epidermis of AD patients.58 Focusing 
on the improvement of the antibacterial defence system, adding sphingosine to the 
lipid formulations may be an important therapeutic approach for reduction of bacterial 
growth in atopic skin. 
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6.3. BARRIER REPAIR STRATEGIES IN THE TREATMENT 
OF PSORIASIS
It is evident that psoriasis has a complex pathogenesis. A role for keratinocytes, 
endothelium as well as T-lymphocytes has been shown, which provide multiple 
targets for anti-psoriatic treatment. As mentioned in chapter 1, psoriasis is associated 
with skin barrier impairment. The improvement of skin barrier and implementation of 
barrier repair strategies could play an important role in the antipsoriatic therapy. 
The first anti-psoriatic therapy that interferes with barrier function, are 
emollients that are widely used in the treatment of psoriasis.14 Generally, emollients 
may interact with the epidermis in several ways. These complex interactions comprise 
physical effects like occlusions, direct effects on the SC and indirect effects on 
epidermal differentiation and hyperproliferation. In psoriasis, especially emollients 
with occlusive properties are widely used to soften the scaly hyperkeratotic surface 
and enhance the penetration of other topical therapies.59 Barrier abnormalities in 
psoriasis are consistent with disturbances in the lipid metabolism.60-63 Theoretically, 
topical lipids may correct these disturbances. It is not unreasonable to speculate that 
an emollient with a specific lipid profile could be advantageous in the correction of 
these psoriasis-specific lipid abnormalities. Unfortunately, since little is known about 
the exact underlying lipid disorder in psoriasis, it is impossible to apply the principle 
of a disease specific barrier strategy, as in atopic skin. Therefore, further research on 
the lipid metabolism in this skin disease is needed. 
In de context of disturbed lipid metabolism another interesting target could 
be the pharmacological modulation of PPAR-α (peroxysome-proliferator-activated 
receptor α). PPAR-α is a key-transcription factor involved in the control of the 
epidermal lipid barrier24 and is downregulated in involved psoriatic epidermis.22 
Further studies should demonstrate if the modulation of PPAR-α with selective 
agonists (e.g. free fatty acid) may have a beneficial action on the impaired skin barrier 
of psoriasis.
We already mentioned that emollients could enhance the penetration of topical 
treatment. Besides occlusive emollients, this could be achieved using an occlusive 
dressing in particular a hydrocolloid dressing.64 In a psoriatic plaque, a combination of 
a hydrocolloid dressing with topical corticosteroids is very effective.65;66 This provides 
evidence for a new pharmacological principle with an intensified topical anti-psoriatic 
action, increased bioavailability, decreased dose and providing optimal patient 
compliance. In addition, occlusion has an anti-psoriatic potential on its own.67 This 
therapy stimulates regeneration of the disturbed granular layer and reduces epidermal 
hyperproliferation, a hallmark of psoriasis.68;69 The exact mechanisms have not been 
elucidated. It has been suggested that occlusion restores the skin barrier, which leads to 
recovery of the keratinization process and a reduction in psoriatic hyperproliferation. 
Contrary, some animal and human experimental studies demonstrated that occlusion, 
which prevents water loss, does not prevent the development of these epidermal 
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abnormalities70;71, denying the need of skin barrier repair in the therapy of psoriasis. 
Despite of these conflicting results, many clinical studies demonstrated the beneficial 
effect of occlusion in psoriasis. 
6.3.1. The relevance of skin barrier function in psoriasis treatment
Topical treatment of psoriasis is an obvious choice. Because of frequent skin 
irritation by anti-psoriatic treatment, topical formulations should be used, which do 
not compromise the skin barrier and give raise to skin irritation. This is impossible 
in the case of dithranol where the skin irritation parallels its therapeutic effect. 
Attempts have been made to reduce this side effect by changing the treatment time 
or the vehicle (e.g. without salicylic acid). Penetration of the epidermis is enhanced 
in a lipophilic vehicle. The other possibility is a pharmacological modulation of 
dithranol irritation. As dithranol induces inflammatory changes in normal skin and 
topical corticosteroids have anti-inflammatory effects, it is likely that this treatment 
represents a complementary approach. The experimental study described in chapter 
5 suggests that a short intervention with a superpotent corticosteroid is an alternative 
to suppress dithranol irritation. The role of topical costicosteroids in the modulation 
of dithranol irritation is controversial. On the one side, corticosteroids may cause in 
short time the clinical and subjective improvement of skin irritation. On the other side, 
it is suggested that sensitivity to dithranol depends on the status of the skin barrier.72 
The frequent use of costicosteroids may influence the skin barrier and make skin more 
vulnerable to skin irritation. From this aspect, new anti-inflammatory agents without 
these negative effects on the skin barrier could be promising. 
Furthermore, in this thesis (chapter 5) we demonstrated a relatively high 
frequency of skin irritation during dithranol treatment. In paragraph 5.3 it was 
shown that dithranol irritation and the treatment results assessed by PASI-scores 
were not associated. Therefore, modulation of dithranol irritation is unlikely to 
improve the therapeutic efficacy, however reduction of dithranol irritation by 
dermatocorticosteroids and other anti-inflammatory treatments can be useful to reduce 
the subject’s discomfort. Controlled, long-term studies with different therapeutical 
approaches in dithranol irritation are needed. 
Conclusion
In conclusion, the field of barrier repair therapies is still in its infancy. Very 
few studies have evaluated the clinical efficacy of barrier repair therapy. A lot of 
work remains to be done before barrier repair therapeutics will have an important 
position in the treatment of skin diseases. There is no doubt that the current efforts 
in understanding the skin barrier repair will lead to the design of new agents, which 
specifically target various abnormalities of the skin barrier repair contributing to these 
skin conditions. 
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GENERAL CONCLUSIONS
These general conclusions are based on the answers to the questions as we 
defined in the introduction.
1.1 In the present thesis it has been shown that expression of E-FABP in 
dithranol induced irritation is comparable to the normal skin. This lack of upregulation 
of E-FABP in such an non-corrosive type of irritation (not associated with skin barrier 
impairment), in contrast to the upregulation following the skin barrier impairment 
in SDS induced irritation, indirectly suggests a possible role of E-FABP in the 
maintenance of epidermal skin repair.
1.2 The expression of E-FABP in atopic skin shows clear differences 
between normal human skin and psoriasis. E-FABP is a good candidate for 
immunohistochemical differentiation of both inflammatory disorders. 
2.1 The pattern of expression of some antimicrobial proteins in the epidermis 
is different in atopic dermatitis and psoriasis. These differences may explain the 
susceptibility of patients with atopic dermatitis to skin infections. Psoriatic epidermis 
expresses high levels of antimicrobial proteins compared to atopic dermis.
3.1 Cipamfylline, a strong phosphodiesterase-4 inhibitor does not show an 
effect on skin barrier repair in SDS induced irritation.
3.2 Topical lipids improve skin barrier in different conditions compared to 
untreated skin. An ideal lipid formulation effective in all clinical situations does not 
exist. The optimal barrier repair therapy should be based on understandings of the 
specific damage and recovery. There is some indication that formulations containing 
skin related lipids might be of benefit in mechanical barrier disruption. 
3.3 Frequent use of topical lipids may be useful in the therapy of hand 
dermatitis and patients should be encouraged to use them. However, we cannot 
confirm the concept of superiority of skin related lipids in a heterogeneous group of 
patients with chronic hand dermatitis.
4.1 Using a repetitive model of dithranol irritation we observed that the potent 
corticosteroids are effective in reducing dithranol erythema, whereas coal tar solution 
does not. 
4.2 Dithranol induced skin irritation occurs preferentially in an early phase of 
dithranol treatment.
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4.3 Skin irritation during short contact therapy with dithranol has not a relevant 
impact on the treatment results. The PASI does not have any predictive value for 
dithranol induced skin irritation.
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SUMMARY
The subject of the present thesis is the epidermal barrier. An intact epidermal 
barrier prevents the penetration of chemicals, protects against physical factors and the 
invasion of microorganisms. We focused on three inflammatory skin diseases, irritant 
contact dermatitis (ICD), atopic dermatitis (AD) and psoriasis vulgaris (PV), with a 
special emphasis on the skin barrier as a target for therapeutic strategies. 
In the general introduction (chapter 1), several aspects of the structure and the 
function of the stratum corneum (SC) are described. Information on the development 
of the skin barrier, with an emphasis on lipid metabolism and the intercellular lipid 
domain, are given. In paragraph 1.2 a brief review is given on clinical features, 
histopathology, pathogenesis and available therapies of the three selected inflammatory 
skin diseases. We outline the impaired skin barrier and its putative involvement in the 
pathogenesis of these skin disorders. In ICD the disturbance of the skin barrier is a 
prominent feature and likely to be important in its pathogenesis. ICD is, therefore, 
reviewed in more detail.
In paragraph 1.3 of this chapter we describe four different models of ICD 
as well as the relationship between these models and skin barrier impairment. We 
give a short review of the clinical and cell-biological changes in the epidermis, 
associated with these models and the effects of different topical treatments. We used 
transepidermal water loss (TEWL) measurements to assess the barrier function of 
the skin. To evaluate the clinical response we used visual scoring. Cell-biological 
changes, associated with impaired epidermal proliferation and differentiation, were 
studied by means of relevant immunohistochemical staining of samples of treated and 
untreated skin. 
In order to extend our knowledge of the repair of the epidermal barrier, we 
investigated the expression of epidermal fatty acid binding protein (E-FABP), a 
protein which is supposed to be involved in the epidermal barrier formation and 
lipid trafficking, in different skin conditions. In chapter 2 the results of these studies 
are described. In paragraph 2.1 we describe the expression of E-FABP in dithranol 
induced irritation. The expression proved to be comparable to normal skin. The lack 
of up-regulation of E-FABP in such a non-corrosive type of irritation, not associated 
with skin barrier impairment, is in contrast to the up-regulation of E-FABP in SDS 
induced skin irritation, suggesting a possible role of E-FABP in epidermal barrier 
repair. In the study, described in paragraph 2.2, we compared the expression of E-
FABP in AD and PV. E-FABP proved to be highly up-regulated in both diseases 
compared to normal skin, but the pattern was markedly different. 
The human epidermis harbors a wide range of proteins, which are potentially 
involved in innate immunity and host defense against microbes. The innate immune 
system provides broad-spectrum recognition and rapid elimination of invading 
microorganism. In AD, a skin disorder associated with bacterial super-infections, a 
failure of the innate immune defense system of skin may be involved. The hypothesis is 
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that an insufficiency in the expression of inflammation-induced antimicrobial proteins 
in the epidermis explains the susceptibility of patients with AD to skin infection. Skin-
derived-antileukoproteinase (SKALP/elafin) and secretory leukoprotease inhibitor 
(SLPI), proteins that are likely to play crucial roles in regulating inflammatory 
responses, are also part of the innate immune system. In chapter 3 we describe a 
study in which we found a lower expression of these peptides in AD as compared 
to PV. This finding provides evidence for the role of a lack of up-regulation of 
host defense proteins in AD, explaining at least in part the increased susceptibility 
for bacterial superinfections of lesional skin of patients with AD. Identification of 
molecules involved in the prevention of bacterial colonization may be important in the 
development of new therapeutic approaches for AD.
In chapter 4 we describe studies on the evaluation of new therapies for 
ICD. Anti-inflammatory agents, without negatively affecting the SC barrier 
function, are promising candidates in the therapy of ICD. An attractive target for 
new anti-inflammatory agents is modulation of the expression of cytokines, since 
up-regulation of cytokines may both play a role in the pathogenesis of ICD and 
on repair processes after barrier disruption. The inhibition of their production may 
diminish the inflammatory response accompanying ICD. In this thesis, we describe 
study on a topical anti-inflammatory agent (cipamfylline), which by inhibition of 
phosphodiesterase-4 (PDE-4) is able to suppress the production of skin inflammation. 
Paragraph 4.1 describes a study, which evaluates the efficacy of cipamfylline in two 
human experimental models of ICD using clinical evaluation, transepidermal water 
loss and immunohistochemical methods. Despite the promising results of PDE-4 
inhibitors in AD, we did not show any effects of this agent in the two models of ICD. 
Possible reasons for the lack of efficacy of this agent are discussed.
SC lipids play a crucial role in skin barrier function. Normal synthesis and 
processing of lipids are important for optimal epidermal barrier formation. Topical 
application of suitable lipids may putatively improve the barrier function. The 
efficacy of topical lipids can be evaluated either in experimental or in clinical studies. 
Paragraph 4.2 describes an experimental study with healthy volunteers investigating 
the efficacy on clinical parameters and barrier repair of a traditional, petrolatum-
based emollient and an emollient containing skin related lipids. With two different 
models of experimentally induced skin irritation and barrier impairment we attempted 
to simulate different types of occupational and environmental irritant effects. 
Tape stripping was chosen as a model for acute barrier perturbation. To mimic the 
development of chronic ICD, we used well-established model of repeated exposure 
of low concentration of a detergent (SDS). In both models repair was accelerated by 
the treatment with emollients. In the acute model of barrier disruption (tape stripping) 
the emollient containing skin related lipids accelerated the repair of barrier damage 
significantly in contrast with the petrolatum-base emollient. In the cumulative SDS-
model, the petrolatum-based emollient, not the emollient with skin related lipids, 
seemed to protect the skin against SDS-irritation. 
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Supplementary to the experimental studies, we performed a clinical, pilot-
study in chronic hand dermatitis. In hand dermatitis, because of frequent exposure 
to environmental factors, barrier repair is likely to be of importance in the healing 
process. Paragraph 4.3 describes a randomized, open study in 32 patients with mild to 
moderate chronic hand dermatitis. The aim of the study was to compare the emollients 
in terms of clinical efficacy and dermatocorticosteroid-sparing effects. Patients were 
treated twice daily during two months with the emollient containing skin related lipids 
or with a traditional petrolatum-based emollient. In case of exacerbation, the patients 
of both treatment groups were allowed to use a mild dermatocorticosteroid. In line 
with the results of the previous experimental studies we observed that both treatment 
regimens significantly improved clinical signs of the dermatitis. However, we did 
not observe significant differences in the improvement of clinical signs, itching, the 
patient’s assessment of efficacy and the usage of topical corticosteroids between 
both treatment groups. Most patients considered both emollients as cosmetically 
acceptable . 
Based on the results of these studies we conclude that the use of topical 
lipids in chronic hand dermatitis and in diseases associated with barrier dysfunction 
is advisable. However, the information provided in this thesis does not support 
the superiority of emollients with skin related lipids. It is still unknown whether 
emollients with skin related lipids are superior in the prevention of irritant and allergic 
reactions and whether they are superior in enhancing barrier repair.
In chapter 5 we focus on dithranol irritation as a unique form of ICD. In 
paragraph 5.1 the effects of a topical corticosteroid, a coal tar solution and their vehicles 
on dithranol irritation of uninvolved skin of patients with psoriasis are described. 
The results indicate that a short intervention with a potent dermatocorticosteroid is 
effective in reducing dithranol irritation. However, a possible negative effect on SC 
barrier function, cannot be excluded. 
In paragraph 5.2 we describe the frequency of dithranol irritation in traditional 
24-hour applications. Most irritation reactions occur at the start of the therapy with 
relatively low concentrations. In paragraph 5.3 we describe the frequency of skin 
irritation in short contact dithranol treatment in comparison to skin irritation in 
calcipotriol treatment. Although many patients experience skin irritation in both 
treatments, the reactions are mild and do not seem to have a relevant impact on 
treatment duration and results.
In the general discussion (chapter 6) future perspectives on barrier repair 
strategies are discussed.
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Het onderwerp van dit proefschrift is de huidbarrière, die voornamelijk wordt 
gevormd door de hoornlaag, het differentiatieproduct van de opperhuid (epidermis). 
Een intacte barrière voorkomt het binnendringen van chemische stoffen, beschermt 
tegen fysische factoren en behoedt voor de invasie van micro-organismen. Wij hebben 
ons, in het voorliggende proefschrift, gericht op drie inflammatoire huidziekten, 
namelijk orthoërgisch eczeem (irritant contact dermatitis, ICD), constitutioneel 
eczeem (atopic dermatitis, AD) en psoriasis vulgaris (PV), waarbij speciaal aandacht 
wordt gegeven aan het functioneren van de epidermale barrière en de wijze waarop 
therapeutica de barrière kan verbeteren.
In de algemene inleiding (hoofdstuk 1), worden meerdere aspecten van de 
structuur en de functie van het stratum corneum (SC) beschreven. Informatie over de 
vorming van de huidbarrière wordt verschaft, waarbij de nadruk is komen te liggen op 
het metabolisme van de epidermale vetten en de opbouw van de intercellulaire ruimte 
in de hoornlaag. In paragraaf 1.2 wordt een kort overzicht gegeven van de klinische 
kenmerken, de histopathologie, de pathogenese en de beschikbare therapieën van de 
drie geselecteerde inflammatoire huidziekten. In hoofdlijnen wordt de vermoedelijke 
betrokkenheid van de huidbarrière in de pathogenese van deze huidaandoeningen 
beschreven. Bij ICD is de verstoring van de huidbarrière het grootst en vervult het 
waarschijnlijk de belangrijkste rol. ICD wordt daarom uitvoeriger belicht.
In paragraaf 1.3 van dit hoofdstuk beschrijven wij vier verschillende modellen 
voor het nabootsen van ICD, alsmede de relatie tussen het model en de verstoring van 
de huidbarrière. Een kort overzicht van de klinische en celbiologische veranderingen 
in de epidermis, die geassocieerd zijn met deze modellen, wordt gegeven en we 
beschrijven de effecten van de verschillende topische behandelingen. Met behulp 
van transepidermaal waterverlies (TEWL) metingen wordt een kwantitatieve mate 
verkregen voor de functie van de huidbarrière. Om de klinische respons te evalueren, 
scoorden wij het erytheem semi-kwantitatief. Celbiologische veranderingen, 
geassocieerd met verstoorde epidermale proliferatie en differentiatie, werden 
bestudeerd met behulp van immunohistochemische kleuringen op relevante epitopen 
in behandelde en onbehandelde huidmonsters.
Om onze kennis van het herstel van de epidermale barrière te vergroten, 
onderzochten wij de expressie van het epidermale vetzuurbindend-eiwit (E-FABP), 
een eiwit dat geacht wordt betrokken te zijn bij de epidermale barrièrevorming en 
transport van vetten, in verschillende huidcondities. In hoofdstuk 2 worden de 
resultaten van deze studies beschreven. In paragraaf 2.1 behandelen wij de expressie 
van E-FABP in dithranol geïnduceerde huidirritatie. De expressie blijkt vergelijkbaar 
te zijn met die van normale huid. Het gebrek aan opregulatie van E-FABP in een 
dergelijk niet-corrosief type van irritatie, niet geassocieerd met verstoring van 
de huidbarrière, is tegengesteld aan de opregulatie van E-FABP in huidirritatie 
geïnduceerd door blootstelling aan een wasactieve stof met een krachtig huidbarrière 
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verstorend effect. Deze bevinding is suggestief voor een mogelijke rol van E-FABP in 
het herstel van de epidermale barrière. In paragraaf 2.2 beschrijven wij de expressie 
van E-FABP bij AD en PV. E-FABP bleek sterk opgereguleerd in beide ziekten in 
vergelijking tot de normale huid, maar het patroon van expressie was duidelijk 
verschillend.
Het aangeboren afweersysteem heeft een breed spectrum aan mogelijkheden 
om micro-organismen te herkennen en te verwijderen. De menselijke epidermis bevat 
een wijd scala aan eiwitten, die mogelijk betrokken zijn bij dit aangeboren systeem. In 
AD, een huidaandoening geassocieerd met bacteriële superinfecties, zou het falen van 
het aangeboren afweersysteem betrokken kunnen zijn. De hypothese is dat door een 
insufficiënte expressie van antimicrobiële eiwitten in de epidermis patiënten met AD 
meer vatbaar zijn voor huidinfecties. De in de huid tot expressie komende eiwitten, 
antileukoproteïnase (SKALP/elafin) en secretorisch leukoprotease inhibitor (SLPI), 
vervullen waarschijnlijk ook een rol in het aangeboren imuunsysteem. In hoofdstuk 
3 beschrijven wij een studie waarbij een lagere expressie van deze peptiden gevonden 
werd in AD in vergelijking met PV. De toegenomen vatbaarheid voor bacteriële 
superinfecties van de huid van patiënten met AD zou (voor een deel) hierdoor kunnen 
worden verklaard. Identificatie van moleculen, die betrokken zijn bij de preventie 
van bacteriële kolonisatie, kan van belang zijn voor de ontwikkeling van nieuwe 
therapeutische middelen in de behandeling van AD.
In hoofdstuk 4 beschrijven wij studies ter evaluatie van nieuwe therapieën 
voor ICD. Ontstekingsremmende middelen, zonder een negatieve invloed op de 
barrièrefunctie, zijn veelbelovend in de therapie van ICD. Een aantrekkelijk doel voor 
nieuwe anti-inflammatoire middelen is de modulatie van de expressie van cytokines, 
aangezien de regulatie van cytokines mogelijk een rol speelt in de pathogenese van 
ICD, maar mogelijk ook op herstelprocessen na barrièreverstoring. Het afremmen van 
hun productie zou de inflammatoire respons bij huidirritatie kunnen verminderen. In 
dit proefschrift beschrijven wij een studie naar een topisch anti-inflammatoire middel 
(cipamfylline), die door remming van het enzym fosfodiesterase-4 (PDE-4) in staat 
is de productie van huidinflammatie te onderdrukken. Paragraaf 4.1 beschrijft een 
studie naar de effectiviteit van cipamfylline in twee humane experimentele modellen 
voor ICD. Ondanks de veelbelovende resultaten van PDE-4 remmers in AD, konden 
wij geen effecten van dit middel aantonen in de twee modellen voor ICD. Mogelijke 
oorzaken voor het gebrek aan effectiviteit van dit middel worden bediscussieerd.
SC lipiden spelen een cruciale rol in de huidbarrière. Topicaal gebruik van 
geschikte lipiden zou mogelijk de barrièrefunctie kunnen verbeteren. De effectiviteit 
van topische lipiden kunnen worden geëvalueerd aan de hand van experimentele, dan 
wel klinische studies. Paragraaf 4.2 beschrijft een experimentele studie met gezonde 
vrijwilligers, waarin de effecten op klinische parameters en barrièreherstel onderzocht 
werden van een traditioneel, vaseline bevattend emolliens en een emolliens met 
lipiden, die gelijkenis vertonen met de van nature in het SC voorkomende lipiden. Met 
twee verschillende experimentele modellen voor huidirritatie en barrièrebeschadiging 
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probeerden wij verschillende typen van beroepsmatige en omgevingsafhankelijke 
irritatieve effecten na te bootsen. Tape-stripping werd gekozen als model voor 
acute mechanische barrièrebeschadiging. Het nabootsen van de ontwikkeling van 
chronische ICD werd bewerkstelligd door middel van een bekend model van herhaalde 
blootstelling aan lage concentraties detergens (sodium-dodecyl-sulphate, SDS). In 
beide modellen werd het herstel versneld door de behandeling met emolliëntia. In 
het acute model voor barrièrebeschadiging (tape-stripping) werd het herstel van 
barrièreschade significant versneld door een emolliens met de SC gerelateerde lipiden, 
echter niet door het vaselinebevattende emolliens. In het cumulatieve SDS-model 
leek het vaseline-bevattende emolliens beter te beschermen tegen SDS geïnduceerde 
irritatie dan het emolliens met SC gerelateerde lipiden.
Aanvullend bij de experimentele studies, voerden wij een klinische pilot-
studie uit bij chronisch handeczeem. Bij handeczeem is het aannemelijk dat het 
barrièreherstel belangrijk is bij het genezingsproces. Paragraaf 4.3 beschrijft een 
gerandomiseerde, open studie met 32 patiënten met een matige tot milde vorm van 
chronische handeczeem. Het doel van de studie was het vergelijken van het effect 
van twee verschillende emolliëntia. Patiënten werden tweemaal daags gedurende 
twee maanden behandeld met het emolliens met de SC gerelateerde lipiden of met 
het vaseline-bevattende emolliens. In geval van verslechtering mochten patiënten 
in beide groepen een licht dermatocorticosteroïd gebruiken. In overeenstemming 
met de resultaten uit de voorgaande experimentele studies zagen wij dat beide 
behandelingswijzen een significante verbetering in het klinisch beeld van het eczeem 
tot gevolg hadden. Echter, wij constateerden geen significante verschillen tussen 
beide groepen met betrekking tot het klinisch beeld, jeuk, eigen inschatting van het 
effect en het gebruik van dermatocorticosteroïden. De meeste patiënten waren van 
mening dat beide emolliëntia cosmetisch acceptabel waren.
Gestoeld op de resultaten van deze studies concluderen wij dat het gebruik 
van topische lipiden bij chronische handeczeem en bij aandoeningen geassocieerd 
met epidermale barrièredysfunctie geadviseerd kan worden. Echter, de informatie 
verkregen door de studies beschreven in dit proefschrift, onderschrijft niet de 
superioriteit van emolliëntia met SC gerelateerde lipiden. 
In hoofdstuk 5 vestigen wij de aandacht op dithranolirritatie als een unieke 
vorm van ICD. In paragraaf 5.1 worden de effecten van een corticosteroïdzalf, 
een koolteeroplossing in een zalfbasis en de vehicula van beide middelen op 
dithranolirritatie van de onbehandelde huid van patiënten met psoriasis bestudeerd. 
De resultaten tonen aan dat een kortdurende interventie met een krachtig 
dermatocorticosteroïd effectief is in het reduceren van dithranolirritatie. Echter, een 
mogelijk negatief effect op de barrièrefunctie kan niet worden uitgesloten.
In paragraaf 5.2 beschrijven wij de frequentie van huidirritatie bij traditionele 
24-uurs behandelingen. De meeste huidirritaties doen zich voor bij het begin van de 
therapie met relatief lage concentraties. In paragraaf 5.3 beschrijven wij de frequentie 
van huidirritatie bij kort contact dithranolbehandeling en vergelijken het voorkomen 
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bij calcipotriolbehandeling. Hoewel vele patiënten klachten van huidirritatie hebben 
bij beide behandelingen, zijn de reacties overwegend mild en lijken zij geen relevante 
invloed te hebben op met name de behandelduur.
In de algemene discussie (hoofdstuk 6) worden toekomstperspectieven van 
nieuwe therapeutische strategieën gericht op het huidbarrièreherstel bij inflammatoire 
huidziekten bediscussieerd. 
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Dit proefschrift is tot stand gekomen met de wetenschappelijke of persoonlijke 
hulp van velen, die elk op hun eigen, unieke wijze een bijdrage hebben geleverd. Het 
is onmogelijk om op deze plaats iedereen persoonlijk hiervoor te bedanken, maar een 
aantal mensen wil ik toch graag afzonderlijk noemen.
Allereerst dank aan de inspirators achter dit proefschrift.
Professor Peter van de Kerkhof, mijn promotor, wil ik bedanken voor het in 
mij gestelde vertrouwen en de steun om dit promotietraject af te ronden. Wat ik altijd 
bewonderde was uw ontembare enthousiasme, creativiteit en effectiviteit als het om 
onderzoek ging. Op cruciale momenten bracht u mij op de goede weg wanneer ik de 
rode draad in mijn onderzoek even was verloren. Bedankt ook voor de praktische tips 
en razendsnelle beoordeling van de manuscripten.
Uiterarad wil ik mijn eerste co-promotor Pieter van der Valk danken, die me 
de kans bood onderzoek te doen op de afdeling dermatologie en die daarmee de eerste 
steen legde voor deze promotie. Beste Pieter, gedurende mijn promotie tijd heb ik 
je leren kennen als een prettig persoon met sterke principes en een kritische blik. 
Ook daardoor was het voor mij zeer uitdagend om jouw wetenschappelijke ideeën 
in uitvoerbare projecten te kneden, voorzien van mijn eigen stempel. Ook al is met 
dit proefschrift voor mij de laatste steen gelegd, hopelijk bouw jij nog jaren door aan 
uitdagende wetenschappelijke projecten. Bedankt voor alles.
Joost Schalkwijk, mijn tweede co-promotor, ben ik veel dank verschuldigd. 
Joost, ondanks het feit dat je in het begin niet betrokken was bij mijn onderzoek, 
was je er altijd om advies te geven. Ook was je degene die me met beide voeten op 
de grond terug wist te zetten, met name bij wetenschappelijke verklaringen van mijn 
immunohistochemische experimenten.
Marisol Kooijmans-Otero, researchverpleegkundige, zonder jouw hulp is 
het uitvoeren van patiëntgebonden onderzoek op de afdeling bijna onmogelijk. 
Niet alleen jouw kennis en praktische tips, maar vooral jouw “luisterende oor” 
hebben mijn promotietraject zeer aangenaam gemaakt. Ook al is een onderzoek 
meestal een collectieve gebeurtenis, jou lukte het om me dagen lang te isoleren op 
onderzoekskamer 3 waar ik met gevoelens van Robinson Crusoé de TEWL-meting 
volgens de richtlijnen kon uitvoeren. Deze tijdelijke, persoonlijke metamorfose 
was mede mogelijk door het op de deur geplakte, gezag uitstralende berichtje (Niet 
storen - TEWL meting), die de meeste collega’s niet gelijk konden ontcijferen en die 
daardoor twijfelend hun deurklopje uitstelden.
  Milan Tjioe, Jürgen Smit, Manon Franssen (destijds Agnio’s); bedankt voor 
alle gezellige, bemoedigende en inspirerende momenten op het lab, in de koffiekamer 
of tijdens de lunch. Onder het genot van een drankje werden de promotieperikelen 
meestal uitgebreid verder besproken in een van de Nijmeegse horeca-instellingen. 
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Milan, jou wil ik apart bedanken omdat je de opmaak van mijn proefschrift uit handen 
hebt willen nemen en omdat je de rol van paranimf bij mijn promotie hebt aanvaard. 
Onvergetelijk is ook jouw hulp in mijn levenslange strijd tegen mijn aartsvijand 
Reference Manager.
Quintus Swinkels. Ik wil je bedanken voor al die late avonden wanneer je 
structureel het gebruikelijke tijdstip van avondeten negeerde en er nog was om mij 
van advies te voorzien. In die late uurtjes kon ik voor een sociale raad, een opbeurend 
gesprek of een opfrissend woord (b.v. “laat maar zitten die promotie”)  bij jou terecht. 
Gelukkig heb ik niet altijd naar je geluisterd...
Sara T’ kint, als een tijdelijke bewoner van kamer 007 wil ik je bedanken voor 
de leuke tijd. In het jaar dat je bij ons vanuit de Vrije Universiteit Brussel een stage 
kwam lopen is het ons gelukt “de boze wereld” buiten de deur van kamer 007 te 
houden en kleurige gesprekken te voeren, niet uitsluitend maar over dermatologie.
Directe collega’s (AGNIO’s en AGIO’s); Marieke, Carine, Astrid, Monique, 
Fransje, Rob, Roland, Mandy, Maurice, Michelle, Tim, Wynand, José, Angelina, 
Saskia, Mirella en Cerpil, bedankt voor de prettige samenwerking en de mogelijkheid 
om indien nodig (b.v. vanwege een deadline voor inclusie voor een nieuwe klinische 
trial)  bij jullie hulp te vragen.
Alle collega’s van het lab, bedankt voor alle gezelligheid. Yvonne van Vlijmen, 
bedankt voor je hulp bij de verschillende immunohistochemische kleuringen. Al 
tijdens mijn wetenschappelijke stage leerde je me de kleurtechnieken en het snijden 
van vriescoupes. Ik kon altijd bij je terecht met vragen over rare verdunningen, 
verkeerde antilichamen, etc. Gijs, gelukkig had je begrip voor mijn structurele 
weigering om statistische methoden te leren. Zonder jouw hulp met statistiek zou 
de totstandkoming van dit proefschrift nog langer duren. Patrick, bedankt voor de 
gezellige uurtjes binnen en buiten werktijd en je niet te evenaren humor.
Alle stafleden, bedankt voor jullie steun en jullie interesse in mijn onderzoek.
Mayke Hornix, Aynur Dogan, Lonneke Lieffers dank ik voor het vele werk dat 
zij gedaan hebben als wetenschappelijke stagiaires.
Hartelijk dank aan alle baliemedewerkers, fotografen, administratief en 
verplegend personeel van de verpleegafdeling en de polikliniek dermatologie voor 
de prettige samenwerking tijdens mijn AGNIO-periode. Speciaal wil ik hierbij de 
medewerkers van de Arbeids- en Tijdsintensieve Behandeling (ATB) noemen die zich 
hebben ingezet voor het goede verloop van de MCO-studie (ó, die ellende met het 
noteren van lege ditranoltubes van 40 patiënten gedurende 1,5 jaar). Verder wil ik 
Marja Geurts niet vergeten die samen met me aan de wieg van de Handeczeem poli 
(HAHAND) heeft gestaan. 
Beste patiënten en gezonde vrijwilligers, bedankt voor het geduld dat jullie 
hadden met die buitenlandse dokter die met een raar kastje en een stokje (TEWL-
apparaat) bepaalde cijfers heeft afgelezen van de onderzoeksplekken op jullie ruggen. 
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Leuk was anders; liggen zonder te bewegen (om aan de kamertemperatuur te wennen), 
geen koffie (want dat stimuleert transpireren), geen praatjes (want dat stoort), maar 
toch zijn jullie trouw tijdens het hele experiment gekomen, ongelovig! Erg bedankt, 
zonder jullie zou dit proefschrift nooit tot stand zijn gekomen.
Peter Paul van Geel wil ik hartelijk danken voor de aanvaarding van de rol van 
paranimf bij mijn promotie. 
Mijn ouders, milí rodičia, d’akujem Vám za lásku s ktorou ste ma pod vrcholmi 
neprekonatel’ných Vysokých Tatier vychovali.
Lieve Michel, bedankt voor al je steun en de stoïcijnse rust waarmee jij me 
altijd in de realiteit terugbracht. Met name de laatste maanden hebben best veel van 
je gevraagd omdat we naar Limburg zijn verhuisd en omdat ons duo met Emilia werd 
versterkt. Voor alles bedankt. 
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Chapter 2 - paragraph 2.1 - figure 1 
- page 68
Chapter 2- paragraph 2.2 - figure 1 - page 78
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